

별첨2. 배제문헌 목록(국외)

배제사유	
1	동물연구 또는 전임상연구
2	원저가 아닌 연구(중설, letter, comment 등)
3	한국어 또는 영어로 출판되지 않은 문헌
4	회색문헌(초록만 발표된 연구, 학위논문, 기관보고서 등 peer-review를 거치지 않은 경우)
5	원문 확보 불가
6	증례보고(3인 이하)
7	환자대조군이 명확하지 않은 경우
8	SPECT 검사를 수행하지 않거나 중재검사의 분석방법이 혼재된 경우
9	적절한 의료결과가 하나이상 보고되지 않은 경우
10	중복문헌

연번	서지정보	배제사유
1	Aarts E, Helmich RC, Janssen MJR, Oyen WJG, Bloem BR, Cools R. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. <i>NeuroImage</i> . 3339;59(4):3339-46.	10
2	Abbasi Gharibkandi N, Hosseinimehr SJ. Radiotracers for imaging of Parkinson's disease. <i>European Journal of Medicinal Chemistry</i> . 2019;166:75-89.	2
3	Abe K, Akahoshi M, Uchiyama Y, Kimura K, Nakajima R, Fukushima K, et al. Clinical impact of CT attenuation correction in I-123 FP-CIT SPECT imaging for diagnosis of dopaminergic system neurodegeneration. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2015;56(SUPPL. 3).	4
4	Abe K, Akahoshi M, Uchiyama Y, Kondo C, Momose M, Fukushima K, et al. Attenuation and scatter correction for I-123 FP-CIT SPECT do not affect the clinical diagnosis of dopaminergic system neurodegeneration. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2016;57(SUPPL. 2).	4
5	Abe K, Fukushima K, Ando K, Maeda Y, Kotoura N, Ishikura R, et al. Combination of multimodal neuroimaging techniques is useful to diagnose multiple system atrophy. <i>Movement Disorders</i> . 2017;32(Supplement 2):578.	4
6	Abe K, Fukushima K, Katuura T, Kitajima K, Maeda Y, Hahiskawa K, et al. Dynamic dopamine transporter images are helpful for diagnosing Parkinsonism. <i>Movement Disorders</i> . 2016;31(Supplement 2):S399.	4
7	Abe K, Fukushima K, Maeda Y, Yoshikawa H. "Dynamic dat" imaging is useful for diagnoses of Parkinsonism with dementia. <i>Parkinsonism and Related Disorders</i> . 2018;46(Supplement 2):e81.	9
8	Abe K, Hayashi T, Akiyama N, Yamamoto M, Fujita M. Arterial spin labeling perfusion MRI compensate for other diagnostic tools in evaluation of Parkinson's disease with dementia. <i>Movement Disorders</i> . 2016;31(Supplement 2):S450.	4
9	Abe K, Kazuhito F, Ando K, Katsuura T, Maeda Y, Kotoura N, et al. Dopamine transporter imaging patterns are useful marker for diagnosing Parkinson's disease. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):213.	4
10	Adriaanse SM, de Wit TC, Stam M, Verwer E, de Bruin KM, Booij J. Clinical evaluation of [123I]FP-CIT SPECT scans on the novel brain-dedicated InSPira HD SPECT system: a head-to-head comparison. <i>EJNMMI Research</i> . 2018;8 (no pagination)(85).	9
11	Ahmed A. Usefulness of (123 I)-FP-CIT SPECT (DaT Scan) in diagnosing drug-induced Parkinsonism (DIP): A retrospective study. <i>Journal of Parkinson's Disease</i> . 2013;1:116-7.	4
12	Akahoshi M, Abe K, Uchiyama Y, Momose M, Fukushima K, Kitagawa K, et al. Attenuation and scatter correction in I-123 FP-CIT SPECT do not affect the clinical diagnosis of dopaminergic system neurodegeneration. <i>Medicine (United States)</i> . 2017;96(45) (no pagination)(e8484).	9

13	Albert NL, Unterrainer M, Diemling M, Xiong G, Bartenstein P, Koch W, et al. Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(7):1315-22.	10
14	Alberto R, Francesco P, Serena A, Francesca DM, Carlo Alberto A, Andrea B, et al. Replacement therapy with rotigotine in tetrahydrobiopterin deficiency: A case report. <i>Movement Disorders</i> . 2015;1):S475-S6.	6
15	Alhusaini S, Kandil M, Krohn L, Mitrovic M, Schaefer SM, Holmes A, et al. The association between SNCA gene top Parkinson's disease variants and basal ganglia imaging traits. <i>Annals of Neurology</i> . 2020;88(SUPPL 25):S194.	9
16	Allainmat L, Le Borgne A, Pina-Jomir G, Moreau-Triby C, Djemoussi FC, Le Rouzic G, et al. SPECT-CT and quantification of 123I-FPCIT: Evaluation of CT contribution. [French]. <i>Medecine Nucleaire</i> . 2011;35(2):54-62.	3
17	Allali G, Garibotto V, Mainta IC, Armand S, Camicioli R, Ratib O, et al. Dopaminergic denervation is not necessary to induce gait disorders in atypical parkinsonian syndrome. <i>Journal of the Neurological Sciences</i> . 2015;351(1-2):127-32.	9
18	Allali G, Garibotto V, Mainta IC, Nicastro N, Assal F. Dopaminergic imaging separates normal pressure hydrocephalus from its mimics. <i>Journal of Neurology</i> . 2018;265(10):2434-41.	9
19	Alvarez-Fischer D, Blessmann G, Trosowski C, Behe M, Schurrat T, Hartmann A, et al. Quantitative [123I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. <i>NeuroImage</i> . 2007;38(1):5-12.	10
20	An YS, Yoon JK, Lee SJ, Jeong E, Kim IH. Anaplastic Oligodendroglioma Found as an Incidental Photopenic Lesion on18F-FP-CIT PET/CT Image. <i>Clinical Nuclear Medicine</i> . 2019;44(3):e168-e9.	6
21	Andringa G, Drukarch B, Bol JGJM, De Bruin K, Sorman K, Habraken JBA, et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. <i>NeuroImage</i> . 2005;26(4):1150-8.	1
22	Anonymous. 9th Convegno Nazionale SINDEM. <i>Journal of Alzheimer's Disease Conference: 9th Convegno Nazionale SINDEM Firenze Italy</i> . 2016;52(Supplement 1).	9
23	Antke C, Sudmeyer M, Beu M, Mamlins E, Nikolaus S, Schnitzler A, et al. Combination of FP-CIT-,IBZM-and MIBG-scintigraphy in the differential diagnosis of degenerative parkinsonism-verification of methodology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2):S183.	4
24	Antonini A, Berto P, Lopatriello S, Tamma F, Annemans L, Chambers M. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. <i>Movement Disorders</i> . 2008;23(15):2202-9.	9
25	Apostolova I, Daley A, Lange C, Kupitz D, Brenner W, Amthauer H, et al. Relationship between cerebral glucose metabolism and striatal dopamine transporter availability in corticobasal degeneration. <i>NuklearMedizin</i> . 2017;56(2):A74.	9
26	Apostolova I, Kupitz D, Lange C, Amthauer H, Brenner W, Meyer P, et al. Added value of follow-up FP-CIT SPECT in clinical routine. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2015;56(SUPPL. 3).	4
27	Apostolova I, Lange C, Frings L, Klutmann S, Meyer PT, Buchert R. Nigrostriatal Degeneration in the Cognitive Part of the Striatum in Parkinson Disease Is Associated with Frontomedial Hypometabolism. <i>Clinical Nuclear Medicine</i> . 2020;45(2):95-9.	9
28	Apostolova I, Schmitz-Steinkruger H, Lange C, Frings L, Klutmann S, Hellwig S, et al. Age correction has only minor impact on the diagnostic accuracy of the specific binding ratio in dopamine transporter SPECT in the diagnosis of parkinsonian syndromes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2020;47(SUPPL 1):S165-S6.	4
29	Apostolova I, Schmitz-Steinkruger H, Lange C, Frings L, Klutmann S, Hellwig S, et al. Impact of age correction on the diagnostic performance of the specific binding ratio in dopamine transporter SPECT. <i>NuklearMedizin</i> . 2020;59(2):182-3.	3
30	Apostolova I, Taleb DS, Lipp A, Galazky I, Kupitz D, Lange C, et al. Utility of Follow-up Dopamine Transporter SPECT with 123I-FP-CIT in the Diagnostic Workup of Patients with Clinically Uncertain Parkinsonian Syndrome. <i>Clinical Nuclear Medicine</i> . 2017;42(8):589-94.	9
31	Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, et al. Use of11C-PE2I PET in differential diagnosis of Parkinsonian disorders. <i>Journal of Nuclear Medicine</i> . 2015;56(2):234-42.	10
32	Arnaldi D, Cellerino M, Lapucci C, Pietranera V, Fama F, De Carli F, et al. Optical coherence tomography in idiopathic REM sleep behavior disorder (RBD). <i>Journal of Sleep Research</i> . 2016;25(Supplement 1):10-1.	9
33	Arnaldi D, Chincarini A, Hu M, Sonka K, Boeve B, Miyamoto T, et al. Dopamine transporter neuroimaging and clinical predictors for phenoconversion of idiopathic REM sleep behavior disorder to overt synucleinopathy: An international multicenter study. <i>Journal of Sleep Research Conference: 25th Congress of the European Sleep Research Society, ESRS</i> . 2020;29(SUPPL 1).	9

34	Arnaldi D, Chincarini A, Hu MT, Sonka K, Boeve B, Miyamoto T, et al. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. <i>Brain</i> . 2021;144(1):278-87.	9
35	Arnaldi D, De Carli F, Fama F, Brugnolo A, Girtler N, Picco A, et al. Prediction of cognitive worsening in de novo Parkinson's disease: Clinical use of biomarkers. <i>Movement Disorders</i> . 2017;32(12):1738-47.	9
36	Arnaldi D, Fama F, Girtler N, Brugnolo A, Pardini M, Mattioli P, et al. Rapid eye movement sleep behavior disorder: A proof-of-concept neuroprotection study for prodromal synucleinopathies. <i>European Journal of Neurology</i> . 2021;28(4):1210-7.	9
37	Arnaldi D, Morbelli S, Brugnolo A, Girtler N, Picco A, Ferrara M, et al. Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson's disease and probable RBD. <i>Parkinsonism and Related Disorders</i> . 2016;29:47-53.	9
38	Asahara Y, Miyagawa S, Suzuki M. Comparison of 123I-MIBG myocardial scintigraphy and 123I-FP-CIT SPECT between dementia with Lewy bodies and Parkinson's disease. <i>Movement Disorders</i> . 2020;35(SUPPL 1):S152.	4
39	Ashraf-Ganjouei A, Moradi K, Aarabi M, Abdolalizadeh A, Kazemi SZ, Kasaeian A, et al. The Association between REM Sleep Behavior Disorder and Autonomic Dysfunction in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> . 2021;11(2):747-55.	9
40	Augimeri A, Cherubini A, Cascini GL, Galea D, Caligiuri ME, Barbagallo G, et al. CADA-computer-aided DaTSCAN analysis. <i>EJNMMI Physics</i> . 2016;3(1) (no pagination)(4).	8
41	Badiavas K, Iakovou I, Molyvda E, Tsolaki M, Psarrakos K, Karatzas N. Creation of a customized Normal Database for 123I-FP-CIT SPECT studies in a major Nuclear Medicine department in Northern Greece. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2):S399.	9
42	Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N. SPECT imaging evaluation in movement disorders: Far beyond visual assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;38(4):764-73.	2
43	Bae YJ, Kim JM, Kim E, Lee KM, Kang SY, Park HS, et al. Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With 123I-FP-CIT SPECT. <i>Movement Disorders</i> . 2016;31(5):684-92.	10
44	Bae YJ, Kim JM, Kim KJ, Kim E, Park HS, Kang SY, et al. Loss of substantia nigra hyperintensity at 3.0-T MR imaging in idiopathic REM sleep behavior disorder: Comparison with 123I-FP-CIT SPECT. <i>Radiology</i> . 2018;287(1):285-93.	9
45	Bae YJ, Song YS, Choi BS, Kim JM, Nam Y, Kim JH. Comparison of susceptibility-weighted imaging and susceptibility map-weighted imaging for the diagnosis of Parkinsonism with nigral hyperintensity. <i>European Journal of Radiology</i> . 2021;134 (no pagination)(109398).	9
46	Bae YJ, Song YS, Kim JM, Choi BS, Nam Y, Choi JH, et al. Determining the degree of dopaminergic denervation based on the loss of nigral hyperintensity on SMWI in parkinsonism. <i>American Journal of Neuroradiology</i> . 2021;42(4):681-7.	7
47	Baig F, O'Donoghue M, Bajaj N. Parinaud's syndrome and Holmes tremor due to a midbrain cavernoma. <i>Movement Disorders</i> . 2011;2):S372.	6
48	Bailly M, Le Rouzic G, Metrard G, Ribeiro MJ. Faster Acquisition for Dopamine Transporter Imaging Using Swiftscan Step and Shoot Continuous SPECT Without Impairing Visual and Semiquantitative Analysis. <i>Frontiers in Medicine</i> . 2020;7 (no pagination)(235).	9
49	Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2013;84(11):1288-95.	2
50	Bajaj N, Hauser RA, Seibyl J, Kupsch A, Plotkin M, Chen C, et al. Association between Hoehn and Yahr, Mini-Mental State Examination, age, and clinical syndrome predominance and diagnostic effectiveness of ioflupane i 123 injection (DaTSCAN™) in subjects with clinically uncertain parkinsonian syndromes. <i>Alzheimer's Research and Therapy</i> . 2014;6(5-8) (no pagination)(67).	9
51	Bajaj N, Jones I, Birchall J. What is the false positive and negative rate of FP-CIT scan in clinical practice? <i>Movement Disorders</i> . 2012;1):S224-S5.	4
52	Bajaj N, Wang L, Gontu V, Bain PG. Accuracy of subjective handwriting assessment for differentiating Parkinson's disease from tremulous subjects without evidence of dopaminergic deficits, (SWEDDs): An FP-CIT validated study. <i>Movement Disorders</i> . 2011;2):S185.	4
53	Bajaj NP, Knobel M, Gontu V, Bain PG. Can spiral analysis predict the FP-CIT SPECT scan result in tremulous patients? <i>Movement Disorders</i> . 2011;26(4):699-704.	8
54	Bajaj NPS, Gontu V, Birchall J, Patterson J, Grosset DG, Lees AJ. Accuracy of clinical diagnosis in tremulous parkinsonian patients: A blinded video study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2010;81(11):1223-8.	7
55	Bani Sadr A, Testart N, Tyłski P, Scheiber C. Reduced Scan Time in 123I-FP-CIT SPECT imaging using a large-field cadmium-zinc-telluride camera. <i>Clinical Nuclear Medicine</i> . 2019;44(7):568-9.	9

56	Barrantes S, Sanchez Egea AJ, Gonzalez Rojas HA, Marti MJ, Compta Y, Valdeoriola F, et al. Differential diagnosis between Parkinson's disease and essential tremor using the smartphone's accelerometer. <i>PLoS ONE</i> . 2017;12(8) (no pagination)(e0183843).	10
57	Barrou Z, Boddaert J, Faucounau V, Habert MO, Greffard S, Dieudonne B, et al. Utility of 123I-FP-CIT SPECT for dementia diagnoses and therapeutic strategies in elderly patients. <i>Journal of Nutrition, Health and Aging</i> . 2014;18(1):50-3.	9
58	Bartova P, Kraft O, Bernatek J, Havel M, Ressner P, Langova K, et al. Transcranial sonography and 123I-FP-CIT single photon emission computed tomography in movement disorders. <i>Ultrasound in Medicine and Biology</i> . 2014;40(10):2365-71.	10
59	Bartova P, Skoloudik D, Kraft O, Bernatek J, Havel M, Ressner P. 123I FP-CIT spect and transcranial sonography findings in patients with movement disorders. <i>European Journal of Neurology</i> . 2011;2:63.	4
60	Bartova P, Skoloudik D, Kraft O, Bernatek J, Havel M, Ressner P. Transcranial sonography and 123I FP-CIT spect in movement disorders. <i>Parkinsonism and Related Disorders</i> . 2012;2:S94.	4
61	Bartova P, Skoloudik D, Kraft O, Bernatek J, Srovnalova H. Changes of basal ganglia detected by transcranial sonography and 123I FP-CIT SPECT. <i>Movement Disorders</i> . 2010;2:S371.	4
62	Bejr-kasem Marco H, Lorenzo-Bosquet C, Alvarez-Sabin J, Hernandez-Vara J. Parkinsonism related to Percheron artery infarct. <i>Journal of the Neurological Sciences</i> . 2017;373:21-2.	6
63	Benaderette S, Fregonara PZ, Apartis E, Nguyen C, Trocello JM, Remy P, et al. Psychogenic parkinsonism: A combination of clinical, electrophysical, and [123I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. <i>Movement Disorders</i> . 2006;21(3):310-7.	7
64	Benamer HTS, Oertel WH, Patterson J, Hadley DM, Pogarell O, Hoffken H, et al. Prospective study of persynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. baseline and 3-month observations. <i>Movement Disorders</i> . 2003;18(9):977-84.	7
65	Benamer HTS, Patterson J, Grosset DG, Booij J, De Bruin K, Van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group. <i>Movement Disorders</i> . 2000;15(3):503-10.	10
66	Benamer HTS, Patterson J, Wyper DJ, Hadley DM, Macphee GJA, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. <i>Movement Disorders</i> . 2000;15(4):692-8.	10
67	Benitez-Rivero S, Marin-Oyaga VA, Garcia-Solis D, Huertas-Fernandez I, Garcia-Gomez FJ, Jesus-Maestre S, et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. <i>Movement Disorders</i> . 2012;1:S373-S4.	4
68	Berbellini A, Cacchio G, Di Luzio E, Di Marzio F, Pianese L, Ottalevi F, et al. 123I-FP-CIT striatal uptake and 123I-MIBG heart scintigraphy in CADASIL patient affected by parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2:S403.	4
69	Berendse HW, Roos DS, Rajmakers P, Doty RL. Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease. <i>Journal of the Neurological Sciences</i> . 2011;310(1-2):21-4.	9
70	Berger HJC, Cools AR, Horstink MWIM, Oyen WJG, Verhoeven EWM, Van Der Werf SP. Striatal dopamine and learning strategy - An 123I -FP-CIT SPECT study. <i>Neuropsychologia</i> . 2004;42(8):1071-8.	10
71	Berti S, Spimpolo A, Gusella S, Poggiali D, Simeone R, Sestini S, et al. 123I-FP-CIT semi-quantification on a large cohort of patients using a novel approach. <i>Clinical and Translational Imaging</i> . 2019;7(Supplement 1):S33-S4.	9
72	Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, et al. Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;37(3):537-44.	9
73	Berti V, Pupi A, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, et al. Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2008;35(12):2220-6.	10
74	Best L, Roberts G, Foster V, Petrides G, Anderson K, Pavese N. The association of early caudate involvement and REM sleep disorder behaviour could influence disease progression in Parkinson's Disease: A PPMI study. <i>European Journal of Neurology</i> . 2020;27(Supplement 1):178.	9
75	Beucke JC, Plotkin M, Winter C, Endrass T, Amthauer H, Juckel G, et al. Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson's disease - a [123I]-ADAM SPECT study. <i>European Journal of Neurology</i> . 2011;18(5):750-5.	10
76	Beucke JC, Uhl I, Plotkin M, Winter C, Assion HJ, Endrass T, et al. Serotonergic neurotransmission in early Parkinson's disease: A pilot study to assess implications for depression in this disorder. <i>World Journal of Biological Psychiatry</i> . 2010;11(6):781-7.	9
77	Biancheri-Mounicq I, Colombie M, Pin JC, Leccoanet A, Adam-Tariel F. Unexpected finding on I-123 FP-CIT SPECT leading to the diagnosis of cerebral meningioma. <i>Clinical nuclear medicine</i> . 2011;36(2):156-7.	6

78	Bianchi C, Poli G, Guerra U, Virota G. Influence of tomographic spatial resolution in the quantification of DaTSCAN SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2):S329.	9
79	Biggans TJ. Same day cerebral perfusion and dopamine transporter imaging for differential diagnosis of cerebral impairment. <i>Medical Engineering and Physics</i> . 2019;64:56-64.	9
80	Bindman D, Nesbitt A, Wasserman D, Higgins S, Duncan I, Gnoni V, et al. REM sleep behaviour disorder : potential sleep and datscan correlates. <i>Sleep Medicine</i> . 2019;64(Supplement 1):S276.	9
81	Birman N, Lorberboym M, Lampl Y, Djaldetti R. Decreased dopamine transporter binding ipsilateral to the clinically more affected side in Parkinson's disease: Which side to take? <i>Movement Disorders</i> . 2014;1):S228.	9
82	Biscarini F, Antelmi E, Donadio V, Pizza F, Incensi A, Liguori R, et al. Different skin phosphorylated alpha-synuclein deposition predicts phenoconversion in isolated rapid-eye-movement sleep behaviour disorder (iRBD). <i>Journal of Sleep Research Conference: 25th Congress of the European Sleep Research Society, ESRS</i> . 2020;29(SUPPL 1).	9
83	Bittner D, Bittner V, Thormann M, Holger A, Heinze HJ, Muller N. FP-cit spect in the diagnosis of possible Lewy Body Dementia without parkinsonism - Report of three cases. <i>Neurodegenerative Diseases Conference: 10th International Conference AD/PD Alzheimer's and Parkinson's Diseases: Advances, Concepts and New Challenges Barcelona Spain Conference Publication</i> .. 2011;8(SUPPL. 1).	9
84	Biundo R, Fiorenzato E, Weis L, Antonini A. The relationship between asymmetric dopamine loss and cognition in early Parkinson's disease patients from PPMI study. <i>Movement Disorders</i> . 2018;33(Supplement 2):S584-S5.	9
85	Biundo R, Fiorenzato E, Weis L, Gasparoli E, Antonini A. The relationship between asymmetric dopamine loss, cognition and brain structural changes in early Parkinson's disease from PPMI study. <i>Movement Disorders Clinical Practice</i> . 2020;7(Supplement 2):S9-S11.	9
86	Bonfante JAF, Pagano G, Politis M. Neuroimaging studies in familial forms of Parkinson's disease: A systematic review. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):507.	10
87	Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. <i>Synapse</i> . 2001;39(2):101-8.	10
88	Booij J, De Jong J, De Bruin K, Knol R, De Win MML, Van Eck-Smit BLF. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: A double-blind, placebo-controlled, crossover study in healthy control subjects. <i>Journal of Nuclear Medicine</i> . 2007;48(3):359-66.	10
89	Booij J, Habraken JBA, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. <i>Journal of Nuclear Medicine</i> . 1998;39(11):1879-84.	9
90	Booij J, Kemp P. Dopamine transporter imaging with [123I]FP-CIT SPECT: Potential effects of drugs. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2008;35(2):424-38.	2
91	Booij J, Speelman JD, Horstink MWIM, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. <i>European Journal of Nuclear Medicine</i> . 2001;28(3):266-72.	7
92	Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AGM, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. <i>Journal of Neurology Neurosurgery and Psychiatry</i> . 1997;62(2):133-40.	7
93	Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. <i>European Journal of Nuclear Medicine</i> . 1997;24(1):68-71.	10
94	Borghammer P, Knudsen K, Ostergaard K, Bluhme H, Bekker AC, Arveschoug A, et al. Half of movement disorder patients with pathological [123I]FP-CIT scans are unaware of their significant olfactory deficit. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2):S188-S9.	4
95	Borghammer P, Knudsen K, Ostergaard K, Danielsen EH, Pavese N, Arveschoug A, et al. Combined DaT imaging and olfactory testing for differentiating parkinsonian disorders. <i>International Journal of Clinical Practice</i> . 2014;68(11):1345-51.	7
96	Bosquet CL, Rodriguez FM, Bielsa IR, Mila M, Aguade Bruix S, Conesa JC. Differential diagnosis of parkinsonism using dopamine transporters brain SPECT. [Spanish]. <i>Medicina Clinica</i> . 2004;122(9):325-8.	3
97	Bostantjopoulou S, Katsarou Z, Gerasimou G, Costa DC, Gotzamani-Psarrakou A. 123I-FP-CIT SPET striatal uptake in parkinsonian patients with the alpha-synuclein (G209A) mutation. <i>Hellenic Journal of Nuclear Medicine</i> . 2008;11(3):157-9.	9
98	Bovi T, Antonini A, Ottaviani S, Antonioli A, Cecchini MP, Di Francesco V, et al. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. <i>Journal of Neurology</i> . 2010;257(11):1882-9.	9
99	Brajkovic L, Svetel M, Kostic V, Stefanova E, Petrovic I, Stojkovic T, et al. Brain SPECT with 123I ioflupane (FP-CIT)-DATSCAN in differential diagnosis of Dopa-Responsive Dystonia and Young-Onset Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2):S402-S3.	4

100	Brajkovic L, Svetel M, Kostic V, Stefanova E, Petrovic I, Stojkovic T, et al. 123I-ioflupane FP-CIT (DaTSCAN) in differential diagnosis of Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2):S401.	4
101	Brajkovic LD, Svetel MV, Kostic VS, Sobic-Saranovic DP, Pavlovic SV, Artiko VM, et al. Dopamine transporter imaging 123I-FP-CIT (DaTSCAN) SPET in differential diagnosis of dopa-responsive dystonia and young-onset Parkinson's disease. <i>Hellenic Journal of Nuclear Medicine</i> . 2012;15(2):134-8+68.	9
102	Branger P, Enilorac B, Bouthiba D, Roth N, Agostini D. First-in-man study in parkinson syndromes with the new czr spect camera (veriton) and 123I-FP-CIT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2018;45(Supplement 1):S269.	9
103	Brigo F, Matinella A, Erro R, Tinazzi M. [1 2 3I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: A meta-analysis. <i>European Journal of Neurology</i> . 2014;21(11):1369-e90.	10
104	Brigo F, Turri G, Tinazzi M. 123I-FP-CIT SPECT in the differential diagnosis between dementia with Lewy bodies and other dementias. <i>Journal of the Neurological Sciences</i> . 2015;359(1-2):161-71.	9
105	Bruggemann N, Rosales RL, Waugh JL, Blood AJ, Domingo A, Heldmann M, et al. Striatal dysfunction in X-linked dystonia-parkinsonism is associated with disease progression. <i>European Journal of Neurology</i> . 2017;24(5):680-6.	9
106	Brumberg J, Lapa C, Spehl T, Isaias IU, Schlogl S, Lassmann M, et al. Influence of CT-based attenuation correction on presynaptic dopamine transporter SPECT with 123I-FP-CIT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S361.	4
107	Buchert R, Hutton C, Lange C, Hoppe P, Makowski M, Bamouza T, et al. Semiquantitative slab view display for visual evaluation of 123I-FP-CIT SPECT. <i>Nuclear Medicine Communications</i> . 2016;37(5):509-18.	10
108	Buchert R, Lange C, Spehl TS, Apostolova I, Frings L, Jonsson C, et al. Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: harmonized multi-center research setting versus typical clinical single-camera setting. <i>EJNMMI Research</i> . 2019;9 (no pagination)(37).	9
109	Buchholz HG, Rosar F, Hoffmann M, Schreckenberger M. Impact of reference databases on evaluation of 123-I-FP-CIT striatal binding: A comparison between Hermes EARL-BRASS and GE DaTQuant. <i>Journal of Nuclear Medicine Conference</i> . 2020;61(Supplement 1).	4
110	Bund C, Ouvreard E, Renaud M, Tranchant C, Namer IJ. Atypical Parkinson Syndrome Hiding a Meningioma. <i>Clinical Nuclear Medicine</i> . 2019;44(12):987-8.	6
111	Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: Description and validation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2007;34(8):1240-53.	9
112	Camacho Marti V, Marquie M, Lleo A, Alves L, Artigas C, Flotats A, et al. Cardiac sympathetic impairment parallels nigrostriatal degeneration in Probable Dementia with Lewy Bodies. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;55(4):476-85.	9
113	Camacho V, Marquie M, Lleo A, Artigas C, Flotats A, Duch J, et al. Cardiac sympathetic impairment parallels nigrostriatal degeneration in probable dementia with Lewy bodies. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2010;51(SUPPL. 2).	9
114	Camardese G, Di Giuda D, Fasano A, Cocciolillo F, Bentivoglio AR, Bruno I, et al. Striatal dopamine transporter (DAT) availability and affective symptoms in movement disorders: A 123I-FP-CIT spect study. <i>European Psychiatry Conference: 19th European Congress of Psychiatry, EPA</i> . 2011;26(SUPPL. 1).	4
115	Caminiti SP, Carli G, Avenali M, Blandini F, Perani D. Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations. <i>Movement Disorders</i> . 2021.	9
116	Caminiti SP, Pagano G, Dervenoulas G, Yousaf T, Wilson H, Politis M. Arterial spin labelling detects subcortical hypoperfusion in early drug-naive patients with Parkinson's disease. <i>Movement Disorder</i> . 2019;34(Supplement 2):S774.	4
117	Caminiti SP, Pagano G, Dervenoulas G, Yousaf T, Wilson H, Politis M. Arterial spin labelling detects striatal hypoperfusion in early drug-naive patients with Parkinson's disease. <i>European Journal of Neurology</i> . 2019;26(Supplement 1):150.	4
118	Canessa A, Pozzi NG, Arnulfo G, Brumberg J, Reich MM, Pezzoli G, et al. Striatal dopaminergic innervation regulates subthalamic beta-oscillations and cortical-subcortical coupling during movements: Preliminary evidence in subjects with Parkinson's disease. <i>Frontiers in Human Neuroscience</i> . 2016;10(DEC2016) (no pagination)(611).	9
119	Cannas A, Solla P, Floris G, Tacconi P, Serra A, Piga M, et al. Reversible Pisa syndrome in patients with Parkinson's disease on dopaminergic therapy. <i>Journal of Neurology</i> . 2009;256(3):390-5.	9
120	Cao R, Chen X, Xie C, Hu P, Wang K. Serial Dopamine Transporter Imaging of Nigrostriatal Function in Parkinson's Disease With Probable REM Sleep Behavior Disorder. <i>Frontiers in Neuroscience</i> . 2020;14 (no pagination)(349).	9

121	Carey G, Gormezoglu M, de Jong JJA, Hofman PAM, Backes WH, Dujardin K, et al. Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review. <i>Movement Disorders</i> . 2021;36(2):327-39.	9
122	Carrillo Garcia F. Parkinson's disease and other parkinsonisms: diagnostic protocol. <i>Medicine (Spain)</i> . 2019;12(73):4313-5.	2
123	Carrillo Garcia F, Gil Neciga E, Alberca R, Garcia-Solis D, Millan J, Rodriguez Uranga JJ, et al. Apolipoprotein epsilon4 in dementia with Lewy bodies. [Spanish]. <i>Neurologia</i> . 2008;23(3):152-6.	3
124	Cascianelli S, Tranfaglia C, Fravolini ML, Bianconi F, Ministrini M, Nuvoli S, et al. Right putamen and age are the most discriminant features to diagnose Parkinson's disease by using 123I-FP-CIT brain SPET data by using an artificial neural network classifier, a classification tree (CIT). <i>Hellenic journal of nuclear medicine</i> . 2017;20(Supplement):165.	4
125	Castelnovo G, Collombier L, Renaud S, De Verdal M, Renard D, Kotzki JP, et al. Presynaptic dopaminergic dysfunction on [123I]-FP-CIT SPECT in patients with long standing essential tremor with associated rest tremor. <i>Parkinsonism and Related Disorders</i> . 2009;15(SUPPL 2):S79-S80.	9
126	Castillo C, Castrillon MA, Ruiz DM, Rivas OM, Loira FJ, Nogueiras JM, et al. Myocardial innervation with 123-MIBG in neurodegenerative movement disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S627.	4
127	Ceravolo R, Antonini A, Volterrani D, Rossi C, Goldwurm S, Di Maria E, et al. Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers. <i>Neurology</i> . 2005;65(12):1971-3.	9
128	Ceravolo R, Frosini D, Poletti M, Kiferle L, Pagni C, Mazzucchi S, et al. Mild affective symptoms in de novo Parkinson's disease patients: Relationship with dopaminergic dysfunction. <i>European Journal of Neurology</i> . 2013;20(3):480-5.	10
129	Ceravolo R, Frosini D, Poletti M, Pagni C, Mazzucchi S, Volterrani D, et al. Mild affective symptoms in de novo Parkinson's disease patients: Relationship with dopaminergic dysfunction. <i>Movement Disorders</i> . 2012;1):S266.	9
130	Ceravolo R, Kiferle L, Volterrani D, Del Prete E, Bonuccelli U. Is the nigrostriatal dysfunction a possible predictive marker of visual hallucinations in Parkinson's disease? Evidences from a 123I-SPECT study. <i>Movement Disorders</i> . 2012;1):S276.	9
131	Ceravolo R, Rossi C, Cilia R, Tognoni G, Antonini A, Volterrani D, et al. Evidence of delayed nigrostriatal dysfunction in corticobasal syndrome: A SPECT follow-up study. <i>Parkinsonism and Related Disorders</i> . 2013;19(5):557-9.	9
132	Ceravolo R, Volterrani D, Gambaccini G, Bernardini S, Rossi C, Logi C, et al. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: Evidence from a dopamine transporter imaging study. <i>Journal of Neural Transmission</i> . 2004;111(8):1065-73.	9
133	Chaturvedi M, Yilmaz R, Gschwandtner U, Greulich K, Reimold M, Fuhr P, et al. FV 4 Electroencephalographic Activity as a potential prodromal marker for Parkinson's disease. <i>Clinical Neurophysiology</i> . 2019;130(8):e122-e3.	4
134	Chen Q, Lowe VJ, Boeve BF, Przybelski SA, Miyagawa T, Senjem ML, et al. Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> . 2021;06.	9
135	Chiaravalloti A, Di Pietro B, Pierantozzi M, Tavolozza M, Di Biagio D, Palombo E, et al. The severity of cardiac sympathetic denervation is not related to presynaptic nigrostriatal degeneration in Parkinson's disease. <i>Clinical and Translational Imaging</i> . 2013;1):S23-S4.	9
136	Chiaravalloti A, Fiorentini A, Lacanfora A, Stefani A, Pierantozzi M, Tavolozza M, et al. Does CSF levels of t-tau, p-tau and beta 1-42 amyloid correlate with the dopaminergic system impairment in patients with clinical diagnosis of Parkinson disease? A 123I FP-CIT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S622.	4
137	Chiaravalloti A, Stefani A, Di Biagio D, Pierantozzi M, Tavolozza M, Di Pietro B, et al. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease. <i>Annals of Nuclear Medicine</i> . 2013;27(5):444-51.	9
138	Chiaravalloti A, Stefani A, Di Pietro B, Pierantozzi M, Tavolozza M, Di Biagio D, et al. The severity of cardiac sympathetic denervation is not related to presynaptic nigrostriatal degeneration in Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2):S554.	4
139	Chiaravalloti A, Stefani A, Fiorentini A, Lacanfora A, Stanzione P, Schillaci O. Do CSF levels of t-Tau, p-Tau and beta-1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;41(11):2137-43.	10
140	Chung YA, Oh JK, Song IU, Choi EK. Evaluation of diagnostic yield for parkinson's disease: Comparison of planar and SPECT imaging. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2015;56(SUPPL. 3).	4
141	Ciarmiello A, Giovacchini G, Guidotti C, Meniconi M, Lazzeri P, Carabelli E, et al. Weighted registration of 123I-FP-CIT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake. <i>Journal of Cellular Physiology</i> . 2013;228(10):2086-94.	10

142	Cocciolillo F, Di Giuda D, Annunziata S, Scolozzi V, Bove F, Vita MG, et al. Difference in striatal dopamine transporter availability and psychiatric symptoms in Parkinson's disease subtypes: 123I-FP-CIT SPECT results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S571-S2.	4
143	Cocciolillo F, Di Giuda D, Bove F, Vita MG, Piano C, Bentivoglio AR, et al. Striatal dopamine transporter availability in Parkinson's disease subtypes: 123I-FP-CIT SPECT results. <i>Clinical and Translational Imaging</i> . 2017;5(Supplement 1):S117.	4
144	Colloby SJ, O'Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, et al. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. <i>NeuroImage</i> . 2004;23(3):956-66.	10
145	Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2005;32(10):1176-85.	10
146	Contaldi E, Magistrelli L, Campini I, Comi C. Striatal dopamine transporter imaging in Parkinson's Disease drug-naive patients: Focus on sexual dysfunction. <i>Movement Disorder</i> . 2021;36(SUPPL 1):S412-S3.	9
147	Contin M, Martinelli P, Mochi M, Albani F, Riva R, Scaglione C, et al. Dopamine transporter gene polymorphism, SPECT imaging, and levodopa response in patients with Parkinson disease. <i>Clinical Neuropharmacology</i> . 2004;27(3):111-5.	9
148	Contin M, Martinelli P, Riva R, Dondi M, Fanti S, Pettinato C, et al. Assessing dopaminergic function in Parkinson's disease: Levodopa kinetic-dynamic modeling and SPECT. <i>Journal of Neurology</i> . 2003;250(12):1475-81.	9
149	Contrafatto D, Lanzafame S, Raciti L, Luca A, Sorbello V, Mostile G, et al. Spect Striatal Asymmetry Index may predict magnitude response at short-term LD test. <i>European Journal of Neurology</i> . 2009;16(S3):174.	4
150	Contrafatto D, Mostile G, Nicoletti A, Dibilio V, Raciti L, Lanzafame S, et al. [123I]FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. <i>Acta Neurologica Scandinavica</i> . 2012;126(1):12-6.	10
151	Coria F, Gimenez-Garcia M, Samaranch L, Mora FJ, Sampol-Bas C, Pastor P. Nigrostriatal dopaminergic function in subjects with isolated action tremor. <i>Parkinsonism and Related Disorders</i> .	10
152	Corragain OO, Crotty GF, O'Sullivan SS. A clinical audit of DaTscan use in Cork University Hospital. <i>Movement Disorders</i> . 2014;1):S87-S8.	4
153	Covelli EM, Brunetti A, Dilauro A, Sullo P, Mazzarella G, Tedeschi E, et al. Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease. [Italian, English]. <i>Radiologia Medica</i> . 2004;108(4):417-25.	7
154	Crosiers D, Pickut B, Ceysens S, Cras P. Dopamine transporter imaging: Importance of medication history? <i>Movement Disorders</i> . 2012;1):S231-S2.	9
155	Cuberas-Borros G, Lorenzo-Bosquet C, Aguade-Bruix S, Hernandez-Vara J, Pifarre-Montaner P, Miquel F, et al. Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and parkinsonism. <i>Clinical Nuclear Medicine</i> . 2011;36(11):991-6.	9
156	Cubo E, Lopez MD, Ceberio JI, Alfonso IL, Martinez BM, Berciano J, et al. Striatal dopamine function in a family with multiple SCA-3 phenotypes. <i>Journal of Neurology</i> . 2011;258(2):308-10.	9
157	Da Silva Freitas T, Kessler IM, Neto OM. Differences in dopamine transporter imaging in patients with parkinson's disease treated with subthalamic deep brain stimulation and contralateral thalamotomy. <i>Stereotactic and Functional Neurosurgery</i> . 2014;1):47.	9
158	Damian A, Pascovich C, Munoz D, Langhain M, Amarin I, Lescano A, et al. 99mTc-TRODAT-1 SPECT in the evaluation of parkinson's disease progression and severity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S570-S1.	8
159	Danan I, Iacobas D, Velisek L, Fekete R. Retrospective review of Parkinsonian features in 123I-FP-CIT SPECT scanned outpatients. <i>Movement Disorders</i> . 2014;1):S376-S7.	4
160	David R, Koulibaly M, Benoit M, Garcia R, Caci H, Darcourt J, et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases. A SPECT study with partial volume effect correction. <i>Clinical Neurology and Neurosurgery</i> . 2008;110(1):19-24.	9
161	Davidsson A, Georgiopoulos C, Dizdar N, Granerus G, Zachrisson H. Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson's disease and atypical parkinsonian syndromes using DaTSCAN SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S623.	10
162	De Michele G, Berbellini A, Cacchio G, Manca A, Di Marzio F, Pianese L, et al. Parkinsonism is a rare feature of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). <i>European Journal of Neurology</i> . 2012;19(SUPPL.1):698.	9
163	De Rosa A, Carducci C, Antonozzi I, Giovanniello T, Filla A, Pappata S, et al. SWEDD phenomenon is not caused by GCH1 gene mutations. <i>Movement Disorders</i> . 2011;2):S239.	9

164	De Rosa A, Carducci C, Peluso S, Lieto M, Mazzella A, Sacca F, et al. Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD). <i>Journal of Neurology</i> . 2014;261(11):2204-8.	9
165	de Souza Silva MA, Mattern C, Decheva C, Huston JP, Sadile AG, Beu M, et al. Intranasal dopamine reduces in vivo [123I]FP-CIT binding to striatal dopamine transporter: Correlation with behavioral changes and evidence for pavlovian conditioned dopamine response. <i>Frontiers in Behavioral Neuroscience</i> . 2016;10(APRIL) (no pagination)(80).	10
166	De Verdal M, Castelnovo G, Colombier L, Renard D, Renaud S, Labauge P. [123I]-FP-CIT SPECT in isolated blepharospasm and in blepharospasm associated with apraxia of eyelid opening. <i>Movement Disorders</i> . 2011;2):S122-S3.	9
167	De Verdal M, Renard D, Collombier L, Boudousq V, Kotzki PO, Labauge P, et al. I123-FP-CIT single-photon emission tomography in patients with long-standing mixed tremor. <i>European Journal of Neurology</i> . 2013;20(2):382-8.	9
168	De Verdal M, Renard D, Collombier L, Castelnovo G. 123I-FP-CIT SPECT imaging in blepharospasm. <i>Revue Neurologique</i> . 2017;173(10):645-9.	9
169	Del Gamba C, Aquila F, Perrini P, Volterrani D, Bonuccelli U, Benedetto N, et al. Predictive value of [123I]FP-CIT-SPECT on surgical outcome in idiopathic adult chronic hydrocephalus: A pilot study. <i>Parkinsonism and Related Disorders</i> . 2016;22:e127.	9
170	Del Gamba C, Bruno A, Frosini D, Volterrani D, Migaleddu G, Benedetto N, et al. Is DAT imaging abnormality in normal pressure hydrocephalus always suggestive of degeneration? <i>Neurological Sciences</i> . 2021;42(2):723-6.	9
171	Del Sole A, Clerici F, Perini G, Dellavedova L, Seghezzi S, Lecchi M, et al. Does [I-123]FP-CIT SPET correlate with UPDRS in patients with possible or probable Lewy Body Dementia? A singlecenter, prospective, pilot stud. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;2):S343.	9
172	Del Sole A, Perini G, Lecchi M, Mariani C, Lucignani G, Clerici F. Correlation Between 123I-FP-CIT Brain SPECT and Parkinsonism in Dementia With Lewy Bodies: Caveat for Clinical Use. <i>Clinical Nuclear Medicine</i> . 2014;06.	9
173	Del Sole A, Perini G, Lecchi M, Mariani C, Lucignani G, Clerici F. Correlation between 123I-FP-CIT brain SPECT and parkinsonism in dementia with lewy bodies: Caveat for clinical use. <i>Clinical Nuclear Medicine</i> . 2015;40(1):32-5.	10
174	Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, et al. Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson's disease: a correlation study. <i>Journal of Neural Transmission</i> . 2019;126(3):279-87.	9
175	Depboylu C, Maurer L, Matusch A, Hermanns G, Windolph A, Behe M, et al. Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry. <i>NeuroImage</i> . 2013;79:191-200.	10
176	Depboylu C, Maurer L, Matusch A, Ries V, Behe M, Oertel WH, et al. Effect of long-term treatment with pramipexole or levodopa on [123I]FP-CIT SPECT in a bi-nigral 6-OHDA mouse model. <i>Movement Disorders</i> . 2013;1):S69.	1
177	Di Censo R, Abdelnour C, Blanc F, Bousiges O, Lemstra AW, Van Steenoven I, et al. CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2020;91(1):109-10.	9
178	Di Giuda D, Calcagni ML, Totaro M, Cocciolillo F, Piano C, Soleti F, et al. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: A preliminary report. <i>Nuclear Medicine Communications</i> . 2012;33(9):933-40.	10
179	Di Giuda D, Camardese G, Bentivoglio AR, Cocciolillo F, Guidubaldi A, Pucci L, et al. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: A 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;39(12):1937-48.	10
180	Di Giuda D, Camardese G, Fasano A, Cocciolillo F, Bruno I, Villani MF, et al. 123I-FP-CIT SPECT in essential tremor and primary dystonia: Relationship between striatal dopamine transporter availability and affective symptoms. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2):S161.	9
181	Di Giuda D, Cocciolillo F, Ieria FP, Lorusso M, Di Franco D, Pettorruso M, et al. Dopamine transporter availability in gambling disorder: Preliminary 123I-FP-CIT SPECT results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S622.	4
182	Di Giuda D, Cocciolillo F, Pettorruso M, Bruno I, Valenza V, Camardese G, et al. Striatal dopaminergic dysfunction in patients with gambling disorder. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2017;44(2 Supplement 1):S599-SS600.	4
183	Di Giuda D, Cocciolillo F, Zollino M, Pettorruso M, Camardese G, Conte G, et al. Dopamine transporter availability in gambling disorder: Preliminary 123I-FP-CIT SPECT results. <i>Clinical and Translational Imaging</i> . 2015;1):S86-S7.	10
184	Di Giuda D, Fasano A, Camardese G, Bruno I, Guidubaldi A, Cocciolillo F, et al. Depression symptoms and clinical subtypes in parkinson's disease patients: A 123I-FP-CIT spect study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2):S547.	4

185	Di Giuda D, Fasano A, Camardese G, Cocciolillo F, Bruno I, Guidubaldi A, et al. Correlations between striatal dopamine transporter (DAT) availability and psychiatric symptoms in movement disorders: A 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2):S217-S8.	4
186	Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P. Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;37(3):556-64.	10
187	Dickson JC, Tossici-Bolt L, Sera T, Booi J, Ziebell M, Morbelli S, et al. The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging. <i>EJNMMI Research</i> . 2017;7(1) (no pagination)(10).	9
188	Ding X, Vija A, Platsch G. SPECT Emission only , u-map Generation for Clinical123I - FP-CIT Applications. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2021;62(SUPPL 1).	9
189	Djaldetti R, Lorberboym M, Karmon Y, Treves TA, Ziv I, Melamed E. Residual striatal dopaminergic nerve terminals in very long-standing Parkinson's disease: A single photon emission computed tomography imaging study. <i>Movement Disorders</i> . 2011;26(2):327-30.	9
190	Djaldetti R, Nageris BI, Lorberboym M, Treves TA, Melamed E, Yaniv E. [123I]-FP-CIT SPECT and olfaction test in patients with combined postural and rest tremor. <i>Journal of Neural Transmission</i> . 2008;115(3):469-72.	9
191	Djaldetti R, Rigbi A, Greenbaum L, Reiner J, Lorberboym M. Can early dopamine transporter imaging serve as a predictor of Parkinson's disease progression and late motor complications? <i>Journal of the Neurological Sciences</i> . 2018;390:255-60.	9
192	Djaldetti R, Treves TA, Ziv I, Melamed E, Lampl Y, Lorberboym M. Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. <i>Neurological Sciences</i> . 2009;30(4):301-5.	9
193	Djaldetti R, Treves TA, Ziv I, Melamed E, Lorberboym M. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with recurrent sudden falls: Are such falls a distinct entity? <i>Journal of Nuclear Medicine Technology</i> . 2007;35(4):232-6.	10
194	Dodel RC, Hoffken H, Moller JC, Bornschein B, Klockgether T, Behr T, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: A decision-analytic approach. <i>Movement Disorders</i> . 2003;18(SUPPL. 7):S52-S62.	4
195	Doepf F, Plotkin M, Siegel L, Kivi A, Gruber D, Lobsien E, et al. Brain parenchyma sonography and 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. <i>Movement Disorders</i> . 2008;23(3):405-10.	10
196	Donaghy PC, O'Brien JT, Colloby SJ, Lloyd J, Petrides G, Taylor JP, et al. FP-CIT imaging in mild neurocognitive disorder with lewy bodies. <i>Alzheimer's and Dementia</i> . 2017;13(7):P745.	9
197	D'Onofrio S, Di Domenicoantonio S, Galli G, Lewandowski R, Massaccesi M, Morabito R, et al. Dopamine transporter imaging with 123I-ioflupane SPECT: Comparison between two different time modality acquisitions. <i>Clinical and Translational Imaging</i> . 2019;7(Supplement 1):S133.	9
198	Doppler K, Jentschke HM, Schulmeyer L, Vadasz D, Janzen A, Luster M, et al. Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. <i>Acta Neuropathologica</i> . 2017;133(4):535-45.	9
199	Dotinga M, van Dijk JD, Vendel BN, Slump CH, Portman AT, van Dalen JA. Clinical value of machine learning-based interpretation of I-123 FP-CIT scans to detect Parkinson's disease: a two-center study. <i>Annals of Nuclear Medicine</i> . 2021;35(3):378-85.	8
200	Dotinga M, Van Dijk JD, Vendel BN, Slump CH, Van Dalen JA. Machine-learning based interpretation of I-123 FP-CIT scans allows high-accuracy detection of Parkinson's Disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2019;46(1 Supplement 1):S29.	4
201	Durante ACR, Sobral DV, Miranda ACC, de Almeida EV, Fuscaldi LL, de Barboza MRFF, et al. Comparative study of two oxidizing agents, chloramine T and Iodo-Gen, for the radiolabeling of beta-CIT with iodine-131: Relevance for Parkinson's disease. <i>Pharmaceuticals</i> . 2019;12(1) (no pagination)(25).	9
202	Durcan R, Brooks D, Burn D, Pavese N. Early caudate involvement in Parkinson's disease may predict future cognitive decline. <i>Movement Disorders</i> . 2017;32(Supplement 2):1024-5.	4
203	Eggers C, Pedrosa DJ, Kahraman D, Maier F, Lewis C, Fink GR, et al. Serial dopamine-transporter imaging of Parkinson's disease: Faster progression of clinical and in-vivo patterns in akinetic-rigid patients. <i>Klinische Neurophysiologie Conference</i> . 2012;43(1).	9
204	Eggers C, Pedrosa DJ, Kahraman D, Maier F, Lewis CJ, Fink GR, et al. Parkinson Subtypes Progress Differently in Clinical Course and Imaging Pattern. <i>PLoS ONE</i> . 2012;7(10) (no pagination)(e46813).	4
205	Eggers C, Pedrosa DJ, Kahraman D, Maier F, Lewis CJ, Fink GR, et al. Different clinical and in-vivo progression in subtypes of Parkinson's disease. <i>Movement Disorders</i> . 2012;1):S233.	9
206	Eggers C, Volk AE, Kahraman D, Fink GR, Leube B, Schmidt M, et al. Are dopa-responsive dystonia and Parkinson's disease related disorders? A case report. <i>Parkinsonism and Related Disorders</i> . 2012;18(5):666-8.	6

207	Eklund M, Joutsa J, Nuutila S, Makinen E, Jaakkola E, Noponen T, et al. Striatal dopaminergic regulation of micrographia in parkinsonism. <i>Movement Disorder</i> . 2019;34(Supplement 2):S340.	4
208	El Fakhri G, Habert MO, Maksud P, Kas A, Malek Z, Kijewski MF, et al. Quantitative simultaneous 99mTc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2006;33(1):87-92.	10
209	El Fakhri G, Ouyang J. Dual-radionuclide brain SPECT for the differential diagnosis of parkinsonism. <i>Methods in molecular biology (Clifton, NJ)</i> . 2011;680:237-46.	2
210	Elias M, Queiroga M, Silva D, Serrano J, Madrid J, Carolino E, et al. Validation of a new reference values's database for semiquantification of 123I-FP-CIT SPECT scans in one nuclear medicine department. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S844.	4
211	Erro R, Pappata S, Amboni M, Vicidomini C, Longo K, Santangelo G, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> . 2012;18(9):1034-8.	9
212	Erro R, Pappata S, Barone P, Pellicchia MT. Comment on di Giuda et al.: Dopaminergic dysfunction and psychiatric symptoms in movement disorders: A 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;40(4):636-7.	10
213	Erro R, Picillo M, Vitale C, Palladino R, Amboni M, Moccia M, et al. Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. <i>Parkinsonism and Related Disorders</i> . 2016;28:137-40.	9
214	Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2009;36(3):454-62.	9
215	Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2006;33(2):200-9.	9
216	Eusebio A, Guedj E, Witjas T, Mundler O, Azulay JP. Extrastriatal [123I] FP-CIT uptake helps discriminate between Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> . 2011;2):S335-S6.	4
217	Evans AH, Costa DC, Gacinovic S, Katzenschlager R, O'Sullivan JD, Heales S, et al. L-dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings. <i>Movement Disorders</i> . 2004;19(10):1232-6.	6
218	Factor SA. Drug induced parkinsonism. <i>Journal of Parkinson's Disease</i> . 2013;1):25.	2
219	Fadrna T, Skoloudik D, Bartova P, Ressler P, Kraft O, Bernatek J, et al. Transcranial sonography and 123I FP-CIT spect findings in patients with movement disorders. <i>Cerebrovascular Diseases</i> . 2011;1):37.	4
220	Farid K, Petras S, Poullias X, Mouraef Y, Caillat Vigneron N. Low dose 123I-FP-CIT (DaTSCAN) SPECT-CT: Same diagnostic value, less radiation exposure and improved cost/effectiveness. <i>Medecine Nucleaire</i> . 2011;35(5):291.	9
221	Farid K, Queneau M, Guernou M, Lussato D, Poullias X, Petras S, et al. First Experience DaTSCAN Imaging Using Cadmium-Zinc-Telluride Gamma Camera SPECT. <i>Clinical Nuclear Medicine</i> . 2012;37(8):e211-e2.	6
222	Fasano A, Baldari S, Di Giuda D, Paratore R, Piano C, Bentivoglio AR, et al. Nigro-striatal involvement in primary progressive freezing gait: Insights into a heterogeneous pathogenesis. <i>Parkinsonism and Related Disorders</i> . 2012;18(5):578-84.	4
223	Fasano A, Baldari S, Di Giuda D, Paratore R, Piano C, Bentivoglio AR, et al. Heterogeneous pathogenesis of primary progressive freezing gait: Insights from imaging of the dopamine transporter. <i>Movement Disorders</i> . 2012;1):S249.	9
224	Fayolle H, Gantet P, Salabert AS, Delrieu J, Brefel-Courbon C, Ory-Magne F, et al. A longitudinal follow-up study of the quantification of dopamine transporters with 123I-Ioflupane (DaTscan). <i>Medecine Nucleaire</i> . 2017;41(1):36-41.	9
225	Fazio L, Blasi G, Taurisano P, Papazacharias A, Romano R, Gelao B, et al. D2 receptor genotype and striatal dopamine signaling predict motor cortical activity and behavior in humans. <i>NeuroImage</i> . 2011;54(4):2915-21.	9
226	Fekete R, Li J. Clinical differentiation of essential tremor and Parkinson's disease. <i>Clinical Medicine Insights: Case Reports</i> . 2013;6:67-74.	6
227	Felix S, Thobois S, Peter-Derex L. Rapid eye movement sleep behaviour disorder symptomatic of a brain stem cavernoma. <i>Journal of Sleep Research</i> . 2016;25(2):211-5.	9
228	Fernandez Bonfante J, Pagano G, Politis M. Neuroimaging studies in familial forms of Parkinson's disease: A systematic review. <i>Movement Disorders</i> . 2017;32(Supplement 2):680.	9
229	Fernandez RC, Sibley-Allen C, Livieratos L, Gnanasegaran G, O'Doherty M. Effect of resolution recovery on quantification and clinical reporting of 123I FP-CIT brain SPECT images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2):S264-S5.	4

230	Filippi L, Bruni C, Padovano F, Schillaci O, Simonetti G. The value of semi-quantitative analysis of 123I-FP-CIT SPECT in evaluating patients with parkinson's disease. <i>Neuroradiology Journal</i> . 2008;21(4):505-9.	10
231	Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. <i>Nuclear Medicine Communications</i> . 2005;26(5):421-6.	10
232	Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, et al. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: A SPECT semiquantitative study. <i>Nuclear Medicine Communications</i> . 2006;27(4):381-6.	10
233	Florian D, Schreiner S, Lobsien E, Plotkin M, Kupsch A, Schreiber S. Hyperechogenicity of the substantia nigra (SN) in idiopathic parkinson's disease (IPS) does not correlate with dopaminergic degeneration as shown by I123-FP-CIT SPECT. <i>Cerebrovascular Diseases</i> . 2010;1):26.	10
234	Frantellizzi V, Ullo M, Follacchio GA, Pontico M, Ricci M, Sollaku S, et al. Use of 123I-MIBG SPECT in association with 123I-FP-CIT in patients with Early Parkinson's Disease: A new point of view. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(1 Supplement 1):S633.	4
235	Frings L, Heimbach B, Meyer PT, Hellwig S, Hornberger M. Intrinsic Alertness Is Impaired in Patients with Nigrostriatal Degeneration: A Prospective Study with Reference to [123I]FP-CIT SPECT and [18F]FDG PET. <i>Journal of Alzheimer's Disease</i> . 2020;78(4):1721-9.	10
236	Frings L, Henninger F, Treppner M, Kober G, Boeker M, Hellwig S, et al. [123I] FP-CIT SPECT in Clinically Uncertain Parkinsonism Predicts Survival: A Data-Driven Analysis. <i>Journal of Parkinson's Disease</i> . 2020;10(4):1457-65.	10
237	Frosini D, Ceravolo R, Kiferle L, Giuntini M, De Feo P, Unti E, et al. Affective symptoms in de novo Parkinson's disease patients: Relationship with dopaminergic dysfunction. <i>European Journal of Neurology</i> . 2012;19(SUPPL.1):662.	4
238	Frosini D, Cosottini M, Donatelli G, Costagli M, Biagi L, Pacchetti C, et al. Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> . 2017;43:105-9.	9
239	Frosini D, Cosottini M, Volterrani D, Ceravolo R. Neuroimaging in Parkinson's disease: Focus on substantia nigra and nigro-striatal projection. <i>Current Opinion in Neurology</i> . 2017;30(4):416-26.	2
240	Frosini D, Kiferle L, Del Prete E, Vanelli F, Volterrani D, Bonuccelli U, et al. Relationship between nigro-striatal dopaminergic dysfunction and affective symptoms in de novo Parkinson's disease. <i>Journal of Neurology</i> . 2012;1):S90-S1.	4
241	Frosini D, Mazzucchi S, Volterrani D, Bonuccelli U, Ceravolo R. The globus pallidus dopaminergic denervation in different clinical phenotypes of Parkinson's disease: Evidence from a 123I FP-CIT SPECT study. [Italian]. <i>Confinia Cephalalgica</i> . 2012;21(1).	3
242	Frosini D, Poletti M, Pagni C, Rossi C, Lucetti C, Volterrani D, et al. Striatal dopamine denervation and cognitive performance: Evidence from a SPECT and clinical study in early never-treated Parkinson's disease patients. <i>Movement Disorders</i> . 2011;2):S241-S2.	4
243	Frosini D, Unti E, Del Gamba C, Fiasconaro E, Bonuccelli U, Volterrani D, et al. Mesocortical dopaminergic dysfunction in Parkinson's disease-depression: Evidence from a 123I-FP-CIT SPECT investigation. <i>Journal of the Neurological Sciences</i> . 2013;1):e73.	4
244	Frosini D, Unti E, Guidoccio F, Del Gamba C, Puccini G, Volterrani D, et al. Mesolimbic dopaminergic dysfunction in Parkinson's disease depression: evidence from a 123I-FP-CIT SPECT investigation. <i>Journal of Neural Transmission</i> . 2015;122(8):1143-7.	9
245	Frosini D, Unti E, Pagni C, Giuntini M, Del Prete E, Volterrani D, et al. Molecular imaging and psychometric predictors of cognitive outcome in Parkinson's disease: Evidences from a 5-year follow-up study. <i>European Journal of Neurology</i> . 2015;1):145.	9
246	Fujishiro H, Okuda M, Torii Y, Iritani S, Ozaki N. Dopamine transporter imaging in middle-aged and older patients with psychiatric disorders. <i>American Journal of Neurodegenerative Diseases</i> . 2015;1):117.	9
247	Funke E, Kupsch A, Buchert R, Brenner W, Plotkin M. Impact of subcortical white matter lesions on dopamine transporter SPECT. <i>Journal of Neural Transmission</i> . 2013;120(7):1053-60.	9
248	Funke E, Kupsch A, Klostermann F, Buchert R, Steffen IG, Brenner W, et al. DAT-SPECT in patients with parkinsonism and SAE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2):S328-S9.	4
249	Gaeta C, Meniconi M, Giovannini E, Carabelli E, Del Sette M, Ciarmiello A. Comparing attenuation correction methods for semiquantitative evaluation of 123I FP CIT SPECT studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S628.	4
250	Gaeta MC, Giovannini E, Carabelli E, Schirinzi E, Del Sette M, Ciarmiello A. CT-based attenuation correction compared to Chang's method for semiquantitative evaluation of 123I-FP-CIT SPECT studies. <i>Clinical and Translational Imaging</i> . 2015;1):S87.	4

251	Gamez J, De Fabregues O, Lorenzo-Bosquet C, Cuberas- Borros G, Salvado M, Carmona F, et al. Progressive degeneration of nigrostriatal pathway in Huntington's disease. A 123I-FP-CIT SPECT three-year follow-up study. <i>Movement Disorders</i> . 2015;1):S532.	4
252	Gamez J, Lorenzo-Bosquet C, Cuberas-Borros G, Carmona F, Hernandez-Vara J, Castillo J, et al. Does reduced [123I]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement? <i>Clinical Neurology and Neurosurgery</i> . 2010;112(10):870-5.	10
253	Gamez J, Lorenzo-Bosquet CC, Cuberas-Borros G, Carmona F, Hernandez-Vara J, Castillo J, et al. [123I]-FP-CIT/SPECT for evaluating dopamine presynaptic terminal involvement in Huntington's disease: A pilot study. <i>Movement Disorders</i> . 2010;2):S272.	4
254	Gan J, Xie-Brustolin J, Gervais-Bernard H, Vallet AE, Broussolle E, Thobois S. Possible Parkinson's disease revealed by a pure head resting tremor. <i>Journal of the Neurological Sciences</i> . 2009;279(1-2):121-3.	6
255	Garcia Solis D, Benitez Rivero S, Garcia Gomez FJ, Marin VA, Huertas I, Jesus S, et al. Clinical usefulness of 123I-FP-CIT SPECT imaging in vascular parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2):S434.	4
256	Garea-Rodriguez E, Eesmaa A, Lindholm P, Schlumbohm C, Konig J, Meller B, et al. Comparative Analysis of the Effects of Neurotrophic Factors CDFN and GDNF in a Nonhuman Primate Model of Parkinson's Disease. <i>PLoS ONE</i> . 2016;11(2) (no pagination)(e0149776).	1
257	Garea-Rodriguez E, Schlumbohm C, Czeh B, Konig J, Helms G, Heckmann C, et al. Visualizing dopamine transporter integrity with iodine-123-FP-CIT SPECT in combination with high resolution MRI in the brain of the common marmoset monkey. <i>Journal of Neuroscience Methods</i> . 2012;210(2):195-201.	1
258	Garriga M, Mila M, Mir M, Al-Baradie R, Huertas S, Castejon C, et al. 123I-FP-CIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component. <i>Frontiers in Systems Neuroscience</i> . 2015;9(July) (no pagination)(99).	10
259	Geisler S, Beindorff N, Cremer M, Hoffmann K, Brenner W, Cumming P, et al. Characterization of [123I]FP-CIT binding to the dopamine transporter in the striatum of tree shrews by quantitative in vitro autoradiography. <i>Synapse</i> . 2015;69(10):497-504.	10
260	Gencturk M, Froelich J, Salavati A, Bhattacharya M. Extrastriatal I123-FP-CIT uptake in brain: Is it constant? <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2018;59(Supplement 1).	9
261	Georgiopoulos C, Davidsson A, Engstrom M, Larsson EM, Zachrisson H, Dizdar N. The diagnostic value of dopamine transporter imaging and olfactory testing in patients with parkinsonian syndromes. <i>Journal of Neurology</i> . 2015;262(9):2154-63.	7
262	Geraci I, Paschetta C, Skanjeti A, Buttari F, Angusti T, Castellano G, et al. Post-processing of SPECT images for semi-quantitative multicentric analysis. <i>Clinical and Translational Imaging</i> . 2015;1):S47.	4
263	Gerasimou G, Costa DC, Papanastasiou E, Bostanjiopoulou S, Arnaoutoglou M, Moralidis E, et al. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson's disease? <i>Annals of Nuclear Medicine</i> . 2012;26(4):337-44.	7
264	Gerasimou G, Papanastasiou E, Moralidis E, Katsarou Z, Ioannidis P, Arnaoutoglou M, et al. The significance of the posterior part of the putamen in I-123-FP-CIT SPECT scanning and the early diagnosis of Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S572.	4
265	Gerasimou GP, Aggelopoulou TC, Costa DC, Gotzamani-Psarrakou A. Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders. <i>Nuclear Medicine Review</i> . 2006;9(2):147-53.	2
266	Gigante AF, Asabella AN, Iliceto G, Martino T, Ferrari C, Defazio G, et al. Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson's disease. <i>Neurological Sciences</i> . 2018;39(3):551-5.	9
267	Gigante AF, Defazio G, Niccoli Asabella A, Superbo M, Ferrari C, Liuzzi D, et al. Smoking in Patients with Parkinson's Disease: preliminary striatal DaT-SPECT findings. <i>Acta Neurologica Scandinavica</i> . 2016;134(4):265-70.	9
268	Gil S, Lomena F, Llado A, Montagut N, Castellvi M, Bosch B, et al. Evaluation of the nigrostriatal pathway in progressive nonfluent aphasia. <i>Dementia and Geriatric Cognitive Disorders</i> . 2012;1):205-6.	9
269	Gil-Navarro S, Lomena F, Cot A, Llado A, Montagut N, Castellvi M, et al. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia. <i>European Journal of Neurology</i> . 2013;20(11):1459-e126.	9
270	Giordano B, Pagano G, Hood J, Ferrara N, Politis M. Hypertension and Parkinson's disease. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):489.	9
271	Goethals I, Dobbela A, Ham H, Santens P, D'Asseler Y. Validation of a resolution-independent method for the quantification of 123I-FP-CIT SPECT scans. <i>Nuclear Medicine Communications</i> . 2007;28(10):771-4.	9

272	Goethals I, Ham H, Dobbeleir A, Santens P, D'Asseler Y. The potential value of a pictorial atlas for aid in the visual diagnosis of 123I FP-CIT SPECT scans. <i>NuklearMedizin</i> . 2009;48(4):173-8.	10
273	Gontu V, Birchall J, Bajaj N. 123I-/V-cu-fluoro-propyl-2beta-carbomethoxy-3beta-(4-iodophenyl) nortropane ([123I] FP-CIT) SPECT in cases of multiple system atrophy. <i>Parkinsonism and Related Disorders</i> . 2009;15(SUPPL 2):S57.	9
274	Greco A, Zannetti A, Coda AR, Albanese S, Nardelli A, Roca A, et al. Effects of thyroid blockade on brain imaging of dopamine transporter in normal mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;2:S448-S9.	4
275	Greco A, Zannetti A, Pappata S, Albanese S, Coda AR, Ragucci M, et al. Measurement of [123I]FP-CIT binding to the dopamine transporter (DAT) in healthy mouse striatum using dedicated small animal SPECT imaging: Feasibility, optimization and validation. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> . 2018;62(1):112-7.	1
276	Greenbaum L, Lorberboym M, Melamed E, Rigbi A, Barhum Y, Kohn Y, et al. Perspective: Identification of genetic variants associated with dopaminergic compensatory mechanisms in early Parkinson's disease. <i>Frontiers in Neuroscience</i> . 2013;(7 APR) (no pagination)(Article 52).	9
277	Greenbaum L, Lorberboym M, Melamed E, Rigbi A, Khlebtovsky A, Barhum Y, et al. Association of TH Val81Met polymorphism with Parkinson's disease severity: Preliminary results and implacability for endogenous compensatory mechanisms. <i>Movement Disorders</i> . 2011;2:S124.	4
278	Greenbaum L, Smith RC, Lorberboym M, Alkelai A, Zozulinsky P, Lifshytz T, et al. Association of the ZFP2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. <i>Psychopharmacology</i> . 2012;220(3):519-28.	10
279	Grosset DG, Tatsch K, Oertel WH, Tolosa E, Bajaj N, Kupsch A, et al. Safety analysis of 10 clinical trials and for 13 years after first approval of ioflupane 123I injection (datscan). <i>Journal of Nuclear Medicine</i> . 2014;55(8):1281-7.	10
280	Guidoccio F, Ceravolo R, Frosini D, Puccini G, Bonuccelli U, Pagliani I, et al. Relationship between freezing of gait and falls in Parkinson's disease and dopaminergic dysfunction. <i>Clinical and Translational Imaging</i> . 2015;1:S88.	4
281	Guidoccio F, Ceravolo R, Puccini G, Frosini D, Manca G, Bonuccelli U, et al. Correlation among freezing of gait, falls and dopaminergic dysfunction in Parkinson's disease: Evidences of a five years follow-up. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1:S570.	4
282	Haanpaa J, Loimaala A. Performance of semi quantitative 123I-FP-CIT parameters in Parkinson's Disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;2:S343.	4
283	Haaxma CA, Bloem BR, Borm GF, Oyen WJG, Leenders KL, Eshuis S, et al. Gender differences in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2007;78(8):819-24.	9
284	Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. <i>Movement Disorders</i> . 2007;22(6):839-42.	9
285	Hall DA, Jennings D, Seibyl J, Tassone F, Marek K. FMR1 gene expansion may be associated with dat/spect SWEDD in parkinsonism patients. <i>Movement Disorders</i> . 2010;2:S484-S5.	4
286	Hannestad J, Seibyl J, Marek K, Laruelle M, Gunn R. Different rates of dopamine transporter loss in parkinson's disease as measured with [123I]beta-cit and [123I]FP-CIT SPECT. <i>Journal of Cerebral Blood Flow and Metabolism</i> . 2016;36(Supplement 1):186-7.	4
287	Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, et al. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. <i>Brain</i> . 2016;139(7):2039-49.	10
288	Happe S, Baier PC, Helmschmied K, Meller J, Tatsch K, Paulus W. Association of daytime sleepiness with nigrostriatal dopaminergic degeneration in early Parkinson's disease. <i>Journal of Neurology</i> . 2007;254(8):1037-43.	9
289	Happe S, Tings T, Koch W, Welsch J, Helmschmied K, Baier PC, et al. Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> . 2007;114(5):589-94.	9
290	Hara T, Takeda Y, Zhou X, Matsusako M, Tanaka Y, Katafuchi T, et al. SPECT/CT and MR image registration for 123I-FP-CIT imaging. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2016;57(SUPPL. 2).	9
291	Hauser RA, Grosset DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. <i>Journal of Neuroimaging</i> . 2012;22(3):225-30.	10
292	Hauser RA, Grosset DG. [123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. <i>Journal of neuroimaging : official journal of the American Society of Neuroimaging</i> . 2012;22(3):225-30.	9
293	Hayashi T, Mishina M, Masanori S, Genki M, Abe A, Kimura K. An effect of brain atrophy in quantitative analysis of 123I-ioflupane SPECT. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):256-7.	4

294	Hayashi T, Mishina M, Sakamaki M, Sakamoto Y, Suda S, Kimura K. Effect of brain atrophy in quantitative analysis of 123I-ioflupane SPECT. <i>Annals of Nuclear Medicine</i> . 2019;33(8):579-85.	9
295	Hayashi T, Nakayama S, Motoi Y, Hattori N. Regional cerebral blood flow spect of dementia with lewy bodies without parkinsonism using dopamine transporter imaging. <i>Alzheimer's and Dementia</i> . 2015;1:P877-P8.	9
296	Heckmann JG, Platsch G, Elstner S, Lang C, Neundorfer B. Painful upper limb stiffness as symptom of early Parkinson's disease. [German]. <i>Zeitschrift fur Allgemeinmedizin</i> . 2003;79(7):358-61.	3
297	Heinzel A, Buchert R, Lange C, Dafotakis M, Mottaghy FM, Winz OH. Semi-quantitative analysis of I-123-FP-CIT-SPECT: Comparison of two fully automated tools with manual analysis. <i>NuklearMedizin</i> . 2016;55(2):A81.	4
298	Helmich RC, Janssen MJR, Oyen WJG, Bloem BR, Toni I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. <i>Annals of Neurology</i> . 2011;69(2):269-81.	9
299	Hemelhoet DM, Vanlander AV, Smet J, Vantroys E, Acou M, Goethals I, et al. Leigh syndrome followed by parkinsonism in an adult with homozygous c.626C>T mutation in MTFMT. <i>Neurology: Genetics</i> . 2018;4(6) (no pagination)(e298).	6
300	Hermann W, Hesse S, Sabri O, Wagner A. Influence of Repetitive Transcranial Magnetic Stimulation (rTMS) on motor disturbances in patients with Parkinson's disease and Wilson's disease. [German]. <i>Klinische Neurophysiologie</i> . 2007;38(3):169-78.	3
301	Hernandez Vara J, del Fuego MR, Lorenzo Bosquet C, Castell Conesa J, Molina Cateriano CA, Miquel Rodriguez F. Usefulness of transcranial sonography in Parkinson's disease. A comparative study using 123I-FP-CIT SPECT. [Spanish]. <i>Medicina Clinica</i> . 2008;131(8):285-9.	3
302	Hernandez-Vara J, Lorenzo-Bosquet C, Cuberas-Borros G, De Fabregues-Boixar O, Palasi-Franco A, Barios-Profitos M, et al. Can 123I-FP-CIT SPECT detect preclinical nigrostriatal deficit in "de novo" Parkinson's disease patients. <i>Movement Disorders</i> . 2010;2):S382.	4
303	Hernandez-Vara J, Saez-Francas N, Lorenzo-Bosquet C, Corominas-Roso M, Cuberas-Borros G, Lucas-Del Pozo S, et al. BDNF levels and nigrostriatal degeneration in "drug naive" Parkinson's disease patients. An "in vivo" study using I-123-FP-CIT SPECT. <i>Parkinsonism and Related Disorders</i> . 2020;78:31-5.	9
304	Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinson's disease patients with or without depression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2009;36(3):428-35.	9
305	Hesse S, Strecker K, Winkler D, Luthardt J, Scherfler C, Reupert A, et al. Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up. <i>Journal of Neurology</i> . 2008;255(7):1059-66.	9
306	Hickey PT, Kuchibhatla M, Scott BL, Gauger L, Stacy MA. Assessment of outcomes in Parkinson's disease subjects randomized to SPECT imaging of the dopamine transporter. <i>Movement Disorders</i> . 2015;1):S381-S2.	4
307	Hida K, Nonokuma M, Kuwabara Y, Tani T, Takano K, Yoshimitsu K. Creation and validation of an I-123 FP-CIT template for statistical image analysis using high-resolution SPECT for parkinsonian patients. <i>Annals of Nuclear Medicine</i> . 2016;30(7):477-83.	9
308	Hirata K, Hattori T, Chen Q, Ohara M, Kina S, Yokota T. Striatal dopamine depletion correlates with variability of stride length in Parkinson's disease. <i>Clinical Neurology</i> . 2019;59(Supplement 1):S413.	9
309	Hjermind LE, Johannsen LG, Blau N, Wevers RA, Lucking CB, Hertz JM, et al. Dopa-responsive dystonia and early-onset Parkinson's disease in a patient with GTP cyclohydrolase I deficiency? <i>Movement Disorders</i> . 2006;21(5):679-82.	9
310	Hoglinger GU, Rissling I, Metz A, Ries V, Heinermann A, Prinz H, et al. Enhancing recognition of early Parkinsonism in the community. <i>Movement Disorders</i> . 2004;19(5):505-12.	9
311	Honkanen E, Kempainen N, Nojonen T, Seppanen M, Joutsa J, Kaasinen V. Bupropion causing misdiagnosis in brain dopamine transporter imaging for parkinsonism. <i>Movement Disorders</i> . 2018;33(Supplement 2):S650-S1.	4
312	Honkanen EA, Eklund M, Nuuttila S, Nojonen T, Jaakkola E, Makinen E, et al. Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials. <i>NeuroImage: Clinical</i> . 2021;32 (no pagination)(102807).	9
313	Honkanen EA, Kempainen N, Nojonen T, Seppanen M, Joutsa J, Kaasinen V. Bupropion Causes Misdiagnosis in Brain Dopamine Transporter Imaging for Parkinsonism. <i>Clinical Neuropharmacology</i> . 2019;42(5):181-3.	9
314	Honkanen EA, Nojonen T, Hirvilampi R, Lindholm K, Parkkola R, Joutsa J, et al. Sex correction improves the accuracy of clinical dopamine transporter imaging. <i>EJNMMI Research</i> . 2021;11(1) (no pagination)(82).	9
315	Horimoto Y, Hayashi E, Ito Y, Iida A, Hibino H, Inagaki A, et al. Dopaminergic performances in patients with parkinsonism-a combination study of dopamine transporter SPECT, dopamine synthesis and receptor pet. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):257.	4

316	Huang J, Hussain S, Vijayakumar V, Goel S, Auchus A. The utility of dopamine transporter imaging in clinically uncertain parkinsonian syndrome: Experience from general neurology practice. Movement Disorders Conference: 1st Pan American Parkinson's Disease and Movement Disorders Congress Miami, FL United States. 2017;32(Supplement 1).	4
317	Huang J, Vijayakumar V, Auchus A. The clinical utility of [123I]-FP-CIT SPECT in tremor type versus non-tremor type clinically uncertain Parkinsonian syndrome. Journal of the Neurological Sciences. 2015;1):e55.	4
318	Hubbich M, Farmakis G, Schaefer A, Behnke S, Schneider S, Hellwig D, et al. FP-CIT SPECT does not predict the progression of motor symptoms in Parkinson's disease. European Neurology. 2011;65(4):187-92.	9
319	Huertas-Fernandez I, Garcia-Gomez FJ, Garcia-Solis D, Benitez-Rivero S, Marin-Oyaga VA, Jesus S, et al. Machine learning models for the differential diagnosis of vascular parkinsonism and Parkinson's disease using [123I]FP-CIT SPECT. European Journal of Nuclear Medicine and Molecular Imaging. 2015;42(1):112-9.	10
320	Huertas-Fernandez I, Jesus S, Gomez-Garre P, Garcia-Gomez FJ, Bernal-Bernal I, Bonilla-Toribio M, et al. GBA variations accelerate degeneration of the nigrostriatal pathway in Parkinson's disease: An [123I]FP-CIT study. Movement Disorders. 2015;1):S10.	9
321	Iacozzi M, Piccardo A, Puntoni M, Morbelli S, Marinelli L, Abruzzese G, et al. Direct correlation between cardiac and striatal 18F-DOPA uptake in de novo Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging. 2012;2):S183-S4.	4
322	Ichinose Y, Ishiura H, Tanaka M, Umeda T, Yamauchi H, Tsuchiya M, et al. Dopamine transporter imaging and glucocerebrosidase activity in Parkinson's disease patients with a heterozygous gross deletion mutation in GBA in a Japanese family. Journal of the Neurological Sciences. 2017;381(Supplement 1):97.	9
323	Ichinose Y, Ishiura H, Tanaka M, Yoshimura J, Doi K, Umeda T, et al. Neuroimaging, genetic, and enzymatic study in a Japanese family with a GBA gross deletion. Parkinsonism and Related Disorders. 2019;61:57-63.	9
324	Ikawa M, Okazawa H, Neishi H, Kitazaki Y, Tsujikawa T, Kikuta K, et al. Dopaminergic neuronal oxidative stress is increased with disease progression in patients with parkinson's disease: A study with pet and spect. Neurology Conference: 69th American Academy of Neurology Annual Meeting, AAN. 2017;88(16 Supplement 1).	9
325	Ikawa M, Okazawa H, Neishi H, Tsujikawa T, Kikuta K, Nakamoto Y, et al. Dopaminergic neuronal oxidative stress is increased with disease severity in patients with Parkinson's disease: A study with PET and SPECT. Journal of Cerebral Blood Flow and Metabolism. 2017;37(1 Supplement 1):230-1.	9
326	Illan IA, Gorrz JM, Ramirez J, Segovia F, Jimenez-Hoyuela JM, Ortega Lozano SJ. Automatic assistance to Parkinson's disease diagnosis in DaTSCAN SPECT imaging. Medical physics. 2012;39(10):5971-80.	9
327	Im HJ, Ha S, Choi H, Park HR, Park KW, Lee DS, et al. Association of Parkinson's Disease Symptom Laterality and 123I-FP-CIT SPECT after Deep Brain Stimulation. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2018;59(Supplement 1).	9
328	Infante J, Sierra M, Martinez-Rodriguez I, Sanchjez-Juan P, Gonz Alez-Aramburu I, Jimenez-Alonso M, et al. Progression to Parkinson's disease in carriers of LRRK2 G2019S mutation: A 4-year prospective study with serial dopamine transporter imaging. Movement Disorders. 2017;32(12):e12.	10
329	Infante J, Sierra M, Martinez-Rodriguez I, Sanchjez-Juan P, Gonzalez-Aramburu I, Jimenez-Alonso M, et al. Progression to Parkinson's disease in carriers of LRRK2 G2019S mutation: A 4-year prospective study with serial dopamine transporter imaging. Movement Disorders. 2017;32(Supplement 2):687-8.	9
330	Inui Y, Kato T, Fukaya N, Ito K. Assessment of pre-synaptic dopaminergic degeneration and occipital hypoperfusion in patients with probable dementiawith lewy bodies using 123I-FP-CIT and 123I-IMP spect. Alzheimer's and Dementia. 2015;1):P410.	9
331	Inukai A, Sakakibara S, Hashimoto R, Katayama T, Kenjo M, Yokokawa Y, et al. A useful marker (change of MDS-UPDRS part 2 score) of underlying pathophysiological progression assessed with [123I]FP-CIT SPECT in patients with Parkinson's disease. Journal of the Neurological Sciences. 2017;381(Supplement 1):351.	9
332	Iranzo A, Lomena F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study. The Lancet Neurology. 2010;9(11):1070-7.	10
333	Iranzo A, Santamaria J, Valldeoriola F, Serradell M, Salamero M, Gaig C, et al. Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. Annals of Neurology. 2017;82(3):419-28.	9
334	Iranzo A, Valldeoriola F, Lomena F, Molinuevo JL, Serradell M, Salamero M, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: A prospective study. The Lancet Neurology. 2011;10(9):797-805.	9
335	Isaias IU, Benti R, Cilia R, Canesi M, Marotta G, Gerundini P, et al. [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. NeuroReport. 2007;18(14):1499-502.	10
336	Isaias IU, Marotta G, Pezzoli G, Sabri O, Hesse S. [123I]FP-CIT SPECT in atypical degenerative parkinsonism. Imaging in Medicine. 2012;4(4):411-21.	2

337	Isaias IU, Marzegan A, Marotta G, Frigo C, Pezzoli G, Cavallari P. Dopaminergic striatal innervation loss predicts arm swing at steady-state linear walking in subjects with Parkinson disease. <i>Gait and Posture</i> . 2012;1):S12-S3.	4
338	Isaias IU, Marzegan A, Pezzoli G, Marotta G, Canesi M, Biella GEM, et al. A role for locus coeruleus in Parkinson tremor. <i>Frontiers in Human Neuroscience</i> . 2012(JANUARY 2012):1-7.	10
339	Isaias IU, Trujillo P, Summers P, Marotta G, Mainardi L, Pezzoli G, et al. Neuromelanin imaging and dopaminergic loss in parkinson's disease. <i>Frontiers in Aging Neuroscience</i> . 2016;8(AUG) (no pagination)(196).	7
340	Isaias IU, Turco F, Rosanova M, Marotta G, Frazzitta G, Landi C, et al. Cortical excitability changes induced by L-dopa mirror the unbalanced nigro-striatal denervation in Parkinson's disease. <i>Movement Disorders</i> . 2015;1):S10-S1.	9
341	Isaias IU, Volkmann J, Marzegan A, Marotta G, Cavallari P, Pezzoli G. The Influence of Dopaminergic Striatal Innervation on Upper Limb Locomotor Synergies. <i>PLoS ONE</i> . 2012;7(12) (no pagination)(e51464).	9
342	Ishii T, Taniguchi K, Hamano T, Tachibana N. Relation between disease duration and striatal dat-spect uptake in patients with idiopathic rem sleep behaviour disorder. <i>Sleep Medicine</i> . 2017;40(Supplement 1):e143.	9
343	Ishii T, Taniguchi K, Hamano T, Tachibana N. Alteration of two imaging biomarkers along with the progression of idiopathic RBD: Mibg myocardial scintigraphy and dat-spect study. <i>Sleep</i> . 2018;41(Supplement 1):A252.	9
344	Iwabuchi Y, Kameyama M, Matsusaka Y, Narimatsu H, Hashimoto M, Seki M, et al. A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2021;48(6):1833-41.	9
345	Iwabuchi Y, Nakahara T, Kameyama M, Matsusaka Y, Minami Y, Ito D, et al. Impact of the cerebrospinal fluid-mask algorithm on the diagnostic performance of 123I-Ioflupane SPECT: an investigation of parkinsonian syndromes. <i>EJNMMI Research</i> . 2019;9(1) (no pagination)(85).	9
346	Iwabuchi Y, Nakahara T, Kameyama M, Yamada Y, Hashimoto M, Matsusaka Y, et al. Impact of a combination of quantitative indices representing uptake intensity, shape, and asymmetry in DAT SPECT using machine learning: comparison of different volume of interest settings. <i>EJNMMI Research</i> . 2019;9 (no pagination)(7).	8
347	Iwabuchi Y, Nakahara T, Kameyama M, Yamada Y, Hashimoto M, Ogata Y, et al. Quantitative evaluation of the tracer distribution in dopamine transporter SPECT for objective interpretation. <i>Annals of Nuclear Medicine</i> . 2018;32(5):363-71.	7
348	Jaakkola E, Joutsa J, Kaasinen V. Predictors of normal and abnormal outcome in clinical brain dopamine transporter imaging. <i>Journal of Neural Transmission</i> . 2016;123(3):205-9.	9
349	Jaakkola E, Joutsa J, Makinen E, Johansson J, Kaasinen V. Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease. <i>European Journal of Neurology</i> . 2017;24(11):1341-7.	9
350	Jaakkola E, Joutsa J, Makinen E, Johansson J, Kaasinen V. Ventral striatal dopaminergic defect is a risk factor for hallucinations in Parkinson's disease. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):93.	9
351	Jaakkola E, Joutsa J, Makinen E, Nojonen T, Pitkonen M, Levo R, et al. No differences in the total burden of non-motor symptoms between Parkinson's disease and non-degenerative parkinsonism. <i>Movement Disorders</i> . 2018;33(Supplement 2):S752.	4
352	Jaakkola E, Joutsa J, Makinen E, Nojonen T, Pitkonen M, Levo R, et al. Burden of non-motor symptoms in unclear parkinsonism and tremor: A study with [123I]FP-CIT SPECT. <i>Journal of the Neurological Sciences</i> . 2019;404:124-7.	9
353	Jackson L, Turcano P, Stitt D, Coon E, Savica R. Autonomic Testing Profiles in Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> . 2020;10(3):945-9.	9
354	Jakobson Mo S, Axelsson J, Jonasson L, Larsson A, Ogren MJ, Ogren M, et al. Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT-a clinical comparison. <i>EJNMMI Research</i> . 2018;8 (no pagination)(100).	7
355	Jakobson Mo S, Larsson A, Linder J, Birgander R, Edenbrandt L, Stenlund H, et al. 123I-FP-Cit and 123I-IBZM SPECT uptake in a prospective normal material analysed with two different semiquantitative image evaluation tools. <i>Nuclear Medicine Communications</i> . 2013;34(10):978-89.	10
356	Jakobson Mo S, Linder J, Forsgren L, Holmberg H, Larsson A, Riklund K. Pre- and postsynaptic dopamine SPECT in idiopathic parkinsonian diseases: A follow-up study. <i>BioMed Research International</i> . 2013;2013 (no pagination)(143532).	9
357	Jakobson Mo S, Linder J, Forsgren L, Riklund K. Accuracy of Visual Assessment of Dopamine Transporter Imaging in Early Parkinsonism. <i>Movement Disorders Clinical Practice</i> . 2015;2(1):17-23.	7
358	Jaukovic L, Ilic TV, Dopudja M, Ajdinovic B. 123I-FP-CIT brain spect (DaTSCAN) imaging in the diagnosis of patients with movement disorders - first results. <i>Vojnosanitetski Pregled</i> . 2012;69(2):157-62.	7

359	Jennings E, O'Sullivan F, O'Malley G, Crotty J, Peters C, O'Connor M, et al. What's Up with dat? Does striatal dopamine transporter imaging add anything to the clinical picture? <i>Irish Journal of Medical Science</i> . 2013;6):S254-S5.	4
360	Jeong EH, Sunwoo MK, Song YS. Serial I-123-FP-CIT SPECT Image Findings of Parkinson's Disease Patients With Levodopa-Induced Dyskinesia. <i>Frontiers in Neurology</i> . 2018;9 (no pagination)(1133).	9
361	Jesus S, Caceres M, Suarez A, Franco E, Gil-Neciga E, Mir P. Corticobasal syndrome in patients with previous stroke: Description of four cases. <i>Journal of Neurology</i> . 2012;1):S93.	9
362	Johnsen K, Cromarty R, Johannesson GH, Johannsson M, Taylor JP. Validation of the sigla indices in an independent cohort: A new way forward for the differential diagnosis of dementias? <i>Alzheimer's and Dementia</i> . 2014;4):P350-P1.	8
363	Joling M, Van Den Heuvel OA, Berendse HW, Booij J, Vriend C. Serotonin transporter binding and anxiety symptoms in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2018;89(1):89-94.	9
364	Joling M, Vriend C, Rajmakers PGHM, van der Zande JJ, Lemstra AW, Berendse HW, et al. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study. <i>NeuroImage: Clinical</i> . 2019;22 (no pagination)(101755).	9
365	Joling M, Vriend C, Van Den Heuvel OA, Rajmakers PGHM, Berendse HW, Booij J. The loss of extrastriatal as well as striatal [123I]FP-CIT Binding Is More Pronounced in MSA-P and PSP than in parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(1 Supplement 1):S632.	4
366	Joling M, Vriend C, Van Den Heuvel OA, Rajmakers PGHM, Jones PA, Berendse HW, et al. Analysis of extrastriatal 123I-FP-CIT binding contributes to the differential diagnosis of parkinsonian diseases. <i>Journal of Nuclear Medicine</i> . 2017;58(7):1117-23.	9
367	Joling M, Vriend C, van der Zande JJ, Lemstra AW, van den Heuvel OA, Booij J, et al. Lower 123I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies. <i>NeuroImage: Clinical</i> . 2018;19:130-6.	9
368	Joutsa J, Johansson J, Seppen M, Noponen T, Kaasinen V. Dorsal-to-ventral shift in midbrain dopaminergic projections and increased thalamic/raphe serotonergic function in early Parkinson disease. <i>Journal of Nuclear Medicine</i> . 2015;56(7):1036-41.	9
369	Jung Y, Jordan LG, Lowe VJ, Kantarci K, Parisi JE, Dickson DW, et al. Clinicopathological and 123I-FP-CIT SPECT correlations in patients with dementia. <i>Annals of Clinical and Translational Neurology</i> . 2018;5(3):376-81.	9
370	Kaasinen V. Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> . 2016;3(1):21-6.	9
371	Kaasinen V, Joutsa J, Noponen T, Johansson J, Seppanen M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease. <i>Neurobiology of Aging</i> . 2015;36(4):1757-63.	10
372	Kaasinen V, Joutsa J, Noponen T, Paivarinta M. Akinetic crisis in parkinson's disease is associated with a severe loss of striatal dopamine transporter function: A report of two cases. <i>Case Reports in Neurology</i> . 2014;6(3):275-80.	6
373	Kaasinen V, Kinos M, Joutsa J, Seppanen M, Noponen T. Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;41(10):1931-7.	9
374	Kahraman D, Eggers C, Holstein A, Schneider C, Pedrosa DJ, Dietlein M, et al. 123I-FP-CIT SPECT imaging of the dopaminergic state: Visual assessment of dopaminergic degeneration patterns reflects quantitative 2D operator-dependent and 3D operator-independent techniques. <i>NuklearMedizin</i> . 2012;51(6):244-51.	10
375	Kahraman D, Eggers C, Timmermann L, Schmidt M. Visual assessment of degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonism and Parkinson's disease. <i>Klinische Neurophysiologie Conference</i> . 2012;43(1).	4
376	Kajimoto Y, Yorozu S, Minamino M, Ito H. A comparison of striatal dopamine transporter function between dementia with lewy bodies and Parkinson disease with dementia. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):800.	9
377	Kanatani M, Adachi T, Sakata R, Nishimura Y, Saito Y, Maegaki Y, et al. Dravet syndrome with parkinsonian symptoms and intact dopaminergic neurons: A case report. <i>Brain and Development</i> . 2021;43(3):486-9.	6
378	Kanenawa T, Ota S, Takaki A, Ito S. Feasibility of an Iodine-123 FP-CIT striatal quantitative measurement method with a partial volume effect correction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2017;44(2 Supplement 1):S285.	9
379	Kanzaki T, Tetsuya H, Takahashi Y, Shimada H, Shrestha S, Suto T, et al. Can [123I] FP-CIT SPECT using the japanese normal database improve diagnostic accuracy of parkinson's disease? <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2018;45(Supplement 1):S768.	4
380	Kas A, Payoux P, Habert MO, Malek Z, Cointepas Y, El Fakhri G, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. <i>Journal of Nuclear Medicine</i> . 2007;48(9):1459-67.	8

381	Kasanuki K, Iseki E, Ota K, Kondo D, Ichimiya Y, Sato K, et al. 123I-FP-CIT SPECT findings and its clinical relevance in prodromal dementia with Lewy bodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2017;44(3):358-65.	9
382	Kasanuki K, Iseki E, Ota K, Kondo D, Suzuki M, Ichimiya Y, et al. Utility of 123I-FP-CIT SPECT for early diagnosis of dementia with lewy bodies: Correlation between 123I-FP-CIT SPECT findings and clinical symptoms. <i>American Journal of Neurodegenerative Diseases</i> . 2015;1:123.	9
383	Kashefi A. Differentiation between Parkinsonian syndromes and essential tremor, using 123I- Ioflupane SPECT. <i>Iranian Journal of Nuclear Medicine</i> . 2012;1:18-9.	4
384	Katzenschlager R, Costa D, Gacinovic S, Lees AJ. [123I]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia. <i>Neurology</i> . 2002;59(12):1974-6.	10
385	Katzenschlager R, Costa D, Gerschlager W, O'Sullivan J, Zijlmans J, Gacinovic S, et al. [123I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. <i>Annals of Neurology</i> . 2003;53(4):489-96.	10
386	Kawasaki H, Yamamoto T, Miyake A, Ikeda K, Mistuhuji T, Ito Y, et al. Sudden onset of parkinsonism in a case of dural arteriovenous fistula. <i>Movement Disorders</i> . 2017;32(Supplement 2):153.	6
387	Kemp PM. Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and Lewy body dementia. <i>Nuclear Medicine Communications</i> . 2005;26(2):87-96.	2
388	Kessler KR, Hamscho N, Morales B, Menzel C, Barrero F, Vives F, et al. Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome. <i>Journal of Neural Transmission</i> . 2005;112(10):1345-53.	9
389	Kiferle L, Ceravolo R, Giuntini M, Linsalata G, Puccini G, Volterrani D, et al. Caudate dopaminergic denervation and visual hallucinations: Evidence from a 123I-FP-CIT SPECT study. <i>Parkinsonism and Related Disorders</i> . 2014;20(7):761-5.	10
390	Kiferle L, Ceravolo R, Nicoletti V, De Feo P, Volterrani D, Bonuccelli U. Is the nigrostriatal dysfunction a possible predictive marker of visual hallucinations in Parkinson's disease? Evidence from a 123I-FP-CIT SPECT study. <i>European Journal of Neurology</i> . 2012;19(SUPPL.1):322.	9
391	Kiferle L, Frosini D, Volterrani D, Mazzucchi S, Bonuccelli U, Ceravolo R. Visual hallucinations in Parkinson's disease: Possible role of FP. <i>Journal of Neurology</i> . 2012;1:S92.	4
392	Kiferle L, Unti E, Volterrani D, Rossi C, Frosini D, Manca G, et al. Nigrostriatal function in Huntington's disease: Evidence from a SPECT study. <i>Movement Disorders</i> . 2010;25:S273.	4
393	Kim J, Kim JM, Kim YK, Shin JW, Choi SH, Kim SE, et al. Dopamine transporter SPECT of a liver cirrhotic with atypical parkinsonism. <i>Industrial Health</i> . 2007;45(3):497-500.	2
394	Kim J, Kim SE, Sung SY. Association of Cognitive impairments and striatal dopaminergic innervation in Multiple System Atrophy. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2017;58(Supplement 1).	9
395	Kim JM, Bae YJ, Kim KJ, Kim E, Park HS, Kang SY, et al. Loss of substantia nigra hyperintensity on 3 Tesla MRI in idiopathic REM sleep behavior disorder. <i>Clinical Neurology</i> . 2016;56(Supplement 1):S358.	4
396	Kim JM, Bae YJ, Song YS, Kim KJ, Kim SE, Jeon B. Three Tesla susceptibility-weighted MR imaging of parkinsonism and idiopathic REM sleep behavior disorder: Comparison with 123I-FPCIT SPECT. <i>Movement Disorders</i> . 2018;33(Supplement 2):S682.	4
397	Kim JM, Hong S, Gyoung PK, Yoon JC, Yu KK, Sung SP, et al. Importance of low-range CAG expansion and CAA interruption in SCA2 parkinsonism. <i>Archives of Neurology</i> . 2007;64(10):1510-8.	10
398	Kim JM, Jeong HJ, Bae YJ, Park SY, Kim E, Kang SY, et al. Loss of substantia nigra hyperintensity on 7 Tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> . 2016;26:47-54.	9
399	Kim JM, Kim JS, Jeong SH, Kim YK, Kim SE, Kim SH, et al. Dopaminergic neuronal integrity in parkinsonism associated with liver cirrhosis. <i>NeuroToxicology</i> . 2010;31(4):351-5.	9
400	Kim JS, Kim JM. Dopamine transporter imaging in drug-induced parkinsonism using [123I]-FP-CIT SPECT. <i>Movement Disorders</i> . 2011;26:S44.	9
401	Kim KJ, Bae YJ, Kim JM. The nigral hyperintensity on 3 Tesla susceptibility-weighted MRI in patients with vascular parkinsonism. <i>Movement Disorders Clinical Practice</i> . 2019;6(Supplement 1):S170.	4
402	Kim KJ, Bae YJ, Kim JM, Kim SE, Jeon BS. The nigral hyperintensity on 3 Tesla susceptibility-weighted MRI in patients with vascular parkinsonism. <i>Movement Disorders</i> . 2018;33(Supplement 2):S66-S7.	4
403	Kim KJ, Kim JM. Diagnosis of parkinsonism with 3T MR image of nigrosome-1: Correlation between susceptibility-weighted imaging and 123I-FPCIT-SPECT findings. <i>Movement Disorders</i> . 2015;1:3384.	4
404	Kim KJ, Kim JM, Bae YJ, Song YS, Kim SE. 123I-FP-CIT SPECT and MRI Findings in a Patient with Parkinsonism after Fenpropoximate Intoxication. <i>Clinical Nuclear Medicine</i> . 2018;43(6):e178-e9.	9

405	Kim R, Jun JS. Association of autonomic symptoms with presynaptic striatal dopamine depletion in drug-naive Parkinson's disease: An analysis of the PPMI data. <i>Autonomic Neuroscience: Basic and Clinical</i> . 2019;216:59-62.	9
406	Kim YE, Kim JM, Lee BC, Kim SE. Development of neurodegenerative disease and dopamine transporter imaging in patients with idiopathic REM sleep behavior disorder: An 8-year follow-up. <i>Movement Disorders</i> . 2014;1):S293.	9
407	Kim YE, Kim YJ, Hwang HS, Ma HI. REM sleep behavior disorder in early Parkinson's disease predicts the rapid dopaminergic denervation. <i>Parkinsonism and Related Disorders</i> . 2020;80:120-6.	9
408	Kim YK, Yoon IY, Kim JM, Jeong SH, Kim KW, Shin YK, et al. The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. <i>European Journal of Neurology</i> . 2010;17(3):487-92.	9
409	Kimura T, Matsuura M, Nakajima T, Fujisawa I. Correlation between two analyses programs for specific binding ratio in 123 I-FP-CIT SPECT in patients with Parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(1 Supplement 1):S664.	4
410	Kita A, Okazawa H, Sugimoto K, Kaido R, Kidoya E, Kimur H. Acquisition Count Dependence of Specific Binding Ratio in 123I-FP-CIT SPECT. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2021;62(SUPPL 1).	9
411	Kita A, Okazawa H, Sugimoto K, Kaido R, Kosaka N, Shibutani T, et al. Acquisition count dependence of the specific binding ratio in 123I-FP-CIT SPECT. <i>Annals of Nuclear Medicine</i> . 2021;35(12):1271-8.	9
412	Kitagawa T, Umehara T, Oka H, Shiraishi T, Sato T, Takatsu H, et al. Association between heart rate variability and striatal dopamine depletion in Parkinson's disease. <i>Journal of Neural Transmission</i> . 2021.	9
413	Klaffke S, Kuhn AA, Plotkin M, Amthauer H, Harnack D, Felix R, et al. Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. <i>Movement Disorders</i> . 2006;21(10):1724-7.	9
414	Knossalla F, Kohl Z, Winkler J, Schwab S, Schenk T, Engelhorn T, et al. High-resolution diffusion tensor-imaging indicates asymmetric microstructural disorganization within substantia nigra in early Parkinson's disease. <i>Journal of Clinical Neuroscience</i> . 2018;50:199-202.	9
415	Knudsen K. Cross-system correction factor in 123I-FP-CIT SPECT DaTscan. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S658.	4
416	Knudsen K, Fedorova TD, Horsager J, Andersen KB, Skjaerbaek C, Berg D, et al. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson's Disease Subtypes. <i>Journal of Parkinson's Disease</i> . 2021;11(4):1677-87.	9
417	Koch W, Hamann C, Radau PE, Tatsch K. Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2007;34(8):1265-73.	7
418	Koch W, Hamann C, Welsch J, Popperl G, Radau PE, Tatsch K. Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies? <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> . 2005;46(11):1804-11.	9
419	Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> . 2005;46(7):1109-18.	9
420	Kogawa S, Oi J, Yabata H. Motor and cognitive functions in PD correlate with caudate DAT availability and hippocampal atrophy. <i>Clinical Neurology</i> . 2018;58(Supplement 1):S381.	4
421	Koh J, Yamamoto K, Sakata M, Murata KY, Ito H. Quantitative reference value of dopamine transporter single-photon emission computed tomography in healthy Japanese older adults. <i>Neurology and Clinical Neuroscience</i> . 2016;4(6):215-9.	9
422	Komatsu H, Kato M, Kinpara T, Ono T, Kakuto Y. Possible multiple system atrophy with predominant parkinsonism in a patient with chronic schizophrenia: A case report. <i>BMC Psychiatry</i> . 2018;18(1) (no pagination)(141).	6
423	Kong Y, Zhang C, Liu K, Wagle Shukla A, Sun B, Guan Y. Imaging of dopamine transporters in Parkinson disease: a meta-analysis of 18F/123I-FP-CIT studies. <i>Annals of Clinical and Translational Neurology</i> . 2020;7(9):1524-34.	2
424	Koros C, Simitsi A, Prentakis A, Beratis I, Papadimitriou D, Kontaxopoulou D, et al. 123I-FP-CIT SPECT [(123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T alpha-synuclein Parkinson's disease cohort versus Parkinson's disease. <i>Movement Disorders</i> . 2018;33(11):1734-9.	9
425	Koros C, Simitsi A, Stamelou M, Prentakis A, Bougea A, Pachi I, et al. 123I-FP-CIT SPECT imaging in early PD patients versus mid and late onset PD: Longitudinal data from the PPMI study. <i>Movement Disorder</i> . 2019;34(Supplement 2):S379.	9

426	Koros C, Simitsi AM, Papagiannakis N, Prentakis A, Bougea A, Papadimitriou D, et al. Baseline olfaction testing in Parkinson's disease patients is correlated with long-term dopaminergic denervation in striatal sub-regions: Longitudinal data from the PPMI study. <i>Movement Disorder</i> . 2021;36(SUPPL 1):S361.	4
427	Koros C, Simitsi AM, Prentakis A, Papagiannakis N, Bougea A, Pachi I, et al. DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study. <i>Parkinsonism and Related Disorders</i> . 2020;77:36-42.	9
428	Korsholm K, Anderberg L, Lonsdale M, Broedsgaard E, Denholt C, Madsen J, et al. A back-to-back comparison of 18F-FE-PE2I-PET/CT and 123I-FP-CIT-SPECT dopamine transport imaging in the diagnostic work-up of patients with clinical features of parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2018;45(Supplement 1):S399.	4
429	Krenn Y, Fischer P. Dementia with Lewy Bodies (DLB). [German]. <i>Journal fur Neurologie, Neurochirurgie und Psychiatrie</i> . 2006;7(1):32-42.	3
430	Krygowska-Wajs A, Kachergus JM, Hulihan MM, Farrer MJ, Searcy JA, Booij J, et al. Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. <i>Journal of Neural Transmission</i> . 2005;112(11):1487-502.	9
431	Kubler D, Schroll H, Buchert R, Kuhn A. Cognitive performance in non-demented patients with Parkinson's disease correlates with dopaminergic innervation of the executive striatum. <i>NuklearMedizin</i> . 2017;56(2):A34.	9
432	Kubler D, Schroll H, Buchert R, Kuhn AA. Cognitive performance correlates with the degree of dopaminergic degeneration in the associative part of the striatum in non-demented Parkinson's patients. <i>Journal of Neural Transmission</i> . 2017;124(9):1073-81.	9
433	Kubler D, Schroll H, Hamker FH, Joutsa J, Buchert R, Kuhn AA. The effect of dopamine on response inhibition in Parkinson's disease relates to age-dependent patterns of nigrostriatal degeneration. <i>Parkinsonism and Related Disorders</i> . 2019;63:185-90.	9
434	Kubler D, Schroll H, Scheller U, Buchert R, Kuhn A. Opposite effects of dopamine on specific NoGo performance in young and late onset Parkinson's disease and the relationship to nigrostriatal degeneration. <i>Movement Disorders</i> . 2018;33(Supplement 2):S587.	9
435	Kupitz D, Apostolova I, Lange C, Ulrich G, Amthauer H, Brenner W, et al. Global scaling for semi-quantitative analysis in FP-CIT SPECT. <i>NuklearMedizin</i> . 2014;53(6):234-41.	9
436	Kuya K, Ogawa T, Shinohara Y, Ishibashi M, Fujii S, Mukuda N, et al. Evaluation of Parkinson's disease by neuromelanin-sensitive magnetic resonance imaging and 123I-FP-CIT SPECT. <i>Acta Radiologica</i> . 2018;59(5):593-8.	9
437	Kuya K, Shinohara Y, Miyoshi F, Fujii S, Tanabe Y, Ogawa T. Correlation between neuromelanin-sensitive MR imaging and 123I-FP-CIT SPECT in patients with parkinsonism. <i>Neuroradiology</i> . 2016;58(4):351-6.	10
438	Kwiatkowski A, Dujardin K, Dellioux M, Duhamel A, Decroix P, Steinling M, et al. Executive dysfunctions: A premotor biomarker of familial Parkinson's disease? <i>Movement Disorders</i> . 2010;25:S320.	4
439	Labrador-Espinosa MA, Grothe MJ, Macias-Garcia D, Jesus S, Adarmes-Gomez A, Munoz-Delgado L, et al. Levodopa-Induced Dyskinesia in Parkinson Disease Specifically Associates with Dopaminergic Depletion in Sensorimotor-Related Functional Subregions of the Striatum. <i>Clinical Nuclear Medicine</i> . 2021;46(6):E296-E306.	9
440	Lange C, Apostolova I, Frings L, Mester J, Klutmann S, Meyer PT, et al. Does the severity of nigrostriatal degeneration in the early symptomatic phase of parkinson's disease predict medium-term cognitive decline? <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2018;45(Supplement 1):S424.	4
441	Lange C, Apostolova I, Spehl TS, Frings L, Meyer PT, Hellwig S, et al. Diagnostic performance of the specific uptake size index for semi-quantitative analysis of I-123-FP-CIT SPECT: Typical clinical single-camera setting versus multi-center trial setting. <i>NuklearMedizin</i> . 2018;57(2):A59.	4
442	Lange C, Chibolela C, Frings L, Brenner W, Meyer PT, Tossici-Bolt L, et al. Diagnostic performance of the specific uptake size index in multicenter I-123-FP-CIT SPECT. <i>NuklearMedizin</i> . 2016;55(2):A65.	9
443	Lange C, Frings L, Meyer PT, Brenner W, Hellwig S, Buchert R. Hottest voxel analysis for semi-quantitative analysis of FP-CIT SPECT to reduce the impact of filtered backprojection versus iterative reconstruction. <i>NuklearMedizin</i> . 2016;55(2):A91.	9
444	Lapa C, Spehl TS, Brumberg J, Isaias IU, Schlogl S, Lassmann M, et al. Influence of CT-based attenuation correction on dopamine transporter SPECT with [123I]FP-CIT. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;5(3):278-86.	10
445	Lauwers E, Beque D, Van Laere K, Nuyts J, Bormans G, Mortelmans L, et al. Non-invasive imaging of neuropathology in a rat model of alpha-synuclein overexpression. <i>Neurobiology of Aging</i> . 2007;28(2):248-57.	1
446	Lavalaye J, Knol RJJ, De Bruin K, Reneman L, Janssen AGM, Booij J. [123I]FP-CIT binding in rat brain after acute and sub-chronic administration of dopaminergic medication. <i>European Journal of Nuclear Medicine</i> . 2000;27(3):346-9.	1
447	Lebedev AV, Westman E, Simmons A, Lebedeva A, Pereira JB, Aarsland D. Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. <i>Movement Disorders</i> . 2014;1):S79.	10

448	Lebedev AV, Westman E, Simmons A, Lebedeva A, Siepel FJ, Pereira JB, et al. Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. <i>Frontiers in Systems Neuroscience</i> . 2014;8(1 APR) (no pagination)(45).	9
449	Lee H, Jeong EH, Kim BS, Yu HJ, Park YK, Seo J, et al. Correlation of dopaminergic denervation and the progression of autonomic dysfunctions in different clinical subtypes of Parkinson's disease: Analysis of the PPMI data. <i>European Journal of Neurology</i> . 2020;27(Supplement 1):315.	9
450	Lee I, Kim JS, Park JY, Byun BH, Park SY, Choi JH, et al. Head-to-head comparison of 18F-FP-CIT and 123I-FP-CIT for dopamine transporter imaging in patients with Parkinson's disease: A preliminary study. <i>Synapse</i> . 2018;72(7) (no pagination)(e22032).	9
451	Lee JW, Song YS, Kim H, Ku BD, Lee WW. Alteration of tremor dominant and postural instability gait difficulty subtypes during the progression of Parkinson's disease: Analysis of the PPMI cohort. <i>Frontiers in Neurology</i> . 2019;10(MAY) (no pagination)(471).	9
452	Lee JW, Song YS, Kim H, Ku BD, Lee WW. Methodological considerations of evaluating the rate of presynaptic dopaminergic denervation in Parkinson disease with radiotracers: Analysis of the PPMI data. <i>Medicine</i> . 2021;100(26):e26534.	9
453	Lee JW, Song YS, Kim H, Ku BD, Lee WW. Patients with scans without evidence of dopaminergic deficit (SWEDD) do not have early Parkinson's disease: Analysis of the PPMI data. <i>PLoS ONE</i> . 2021;16(2 February) (no pagination)(e0246881).	9
454	Lee JY, Lao-Kaim NP, Pasquini J, Deuschl G, Pavese N, Piccini P. Pallidal dopaminergic denervation and rest tremor in early Parkinson's disease: PPMI cohort analysis. <i>Parkinsonism and Related Disorders</i> . 2018;51:101-4.	9
455	Lee MJ, Pak K. Genetic variations of SNCA and striatal dopaminergic dysfunction in patients with Parkinson's disease. <i>Movement Disorders</i> . 2018;33(Supplement 2):S627-S8.	9
456	Lee MJ, Pak K, Kim JH, Kim YJ, Yoon J, Lee J, et al. Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease. <i>Neurology</i> . 2019;93(7):E665-E74.	9
457	Lepej J, Skicka L, Sudzina R, Puskas T, Kahancova E, Marinova B. 123I-FP-CIT brain SPECT study: Analysis of clinical impact and utility of different semi-quantification of striatal uptake. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;2:S143-S4.	4
458	Liepe K, Sixel-Doring F, Kempers B, Trenkwalder C. 123I-FP-CIT (DaTSCAN/TM) scintigraphy in the diagnosis of Parkinson's disease and visualization of a possible neuroprotective effect of rasagiline. <i>Journal of the Neurological Sciences</i> . 2009;1:S72.	4
459	Lievano P, Gonzalez M, De La Cueva L, Ananos M, Navarro P, Arroyo E, et al. Usefulness of 123I-IBZM SPECT in treatment assessment of Parkinson-plus disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2:S404.	4
460	Limouris GS, Konstantinidis E, Triantafyllou N, Paphiti M, Valais I, Paraskevas G, et al. Standardization of normative data as 'reference data' in a single institute for the qualitative and quantitative DaTSCAN evaluation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1:S579-S80.	4
461	Linder J, Wenngren BI, Stenlund H, Forsgren L. Impaired oculomotor function in a community-based patient population with newly diagnosed idiopathic parkinsonism. <i>Journal of Neurology</i> . 2012;259(6):1206-14.	9
462	Ling H, Lees AJ, Bajaj N. Reduced striatal [(123I)]FP-CIT SPECT in acquired hepatocerebral degeneration. <i>Movement Disorders</i> . 2013;1:S294.	6
463	Lipczynska-Lojkowska W, Jedrzejczak T, Kuran W, Kulczycki J, Kozłowicz-Gudzinska I, Sienkiewicz-Jarosz H, et al. The role of DaTSCAN SPET examination in the diagnosis of the extrapyramidal system diseases - Original observations. [Polish]. <i>Postepy Psychiatrii i Neurologii</i> . 2007;16(1):23-9.	3
464	Lloyd JJ, Petrides G, Donaghy PC, Colloby SJ, Attems J, O'Brien JT, et al. A new visual rating scale for Ioflupane imaging in Lewy body disease. <i>NeuroImage: Clinical</i> . 2018;20:823-9.	9
465	Loberboym M, Traves TA, Melamed E, Lampl Y, Hellman M, Djaldetti R. [123 I]-EP/CIT SPECT imaging for distinguishing drug-induced Parkinsonism from Parkinson's disease. <i>Movement Disorders</i> . 2006;21(4):510-4.	9
466	Lobsien E, Schreiner S, Plotkin M, Kupsch A, Schreiber SJ, Doepp F. No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease. <i>Movement Disorders</i> .	9
467	Lokkegaard A, Werdelin LM, Regeur L, Karlsborg M, Jensen SR, Brodsgaard E, et al. Dopamine transporter imaging and the effects of deep brain stimulation in patients with Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2007;34(4):508-16.	9
468	Lonngren C, Maggs T, Gontu V, Bajaj N. Clinical features that best differentiate patients with adult onset dystonic tremor from tremulous Parkinson's disease. <i>Movement Disorders</i> . 2010;2:S529.	4
469	Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> . 2004;45(10):1688-93.	9
470	Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. <i>Journal of Nuclear Medicine</i> . 2004;45(10):1688-93.	10

471	Lorenzo IBC, Cuberas Borros G, Rodriguez FM, Caresia P, Aguade Bruix S, Castell Conesa J. Quantitative evaluation of 123I-FP-CIT SPECT: Validation of a semiautomated method. [Spanish]. <i>Revista Espanola de Medicina Nuclear</i> . 2005;24(4):244-9.	3
472	Lorenzo-Bosquet C, Hernandez-Vara J, Castell-Conesa J, Miquel-Rodriguez F. Functional neuroimaging with SPECT in Parkinson's disease and parkinsonisms. [Spanish]. <i>Revista de Neurologia</i> . 2008;46(7):430-5.	3
473	Lorenzo-Bosquet C, Hernandez-Vara J, Cuberas-Borros G, Alvarez-Sabin J, Castell-Conesa J. Could FP-CIT SPECT detects bilateral impairment of nigrostriatal pathway in Parkinson disease Hoehn & Yahr 1 stage? <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2:S400.	4
474	Loser J, Luthardt J, Rullmann M, Weise D, Sabri O, Meixensberger J, et al. Striatal dopamine transporter availability and individual clinical course within the 1-year follow-up of deep brain stimulation of the subthalamic nucleus in patients with Parkinson's disease. <i>Journal of neurosurgery</i> . 2021;1-7.	9
475	Luca CC, Nahab FB. Neuroimaging in Essential Tremor. <i>Neuroimaging of Movement Disorders</i> . 2013;Current Clinical Neurology. 44:185-99.	2
476	Lyra ME, Sotiropoulos M, Lagopati N, Kapaki E, Gouliamos A, Limouris GS. Quantification of [123I]-fp-cit (datscan) volume imaging by matlab for the differentiation and grading of parkinsonism and essential tremor. <i>Neuroradiology</i> . 2009;1:S59.	4
477	Maekawa T, Sato N, Ota M, Sugiyama A, Sone D, Enokizono M, et al. Correlations between dopamine transporter density measured by 123I-FP-CIT SPECT and regional gray matter volume in Parkinson's disease. <i>Japanese Journal of Radiology</i> . 2017;35(12):755-9.	9
478	Makinen E, Joutsa J, Isotalo J, Kaasinen V. No relevant midbrain atrophy in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> . 2015.	10
479	Makinen E, Joutsa J, Isotalo J, Kaasinen V. No relevant midbrain atrophy in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> . 2016;134(5):378-81.	2
480	Makinen E, Joutsa J, Jaakkola E, Noponen T, Johansson J, Pitkonen M, et al. Contribution of individual motor signs to striatal dopamine deficiency in parkinsonism. <i>Movement Disorders</i> . 2018;33(Supplement 2):S660-S1.	4
481	Makinen E, Joutsa J, Jaakkola E, Noponen T, Johansson J, Pitkonen M, et al. Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT. <i>Journal of Neurology</i> . 2019;266(4):826-34.	9
482	Makinen E, Joutsa J, Johansson J, Maki M, Seppanen M, Kaasinen V. Visual versus automated analysis of [I-123]FP-CIT SPECT scans in parkinsonism. <i>Journal of Neural Transmission</i> . 2016;123(11):1309-18.	9
483	Makinen E, Joutsa J, Johansson J, Maki M, Seppanen M, Kaasinen V. Visual vs. automated analysis of [123I]FP-CIT SPECT scans in patients with Parkinsonism. <i>Movement Disorders</i> . 2016;31(Supplement 2):S407-S8.	4
484	Makinen E, Joutsa J, Vahlberg T, Kaasinen V. Survival in Parkinson's disease in relation to striatal dopamine transporter binding. <i>Parkinsonism and Related Disorders</i> . 2017;42:66-72.	9
485	Malaroda A, Toop R, Tossici-Bolt L, Fleming J, Johns S, Kemp P. Preliminary results of a shorter acquisition time in 123I FP-CIT imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2:S330.	9
486	Malek N, Grosset DG. Overview of dopamine transporter imaging in Parkinson's disease, dementia with lewy bodies and other dementias. <i>Current Geriatrics Reports</i> . 2015;4(2):124-30.	2
487	Maltais DD, Jordan L, Min HK, Miyagawa T, Murray ME, Przybelski SA, et al. COMPARISON OF 123I-FP-CIT SPECT THREE QUANTIFICATION METHODS: A CLINICOPATHOLOGIC ANALYSIS IN 23 PATIENTS. <i>Alzheimer's and Dementia</i> . 2019;15(7 Supplement):P1394.	10
488	Maltais DD, Jordan LG, Min HK, Miyagawa T, Przybelski SA, Lesnick TG, et al. Confirmation of 123I-FP-CIT SPECT quantification methods in dementia with lewy bodies and other neurodegenerative disorders. <i>Journal of Nuclear Medicine</i> . 2020;61(11):1628-35.	9
489	Maltais DD, Lowe VJ, Boeve BF, Kantarci K, Miyagawa T, Min HK, et al. COMPARISON OF 123I-FP-CIT SPECT THREE QUANTIFICATION METHODS: A CLINICOPATHOLOGIC ANALYSIS IN 23 PATIENTS. <i>Alzheimer's and Dementia</i> . 2019;15(7 Supplement):P50.	4
490	Maremmani C, Cavallo F, Purcaro C, Rossi G, Salvadori S, Rovini E, et al. Combining olfactory test and motion analysis sensors in Parkinson's disease preclinical diagnosis: a pilot study. <i>Acta Neurologica Scandinavica</i> . 2018;137(2):204-11.	9
491	Marotta G, Casarotto S, Turco F, Comanducci A, Perretti A, Pezzoli G, et al. Excitability of the supplementary motor area depends on subcortical damage in Parkinson's disease. <i>Clinical and Translational Imaging</i> . 2019;7(Supplement 1):S33.	4
492	Marotta G, Isaias IU, Benti R, Marzegan A, Voltini F, Cavallari P, et al. Influence of dopaminergic striatal innervation on upper limb locomotor synergies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2:S440.	4
493	Marotta G, Isaias IU, Moisello C, Cavallari P, Voltini F, Pezzoli G, et al. Inter-limb transfer of implicit motor learning is related to dopamine innervation of the striatum. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2:S328.	4

494	Marotta G, Isaias IU, Pezzoli G, Cavallari P, Marzegan A, Volmann J, et al. The influence of dopaminergic striatal innervation on upper limb locomotor synergies. <i>Clinical and Translational Imaging</i> . 2013;1):S23.	4
495	Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. <i>Nuclear Medicine Communications</i> . 2006;27(12):933-7.	7
496	Marshall VL, Reiningner CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3-year European multicenter study with repeat [123I]FP-CIT SPECT. <i>Movement Disorders</i> . 2009;24(4):500-8.	10
497	Marti G, Saez N, Corominas M, Cuberas G, Lorenzo C, De Fabregues O, et al. Nigrostriatal degeneration and serum BDNF levels in patients with "de novo" untreated Parkinson's disease. <i>Movement Disorders</i> . 2016;31(Supplement 2):S402.	4
498	Martikainen MH, Paivarinta M, Hietala M, Kaasinen V. Novel SNCA mutation causes autosomal dominant Parkinson's disease. <i>Movement Disorders</i> . 2014;1):S56.	9
499	Martikainen MH, Paivarinta M, Hietala M, Kaasinen V. Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation. <i>Neurology: Genetics</i> . 2015;1(4) (no pagination)(e27).	9
500	Martinez Del Valle Torres MD, Ramos Moreno E, Amrani Raissouni T, Ortega Lozano SJ, Sanz Viedma S, Jimenez-Hoyuela JM. Functional assessment of nigro-striatal pathway with FP-CIT in patients with multiple system atrophy subtype C. [Spanish]. <i>Medicina Clinica</i> . 2011;137(10):440-3.	3
501	Martinez Pimienta G, Gomez Llopico R, Bajen M, Benitez Segura A, Puig O, Rojas Camacho J, et al. Contribution of cardiac 123-I metaiodobenzylguanidine (MIBG) scintigraphy of combined whit FP-CIT SPECT in the differential diagnosis of the Parkinson disease and atypical parkinsonian syndromes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S564-S5.	4
502	Maschur A, Spiegel J, Grgic A, Hellwig AP, Farmakis G, Dillmann U, et al. Statistical parametric mapping of FP-CIT SPECT reveals regional differences in striatal dopamine transporter density between tremor-dominant and akinetic-rigid subtypes of early Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2):S401.	4
503	Maschur A, Spiegel J, Grgic A, Hellwig AP, Farmakis G, Dillmann U, et al. Statistical parametric mapping of FP-CIT SPECT reveals no regional differences in striatal dopamine transporter density between patients with essential tremor and normal controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2):S329.	9
504	Masciocchi S, Pilotto A, Premi E, Toffali M, Imarisio A, Barbara P, et al. Sexual divergencies in monoaminergic projections in Parkinson's disease: A 123I-FP-CIT SPECT study. <i>Journal of the Neurological Sciences</i> . 2021;Conference: World Congress of Neurology (WCN 2021). Rome Italy. 429(Supplement) (no pagination)(119484).	9
505	Masciocchi S, Pilotto A, Premi E, Toffali M, Imarisio A, Paghera B, et al. Sexual divergencies in monoaminergic projections in Parkinson's disease: A123I-FP-CIT SPECT study. <i>Movement Disorder</i> . 2021;36(SUPPL 1):S368.	4
506	Masciocchi S, Pilotto A, Toffali M, Nocivelli S, Imarisio A, Scalvini A, et al. Plasma NfL correlates with widespread extrastriatal monaminergic deficits in early Parkinson's disease. <i>European Journal of Neurology</i> . 2020;27(Supplement 1):905.	9
507	Masrori P, Van Weehaeghe D, Van Laere K, Van Damme P. Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> . 2021;62(9):1318-9.	6
508	Mateos JJ, Lomena F, Parellada E, Font M, Fernandez E, Pavia J, et al. Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone. [Spanish]. <i>Revista Espanola de Medicina Nuclear</i> . 2006;25(3):159-65.	3
509	Mateos JJ, Lomena F, Parellada E, Font M, Fernandez E, Pavia J, et al. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. <i>Psychopharmacology</i> . 2005;181(2):401-6.	9
510	Mateos JJ, Lomena F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, et al. Lower striatal dopamine transporter binding in neuroleptic-naïve schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. <i>Psychopharmacology</i> . 2007;191(3):805-11.	10
511	Matesan MC, Elojeimy S, Minoshima S. 123I-FP-CIT and 99mTc-HMPAO in Pathologically Confirmed Progressive Supranuclear Palsy. <i>Clinical Nuclear Medicine</i> . 2016;18.	6
512	Matsuda H, Maikusa N, Imabayashi E, Ogawa M, Murata M, Hirano S, et al. Normal database construction of dopamine transporter SPECT in Japan. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2017;58(Supplement 1).	9
513	Matsumoto Y, Suzuki A, Kobayashi R, Otani K. Detection of decreased striatal dopamine transporter availability by 123I-FP-CIT SPECT in a patient of carbon monoxide poisoning with severe cognitive deficits but mild parkinsonian symptoms. <i>Asian Journal of Psychiatry</i> . 2019;42:10-1.	9
514	Matsusue E, Fujihara Y, Tanaka K, Aozasa Y, Shimoda M, Nakayasu H, et al. The utility of the combined use of 123I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes. <i>Acta Radiologica</i> . 2019;60(2):230-8.	7

515	Matsutomo N, Nagaki A, Yamao F, Sasaki M. Optimization of iterative reconstruction parameters with 3-dimensional resolution recovery, scatter and attenuation correction in 123I-FP-CIT SPECT. <i>Annals of Nuclear Medicine</i> . 2015;29(7):636-42.	10
516	Mattioli P, Pardini M, Fama F, Girtler N, Brugnolo A, Orso B, et al. Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2021;48(9):2834-45.	9
517	Mayer G, Kesper K, Oertel W, Hoffken H, Stiasny-Kolster K. Rem sleep behavior disorder (RBD) in narcoleptic patients can be a predictor of neurodegeneration: Results of a prospective clinical and imaging study. <i>Sleep</i> . 2013;1:A236.	9
518	McAuley J, Hughes G. Neurosyphilis presenting as parkinsonism. <i>BMJ Case Reports</i> . 2015;2015 (no pagination)(A1497).	9
519	McCarter S, Min HK, Lowe V, Benarroch E, Jones D, Boeve B, et al. Striatal dopamine motor and non-motor network and cortical activity in parkinson disease: A correlation study between 123I-FP-CIT spect and FDG pet. <i>Neurology Conference: 72nd Annual Meeting of the American Academy of Neurology, AAN</i> . 2020;94(15 Supplement).	9
520	McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. <i>Cochrane Database of Systematic Reviews</i> . 2015;2017(6) (no pagination)(CD010633).	10
521	Meles SK, Vadasz D, Renken RJ, Sittig-Wiegand E, Mayer G, Depboylu C, et al. FDG PET, dopamine transporter SPECT, and olfaction: Combining biomarkers in REM sleep behavior disorder. <i>Movement Disorders</i> . 2017;32(10):1482-6.	9
522	Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, et al. Parkinson's disease in GTP cyclohydrolase-1 mutation carriers. <i>Movement Disorders</i> . 2014;1:S57.	4
523	Mendez-Guerrero A, Laespada-Garcia MI, Gomez-Grande A, Ruiz-Ortiz M, Blanco-Palmero VA, Azcarate-Diaz FJ, et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. <i>Neurology</i> . 2020;95(15):e2109-e18.	9
524	Mendonca M, Silva J, Oliveira F, Oliveira-Maia A, Ferreira J, Costa D, et al. Inertial-sensor based full-body kinematics reveals an unstable gait with increased variability in patients with evidence of dopaminergic denervation with 123I-FP-CIT SPECT. <i>Movement Disorders</i> . 2020;35(SUPPL 1):S256.	9
525	Metcalfe A, Udow S, Sharmarke H, Shirzadi Z, Long D, Duff-Canning S, et al. U-shaped dopamine resting state connectivity response function related to working memory performance in adults with early-stage Parkinson's disease. <i>Movement Disorders</i> . 2017;32(Supplement 2):1055-7.	9
526	Metcalfe AWS, Udow S, Sharmarke H, Shirzadi Z, Long D, Duff-Canning S, et al. Cognitive performance and functional connectivity are modulated by striatal dopaminergic deficit in adults with Parkinson's disease. <i>Alzheimer's and Dementia</i> . 2016;12(7 Supplement):P1082.	9
527	Meyer PT, Amtage F, Hellwig S. Differential diagnostics of Parkinson's disease with nuclear medicine procedures. [German]. <i>Nervenarzt</i> . 2014;85(6):680-9.	3
528	Meyer PT, Hellwig S. Update on SPECT and PET in parkinsonism - Part 1: Imaging for differential diagnosis. <i>Current Opinion in Neurology</i> . 2014;27(4):390-7.	2
529	Meyer PT, Winz OH, Dafotakis M, Werner CJ, Krohn T, Schafer WM. Improved visual [123I]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;55(3):301-9.	10
530	Michelis JP, Bedarf JR, Gaertner F, Paus S. Phenomenology and dopamine transporter density in a patient with amphetamine induced hyperkinetic facial movement disorders. <i>Movement Disorders</i> . 2015;1:S296-S7.	6
531	Mila M, Cuberas G, Rovira A, Porta F, Negre M, Rossi S, et al. Can I-123-FP-CIT images give us a clue that implies a vascular parkinsonism? <i>Clinical Nuclear Medicine</i> . 2007;32(11):886-8.	6
532	Milenkovic I, Bartova L, Papageorgiou K, Kasper S, Traub-Weidinger T, Winkler D. Case Report: Bupropion Reduces the [123I]FP-CIT Binding to Striatal Dopamine Transporter. <i>Frontiers in Psychiatry</i> . 2021;12 (no pagination)(631357).	6
533	Minnerop M, Kornblum C, Joe AY, Tatsch K, Kunz WS, Klockgether T, et al. Dopamine transporter SPECT in patients with mitochondrial disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2005;76(1):118-20.	9
534	Mito Y, Yabe I, Yaguchi H, Sato C, Takei T, Terae S, et al. Relationships of drooling with motor symptoms and dopamine transporter imaging in drug-naive Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> . 2020;195 (no pagination)(105951).	9
535	Mito Y, Yabe I, Yaguchi H, Sato C, Takei T, Terae S, et al. Relations of clinical symptoms with dopamine transporter imaging in drug-naive Parkinson's disease. <i>Clinical Neurology and Neurosurgery</i> . 2020;196 (no pagination)(105960).	9
536	Mito Y, Yabe I, Yaguchi H, Takei T, Terae S, Tajima Y. Relation of overactive bladder with motor symptoms and dopamine transporter imaging in drug-naive Parkinson's disease. <i>Parkinsonism and Related Disorders</i> . 2018;50:37-41.	9
537	Mito Y, Yaguchi H, Tajima Y. Relations of clinical symptoms with dopamine transporter imaging in untreated Parkinson's disease. <i>Movement Disorder</i> . 2019;34(Supplement 2):S814.	9

538	Mitsuhashi M, Sawamoto N, Shima A, Furukawa K, Kambe D, Takahashi R. Severity of motor symptoms and degree of dopaminergic damage in the terminal and the soma in advanced Parkinson's disease. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):126-7.	9
539	Miyamoto T, Miyamoto M, Numahata K, Onoue H, Akaiwa Y, Sairenchi T. Reduced dopamine transporter binding predicts early transition to Lewy body disease in Japanese patients with idiopathic rapid eye movement sleep behavior disorder. <i>Journal of the Neurological Sciences</i> . 2020;414 (no pagination)(116821).	9
540	Miyae N, Ando R, Iwaki T, Yabe H, Nishikawa N, Nagai M, et al. Movement disorders are the common signs as the first neurological deficit in cases with spinocerebellar ataxia type 2 (SCA2). <i>Movement Disorders</i> . 2016;31(Supplement 2):S337.	9
541	Miyae N, Tada S, Ando R, Iwaki H, Yabe H, Nishikawa N, et al. DAT SPECT may have diagnostic value in prodromal SCA2 patients with parkinsonism. <i>Parkinsonism and Related Disorders</i> . 2017;44:137-41.	9
542	Mizumura S, Nishikawa K, Murata A, Yoshimura K, Ishii N, Kokubo T, et al. Improvement in the measurement error of the specific binding ratio in dopamine transporter SPECT imaging due to exclusion of the cerebrospinal fluid fraction using the threshold of voxel RI count. <i>Annals of Nuclear Medicine</i> . 2018;32(4):288-96.	9
543	Mo SJ, Linder J, Blomstedt P, Granasen G, Forsgren L, Hariz M. Long-term dopamine transporter imaging in Parkinson s disease treated with zona incerta stimulation. <i>Nuclear Medicine Communications</i> . 2016;37(5):499-508.	9
544	Mo SJ, Linder J, Forsgren L, Larsson A, Johansson L, Riklund K. Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: A population-based study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;37(11):2154-64.	9
545	Moccia M, Pappata S, Erro R, Picillo M, Vitale C, Amboni M, et al. Uric acid relates to dopamine transporter availability in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> . 2015;131(2):127-31.	9
546	Mochida I, Matsunaga K, Watanabe S, Isohashi K, Watabe T, Tatsumi M, et al. Initial experience of the dopamine transporter SPECT in three pediatric patients with rare neurodegenerative disorder. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S559-S60.	6
547	Mochida I, Shimosegawa E, Matsunaga K, Watabe T, Isohashi K, Tatsumi M, et al. The experience of the dopamine transporter SPECT in three pediatric patients with neurodegeneration with brain iron accumulation. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2016;57(SUPPL. 2).	6
548	Morita M, Makiko Y, Suzuki M. Dopamine transporter imaging with [(123)I]-FP-CIT in subtypes of progressive supranuclear palsy. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):585.	4
549	Moschella V, Massimetti MC, Olivola E, Stefanini A, Stanzione P, Stefani A. An atypical case of Pure Akinesia with gait freezing. <i>Neurological Sciences</i> . 2015;36(2 Supplement 1):S188-S9.	4
550	Mossa EP, Niccoli Asabella A, Luele F, Ianora AAS, Giganti M, Rubini G. Striatal dopamine transporter levels in patients with REM sleep behavior disorder: Assessment with 123I-FP-CIT SPECT. [Italian]. <i>Recenti Progressi in Medicina</i> . 2012;103(11):500-4.	3
551	Mossa EP, Niccoli Asabella A, Renna MA, Notaristefano A, Rubini D, Rubini G. Striatal dopamine transporter levels in REM sleep behaviour disorder: A 123I-FP-CIT SPET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2):S161.	4
552	Muellner J, Gharrad I, Habert MO, Kas A, Martini JB, Cormier-Dequaire F, et al. Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> . 2015;21(5):471-6.	9
553	Muellner J, Gharrad I, Kas A, Martini JB, Tahiri K, Cormier F, et al. Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease. <i>Movement Disorders</i> . 2014;1):S144-S5.	4
554	Muinjonov B, Giyazitdinova E, Rakhimbaeva G. Progressive supranuclear palsy as a manifestation of the second stage of CADASIL syndrome. <i>Movement Disorders</i> . 2016;31(Supplement 2):S64.	4
555	Mukai Y, Watanabe H, Mochizuki H, Hattori N, Takahashi R, Murata M. The overview of the Japan Parkinson's Progression Markers Initiative (J-PPMI). <i>Movement Disorders</i> . 2016;31(Supplement 1):S23.	4
556	Muller C, Meschede A, Zinke A, Schroeder HWS, Sabolek M. Secondary parkinsonism after subdural hematomas: Presynaptic dopaminergic deficit as possible mechanism? <i>Basal Ganglia</i> . 2013;3(3):171-4.	6
557	Munoz E, Iranzo A, Rauek S, Lomena F, Gallego J, Ros D, et al. Subclinical nigrostriatal dopaminergic denervation in the cerebellar subtype of multiple system atrophy (MSA-C). <i>Journal of Neurology</i> . 2011;258(12):2248-53.	9

558	Murakami H, Kon R, Owan Y, Ono K. Cognitive domain correlates with striatal accumulation of dopamine transporter scintigraphy in drug naive Parkinson's disease. <i>Alzheimer's and Dementia</i> . 2017;13(7):P1053-P4.	9
559	Muscio C, Tiraboschi P, Corso A, Vidale S, Merello M, Stefanini S, et al. Comparative value of [(123)I]-FP-CIT SPECT [(123)I] and [(123)I] MIBG myocardial scintigraphy in distinguishing between dementia with lewy bodies and other types of dementia. <i>American Journal of Neurodegenerative Diseases</i> . 2015;1:126.	9
560	Muthuraman M, Hossen A, Heute U, Deuschl G, Raethjen J. A new diagnostic test to distinguish tremulous Parkinson's disease from advanced essential tremor. <i>Movement Disorders</i> . 2011;26(8):1548-52.	9
561	Nagy A, Noyce A, Lees A, Warner T, Ling H. Two cases of abnormal dopamine transporter scan in chorea-acanthocytosis. <i>Movement Disorders</i> . 2014;1:S195-S6.	4
562	Nagy A, Noyce A, Velayos-Baeza A, Lees AJ, Warner TT, Ling H. Late Emergence of Parkinsonian Phenotype and Abnormal Dopamine Transporter Scan in Chorea-Acanthocytosis. <i>Movement Disorders Clinical Practice</i> . 2015;2(2):182-6.	6
563	Nakadate M, Miyamoto N, Starkey J, Torihara A, Tateishi U. Anterograde degeneration of the nigrostriatal pathway visualized by 123I-FP-CIT SPECT in a patient with artery of percheron infarction. <i>Clinical Nuclear Medicine</i> . 2016;41(6):483-4.	10
564	Nakajima A, Shimo Y, Sekimoto S, Kamagata K, Takayuki J, Oyama G, et al. Dopamine transporter imaging predicts motor response to dopaminergic therapy for patients with advanced Parkinson's disease: Possible role in patient selection for subthalamic deep brain stimulation. <i>Movement Disorders</i> . 2017;32(Supplement 2):1001.	9
565	Nakajima K, Saito S, Chen Z, Komatsus J, Inaki A, Watanabe S, et al. Creation of machine learning based classifiers for interpretation of I-123 Ioflupane images. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2021;62(SUPPL 1).	9
566	Nakano Y, Hirano S, Kojima K, Ishikawa A, Li H, Tai H, et al. Reduced prefrontal perfusion and decreased striatal dopamine transporter activity are associated with pain symptom in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):589.	9
567	Nakano Y, Hirano S, Kojima K, Ishikawa A, Sakurai T, Li H, et al. Diagnostic value of striatal-prefrontal projection estimated by cerebral blood flow and dopamine transporter spect in Parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> . 2018;46(Supplement 2):e17.	4
568	Nakano Y, Hirano S, Kojima K, Li H, Ishikawa A, Sakurai T, et al. Striato-prefrontal projection in parkinsonian syndrome with perfusion and dopamine transporter SPECT. <i>Clinical Neurology</i> . 2018;58(Supplement 1):S380.	4
569	Nakatsuka T, Kitamura N, Kasuya S, Inaoka T, Terada H. Correlation between occipital hypoperfusion measured with a three-dimensional stereotaxic ROI template on 99mTc-ECD SPECT and cardiac uptake on 123I-MIBG scintigraphy in Parkinson's disease. <i>Neuroradiology</i> . 2018;60(1 Supplement 1):372-3.	9
570	Navarro-Otano J, Gaig C, Muxi A, Lomena F, Compta Y, Buongiorno MT, et al. 123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease. <i>Parkinsonism and Related Disorders</i> . 2014;20(2):192-7.	10
571	Neishi H, Ikawa M, Okazawa H, Tsujikawa T, Arishima H, Kikuta KI, et al. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT. <i>European Neurology</i> . 2017;78(3-4):161-8.	10
572	Ng J, Cortes-Saladelafont E, Abela L, Termsarasab P, Mankad K, Sudhakar S, et al. DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia. <i>Movement Disorders</i> . 2020;35(8):1357-68.	9
573	Nicastro N, Burkhard PR, Garibotto V. Combined 123I-FP-CIT SPECT semiquantitative and visual assessment in parkinsonian syndromes and dementia with Lewy bodies - response to Kawada et al. <i>Journal of the Neurological Sciences</i> . 2018;392:126-7.	2
574	Nicastro N, Burkhard PR, Garibotto V. Scan without evidence of dopaminergic deficit (SWEDD) in degenerative parkinsonism and dementia with Lewy bodies: A prospective study. <i>Journal of the Neurological Sciences</i> . 2018;385:17-21.	7
575	Nicastro N, Burkhard PR, Garibotto V. Preserved Extrastriatal 123I-FP-CIT Binding in Scans Without Evidence of Dopaminergic Deficit (SWEDD). <i>Molecular Imaging and Biology</i> . 2020;22(6):1592-9.	9
576	Nicastro N, Fleury V, Broc N, Burkhard PR, Garibotto V. Extrastriatal 123I-FP-CIT SPECT impairment in degenerative parkinsonisms. <i>Parkinsonism and Related Disorders</i> . 2020;78:38-43.	9
577	Nicastro N, Garibotto V, Allali G, Assal F, Burkhard PR. Added value of combined semi-quantitative and visual 123I-FP-CIT SPECT analyses for the diagnosis of dementia with Lewy bodies. <i>Swiss Medical Weekly</i> . 2016;146(Supplement 219):98S.	4
578	Nicastro N, Garibotto V, Allali G, Assal F, Burkhard PR. Added Value of Combined Semi-Quantitative and Visual [123I]FP-CIT SPECT Analyses for the Diagnosis of Dementia with Lewy Bodies. <i>Clinical Nuclear Medicine</i> . 2017;42(2):e96-e102.	9

579	Nicastro N, Garibotto V, Burkhard PR. The added value of combined visual and semi-quantitative assessment for 123I-FP-CIT SPECT and reply to Ueda et al. <i>Neurological Sciences</i> . 2017;38(10):1883-4.	2
580	Nicastro N, Garibotto V, Burkhard PR. 123I-FP-CIT SPECT Accurately Distinguishes Parkinsonian from Cerebellar Variant of Multiple System Atrophy. <i>Clinical Nuclear Medicine</i> . 2018;43(2):e33-e6.	4
581	Nicastro N, Garibotto V, Burkhard PR. Extrastriatal 123I-FP-CIT SPECT impairment in Parkinson's disease-the PPMI cohort. <i>BMC Neurology</i> . 2020;20(1) (no pagination)(192).	9
582	Nicastro N, Garibotto V, Poncet A, Badoud S, Burkhard PR. Establishing On-Site Reference Values for 123I-FP-CIT SPECT (DaTSCAN) Using a Cohort of Individuals with Non-Degenerative Conditions. <i>Molecular Imaging and Biology</i> . 2016;18(2):302-12.	10
583	Nicastro N, Stripeikyte G, Assal F, Garibotto V, Blanke O. Premotor and fronto-striatal mechanisms associated with presence hallucinations in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> . 2021;32 (no pagination)(102791).	9
584	Nicastro N, Wegrzyk J, Preti MG, Fleury V, Van de Ville D, Garibotto V, et al. Classification of degenerative parkinsonism subtypes by support-vector-machine analysis and striatal 123I-FP-CIT indices. <i>Journal of Neurology</i> . 2019;266(7):1771-81.	8
585	Niccoli Asabella A, Liuzzi D, Taurisano P, Roselli F, Notaristefano A, Rubini D, et al. External globus pallidus and pontine nuclei are involved in RSBD in dementia with lewy bodies: A DAT/SERT statistical parametric mapping 123I-FP-CIT SPECT stud. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;2:S255.	9
586	Niccolini F, Mencacci NE, Yousof T, Rabiner EA, Salpietro V, Pagano G, et al. PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. <i>Movement Disorders</i> . 2018;33(12):1961-5.	9
587	Nichols K, Chen B, Tomas MB, Palestro C. Comparison of absolute tracer uptake quantitation to demographic indexing in evaluating dopamine transporter SPECT scans for Lewy body dementia. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2017;58(Supplement 1).	4
588	Nieto-Serrano R, Becerra-Garcia D, Ortega JDDF, Fernandez-Mayorga MA, Davila-Arias C, Carrero-Lerida MJ, et al. Neuroimaging of dopamine transporters with 123I-FP-CIT SPECT: Sensitivity and specificity in distinguishing drug-induced parkinsonism from Parkinsonian syndrome. <i>European Journal of Neurology</i> . 2009;16(S3):500.	9
589	Niimi Y, Ito S, Murate K, Hirota S, Hikichi C, Ishikawa T, et al. Combinatory use of 123I-FP-CIT-SPECT and cardiac 123I-metaiodobenzylguanidine scintigraphy for the diagnosis of parkinsonisms. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):590.	4
590	Nikolaus S, Antke C, Beu M, Kley K, Larisch R, Wirrwar A, et al. In-vivo quantification of dose-dependent dopamine transporter blockade in the rat striatum with small animal SPECT. <i>Nuclear Medicine Communications</i> . 2007;28(3):207-13.	1
591	Nikolaus S, Beu M, Hautzel H, De Souza Silva AM, Antke C, Wirrwar A, et al. Effects of L-DOPA on striatal iodine-123-FP-CIT binding and behavioral parameters in the rat. <i>Nuclear Medicine Communications</i> . 2013;34(12):1223-32.	1
592	Nikolaus S, Larisch R, Vosberg H, Beu M, Wirrwar A, Antke C, et al. Pharmacological challenge and synaptic response - Assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET). <i>Reviews in the Neurosciences</i> . 2011;22(6):625-45.	10
593	Nikolaus S, Wirrwar A, Antke C, Arkian S, Schramm N, Muller HW, et al. Quantitation of dopamine transporter blockade by methylphenidate: First in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2005;32(3):308-13.	10
594	Ninerola-Baizan A, Gallego J, Cot A, Lomena F, Ros D, Pavia J. Statistical variance in standardised striatal uptake ratio in [123I]FP-CIT SPECT imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1:S300-S1.	9
595	Ninerola-Baizan A, Rojas S, Bonastre M, Tudela R, Lomena F, Pavia J, et al. In vivo evaluation of the dopaminergic neurotransmission system using [123I]FP-CIT SPECT in 6-OHDA lesioned rats. <i>Contrast Media and Molecular Imaging</i> . 2015;10(1):67-73.	10
596	Ninerola-Baizan A, Rojas S, Roe-Vellve N, Lomena F, Ros D, Pavia J. Dopamine transporter imaging in the aged rat: A [123I]FP-CIT SPECT study. <i>Nuclear Medicine and Biology</i> . 2015;42(4):395-8.	10
597	Nishida H, Hayashi Y, Kobayashi M, Sakurai T. Dementia with lewy bodies with pure agraphia for kanji (japanese morphograms). <i>Internal Medicine</i> . 2020;59(24):3217-24.	3
598	Nishimori M, Murata Y, Iwasa H, Miyatake K, Tadokoro M, Kohsaki S, et al. Comparison of MRI and 123I-FP-CIT SPECT for the evaluation of MSA-P clinical severity. <i>Biomedical Reports</i> . 2018;8(6):523-8.	9
599	Nissen T, Malek N, Grosset KA, Newman EJ, Patterson J, Hadley D, et al. Baseline [123I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> . 2014;129(3):204-8.	10
600	Nissen T, Newman EJ, Patterson J, Hadley DM, Grosset KA, Grosset DG. Diagnostic [123I]FP-CIT SPECT grading at baseline is correlated with motor severity at 36 months in patients with Parkinson's disease. <i>Movement Disorders</i> . 2011;26:S249.	4

601	Nobili F, Arnaldi D, Morbelli S, Bauckneht M, Pardini M, Donegani I, et al. Associations between grey matter metabolism and dopaminergic and serotonergic systems degeneration in De novo PD. <i>European Journal of Neurology</i> . 2021;28(SUPPL 1):113.	9
602	Nobili F, Campus C, Arnaldi D, De Carli F, Cabassi G, Brugnolo A, et al. Cognitive-nigrostriatal relationships in de novo, drug-naive Parkinson's disease patients: A [I-123]FP-CIT SPECT Study. <i>Movement Disorders</i> . 2010;25(1):35-43.	9
603	Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi-quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: Results from the ENC-DAT database. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;40(4):565-73.	9
604	Nogareda Seoane Z, Garcia Lucero E, Menendez Alonso R, Alvarez Alonso A, Zeidan N. Normal pre-synaptic imaging with SPECT 123I-FP-CIT in suspected Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2:S627.	9
605	Nonokuma M, Kuwabara Y, Hida K, Tani T, Takano K, Yoshimitsu K. Optimal ROI setting on the anatomically normalized I-123 FP-CIT images using high-resolution SPECT. <i>Annals of Nuclear Medicine</i> . 2016;30(9):637-44.	9
606	Noponen T, Jaakkola E, Makinen E, Eklund M, Nuutila S, Lindholm K, et al. Reliability of occipital reference region in [123I]-FP-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2020;47(SUPPL 1):S168.	9
607	Novellino F, Arabia G, Bagnato A, Cascini GL, Salsone M, Nicoletti G, et al. Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors. <i>Movement Disorders</i> . 2009;24(15):2242-8.	9
608	Nuutila S, Eklund M, Joutsa J, Jaakkola E, Makinen E, Honkanen EA, et al. Diagnostic accuracy of glabellar tap sign for Parkinson's disease. <i>Journal of Neural Transmission</i> . 2021;128(11):1655-61.	7
609	Nuutila S, Joutsa J, Eklund M, Jaakkola E, Makinen E, Noponen T, et al. Glabellar tap predicts dopamine transporter deficiency in parkinsonism. <i>Movement Disorder</i> . 2019;34(Supplement 2):S406.	4
610	O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with lewy bodies. <i>Archives of Neurology</i> . 2004;61(6):919-25.	7
611	Ogawa T, Fujii S, Kuya K, Kitao SI, Shinohara Y, Ishibashi M, et al. Role of neuroimaging on differentiation of Parkinson's disease and its related diseases. <i>Yonago Acta Medica</i> . 2018;61(3):145-55.	2
612	Ogawa T, Kuya K, Kitao SI, Kato A, Shinohara Y, Ishibashi M, et al. Diagnosis of dementia with lewy bodies using neuroimaging diagnostic approach and differential diagnosis. <i>Neuroradiology</i> . 2017;59(1 Supplement 1):S71.	4
613	Ogawa T, Kuya K, Shinohara Y, Fujii S, Miyoshi F, Tanabe Y. Neuromelanin mr imaging in patients with parkinsonian disorder: Comparison with 123I-FP-CIT spect. <i>Neuroradiology</i> . 2015;1:S141.	4
614	Ogawa T, Kuya K, Shinohara Y, Miyoshi F, Fujii S, Tanabe Y. Evaluation of Parkinson's disease by neuromelanin-sensitiveMR imaging and 123I-FP-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(1 Supplement 1):S252-S3.	4
615	Oh ES, Kim JM, Kim YE, Yun JY, Kim JS, Kim SE, et al. The prevalence of essential tremor in elderly Koreans. <i>Journal of Korean medical science</i> . 2014;29(12):1694-8.	9
616	Oh ES, Kim JM, Park SS, Kim YK, Kim SE, Oh SH, et al. Hemiparkinsonism-hemiatrophy syndrome: Neuroimaging and genetics. <i>Parkinsonism and Related Disorders</i> . 2012;2:S50-S1.	6
617	Oh JK, Choi EK, Song IU, Kim JS, Chung YA. Comparison of I-123 MIBG planar imaging and SPECT for the detection of decreased heart uptake in Parkinson disease. <i>Journal of Neural Transmission</i> . 2015;122(10):1421-7.	8
618	Ohta Y, Yamashita T, Hishikawa N, Sato K, Matsuzono K, Tsunoda K, et al. Potential multisystem degeneration in Asidan patients. <i>Journal of the Neurological Sciences</i> . 2017;373:216-22.	9
619	Okazawa H, Ikawa M, Tsujikawa T, Mori T, Makino A, Kiyono Y, et al. Evaluation of nigrostriatal oxidative stress intensity in patients with Parkinson's disease using [Cu-62]ATSM PET and FP-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1:S273.	4
620	Okazawa H, Islam MM, Rahman MGM, Tsujikawa T. Development of an automatic calculation method for the specific binding ratio in [I-123]ioflupne SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2020;47(SUPPL 1):S401.	4
621	Okizaki A, Nakayama M, Takahashi K. An investigation for intra-observer reproducibility of FPCIT SPECT in patients with DLB. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2017;44(2 Supplement 1):S611.	4
622	Okizaki A, Nakayama M, Takahashi K. An investigation for reproducibility of FP-CIT SPECT in patients with DLB. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2017;58(Supplement 1).	9

623	Okuzumi A, Hatano T, Kamagata K, Hori M, Aoki S, Hattori N. Prognostic factors of motor symptoms in Parkinson's disease using neuromelanin imaging and the relationship with (123)I-FP-CITSPECT. <i>Movement Disorders</i> . 2016;31(Supplement 2):S398-S9.	4
624	Olivares Romero J, Arjona Padillo A. Diagnostic accuracy of 123I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: A prospective study. [Spanish]. <i>Neurologia</i> . 2013;28(5):276-82.	10
625	Oliveira FPM, Borges Faria D, Campos Costa D, Tavares JMRS. A robust computational solution for automated quantification of a specific binding ratio based on [123I]FP-CIT SPECT images. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;58(1):74-84.	10
626	Oliveira FPM, Castelo-Branco M. Computer-aided diagnosis of Parkinson's disease based on [123I]FP-CIT SPECT binding potential images, using the voxels-as-features approach and support vector machines. <i>Journal of Neural Engineering</i> . 2015;12(2) (no pagination)(026008).	10
627	Oliveira FPM, Faria DB, Costa DC, Castelo-Branco M, Tavares JMRS. Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson's disease based on [123I]FP-CIT SPECT images. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2018;45(6):1052-62.	8
628	Oliveira FPM, Walker Z, Walker RWH, Attems J, Castanheira JC, Silva A, et al. 123 I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease: A new quantitative analysis of autopsy confirmed cases. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2021;92(6):662-7.	7
629	Oliver-Evans A, Colloby S, Thomas A, Erskine D, Attems J. Serotonergic 123I-FP-CIT binding is associated with depression and not neuropathology. <i>Neuropathology and Applied Neurobiology</i> . 2019;45(Supplement 1):46.	9
630	Onishi H, Furuta A, Nakamoto K, Takayama M, Amijima H. Impact of brain ventricle size on semi-quantitative index derived from 123-I-FP-CIT images using a novel 3D-striatum digital brain (3D-SDB). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2017;44(2 Supplement 1):S391-S2.	4
631	Orso B, Arnaldi D, Fama F, Girtler N, Brugnolo A, Doglione E, et al. Anatomical and neurochemical bases of theory of mind in de novo Parkinson's Disease. <i>Cortex</i> . 2020;130:401-12.	9
632	Orso B, Arnaldi D, Girtler N, Brugnolo A, Doglione E, Mattioli P, et al. Dopaminergic and Serotonergic Degeneration and Cortical [18F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease. <i>Movement Disorders</i> . 2021;36(10):2293-302.	9
633	Ortega Lozano SJ, Martinez Del Valle Torres MD, Jimenez-Hoyuela Garcia JM, Delgado Garcia A, Campos Arillo V. Application of 123I-FE-CIT in the clinical practice in Parkinsonism patients. [Spanish]. <i>Revista Espanola de Medicina Nuclear</i> . 2005;24(4):224-33.	3
634	O'Sullivan JD, Costa DC, Gacinovic S, Lees AJ. SPECT imaging of the dopamine transporter in juvenile-onset dystonia. <i>Neurology</i> . 2001;56(2):266-7.	9
635	Ottaviani S, Tinazzi M, Pasquin I, Nothdurfter W, Tomelleri G, Fincati E, et al. Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease. <i>Neurological Sciences</i> . 2006;27(6):397-401.	10
636	Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. <i>Neurology</i> . 2018;91(10):e894-e905.	4
637	Pagano G, Niccolini F, Politis M. Constipation in early de novo Parkinson's disease: Prevalence and correlates with clinical features, imaging and non-imaging biomarkers. <i>Movement Disorders</i> . 2016;31(Supplement 2):S256.	9
638	Pagano G, Niccolini F, Politis M. alpha-synuclein CSF levels correlate with urinary dysfunction in early de novo Parkinson's disease patients. <i>Movement Disorders</i> . 2016;31(Supplement 2):S266.	4
639	Pagano G, Politis M. Molecular Imaging of the Serotonergic System in Parkinson's Disease. <i>International Review of Neurobiology</i> . 2018;141:173-210.	2
640	Pak K, Kim H, Seok JW, Lee MJ, Shin S, Kim K, et al. Prediction of future weight change with dopamine transporter in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> . 2019;126(6):723-9.	9
641	Pak K, Kim K, Lee MJ, Lee JM, Kim BS, Kim SJ, et al. Correlation between the availability of dopamine transporter and olfactory function in healthy subjects. <i>European Radiology</i> . 2018;28(4):1756-60.	9
642	Pak K, Kim S, Kim I. Effects of rs591323 on serotonin transporter availability in healthy male subjects effects of rs591323 on serotonin transporter availability in healthy male subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2018;45(Supplement 1):S401-S2.	4
643	Pak K, Lee MJ, Kim K, Kim IJ. No effect of Parkinson's disease-polygenic load on striatal density of dopaminergic neuron in healthy subjects. <i>Annals of Nuclear Medicine</i> . 2021;35(11):1187-92.	9
644	Pak K, Nam HY, Shin S, Kim K, Lee MJ, Kim EJ, et al. Effects of rs591323 on serotonin transporter availability in healthy male subjects. <i>Annals of Nuclear Medicine</i> . 2018;32(7):431-6.	9
645	Pak K, Shin HK, Kim EJ, Lee JH, Lyoo CH, Son J, et al. Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> . 2018;51:67-72.	10

646	Pak KJ, Lee MJ. Effect of polygenic load on striatal dopaminergic deterioration in Parkinson's disease. <i>Movement Disorder</i> . 2019;34(Supplement 2):S188-S9.	10
647	Pak KJ, Shin HK, Kim EJ, Lee JH, Lyoo CH, Son JS, et al. Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease. <i>Movement Disorders</i> . 2018;33(Supplement 2):S744-S5.	4
648	Palermo G, Ceravolo R. Molecular imaging of the dopamine transporter. <i>Cells</i> . 2019;8(8) (no pagination)(872).	2
649	Palermo G, Frosini D, Giannoni S, Giuntini M, Volterrani D, Bonuccelli U, et al. Age-related failure in compensatory mechanisms and its relation to the Parkinson phenotype: Evidence from a SPECT study in early and late-onset PD. <i>Movement Disorder</i> . 2019;34(Supplement 2):S820.	4
650	Palermo G, Giannoni S, Frosini D, Morganti R, Volterrani D, Bonuccelli U, et al. Dopamine transporter, age and motor complications in Parkinson's disease: A clinical and SPECT study. <i>European Journal of Neurology</i> . 2020;27(Supplement 1):320.	4
651	Palmieri A, Zocco A. Qualitative and quantitative analysis of 123I-DaTSCAN SPECT in the diagnosis of Parkinson's diseases: Body-contouring versus circular orbit acquisition. <i>Clinical and Translational Imaging</i> . 2015;1):S142.	4
652	Palmisano C, Brandt G, Pozzi NG, Brumberg J, Leporini A, Marotta G, et al. A selective role of striatal dopamine in the timing of anticipatory postural adjustments at gait initiation in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> . 2018;46(Supplement 2):e76-e7.	4
653	Palumbo B, Bianconi F, Nuvoli S, Spanu A, Fravolini ML. Artificial intelligence techniques support nuclear medicine modalities to improve the diagnosis of Parkinson's disease and Parkinsonian syndromes. <i>Clinical and Translational Imaging</i> . 2021;9(1):19-35.	2
654	Palumbo B, Buresta T, Cascianelli S, Fravolini ML, Sabalich I, Ministrini M, et al. Classification tree analysis by means of 123I-FP-CIT brain spect semiquantitative data provides cut-off values to diagnose Parkinson's disease. <i>Clinical and Translational Imaging</i> . 2015;1):S42.	4
655	Palumbo B, Cascianelli S, Sabalich I, Santonicola A, Buresta T, Fravolini ML, et al. Cut-off values to diagnose Parkinson's disease by means of 123I-FP-CIT brain SPECT semiquantitative data as evaluated by classification tree algorithm. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S568.	4
656	Palumbo B, Cascianelli S, Santonicola A, Ministrini M, Buresta T, Fravolini ML, et al. 123I-FP-CIT brain SPECT: Tracer uptake values of right putamen are the most discriminant to diagnose Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(1 Supplement 1):S631.	4
657	Palumbo B, Fravolini ML, Buresta T, Pompili F, Forini N, Nigro P, et al. Diagnostic accuracy of parkinson disease by support vector machine (SVM) analysis of 123I-FP-CIT brain SPECT data. <i>Medicine (United States)</i> . 2014;93(27) (no pagination)(228).	8
658	Palumbo B, Fravolini ML, Nuvoli S, Spanu A, Paulus KS, Schillaci O, et al. Erratum: Comparison of two neural network classifiers in the differential diagnosis of essential tremor and Parkinson's disease by 123I-FP-CIT brain SPECT (<i>European Journal of Nuclear Medicine and Molecular Imaging</i> DOI: 10.1007/s00259-010-1481-6). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;37(11):2199.	9
659	Palumbo B, Fravolini ML, Nuvoli S, Spanu A, Paulus KS, Schillaci O, et al. Comparison of two neural network classifiers in the differential diagnosis of essential tremor and Parkinson's disease by 123I-FP-CIT brain SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;37(11):2146-53.	10
660	Palumbo B, Nuvoli S, Cascianelli S, Santonicola A, Fravolini ML, Tambasco N, et al. Comparison of the diagnostic performance of two methods of semiquantitative analysis of 123I-FP-CIT brain SPECT images in mild Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(1 Supplement 1):S630-S1.	4
661	Palumbo B, Nuvoli S, Fravolini ML, Pietroniro D, Rossi A, Spanu A, et al. Comparison of the diagnostic performance of three methods of semiquantitative analysis for 123I-FP-CIT brain SPECT data in identifying Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2):S555.	4
662	Palumbo B, Nuvoli S, Pompili F, Fravolini ML, Sabalich I, Tambasco N, et al. Evaluation of the performance of two methods of semiquantitative analysis of 123I-FP-CIT brain SPECT data by means of a support vector machine classifier (SVM) to diagnose Parkinson's disease. <i>Clinical and Translational Imaging</i> . 2013;1):S92-S3.	4
663	Palumbo B, Nuvoli S, Pompili F, Fravolini ML, Sabalich I, Tambasco N, et al. Support Vector Machine classifier (SVM) in investigating the ability of two Methods of semiquantitative analysis of 123I-FP-CIT brain SPECT to correctly diagnose Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;2):S452.	4
664	Palumbo B, Santonicola A, Cascianelli S, Nuvoli S, Fravolini ML, Ministrini M, et al. Role of an artificial neural network classifier, a classification tree (CIT), to diagnose Parkinson's disease in early phase by using 123I-FP-CIT brain SPECT data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2017;44(2 Supplement 1):S191.	4
665	Papadaki E, Spanaki K, Bourogianni O, Galanopoulos K, Aefantinou M, Tsaroucha A, et al. The contribution of myocardial 123I-MIBG scintigraphy in differentiation of Parkinson Disease from Atypical Parkinsonian Syndromes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S624.	4
666	Papathanasiou N, Rondogianni P, Chroni P, Themistocleous M, Boviatsis E, Pedeli X, et al. Interobserver variability, and visual and quantitative parameters of 123I-FP-CIT SPECT (DaTSCAN) studies. <i>Annals of Nuclear Medicine</i> . 2012;26(3):234-40.	10
667	Papesh K, Mari Z. Look Again: The diagnostic value of repeat dopamine transporter imaging. <i>Movement Disorders</i> . 2020;35(SUPPL 1):S262.	6

668	Park E. A new era of clinical dopamine transporter imaging using 123I-FP-CIT. <i>Journal of Nuclear Medicine Technology</i> . 2012;40(4):222-8.	2
669	Park HR, Ha S, Lee DS, Im HJ, Paek SH. Determination of Parkinson Disease Laterality after Deep Brain Stimulation Using 123I FP-CIT SPECT. <i>Clinical Nuclear Medicine</i> . 2020;45(4):E178-E84.	10
670	Park M, Park H. Transcranial brain sonography can distinguish drug induced parkinsonism from idiopathic Parkinson's disease in Korean? <i>Movement Disorders</i> . 2020;35(SUPPL 1):S40.	4
671	Pasquini J, Ceravolo R, Brooks DJ, Bonuccelli U, Pavese N. Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study. <i>Parkinsonism and Related Disorders</i> . 2020;77:170-5.	9
672	Pasquini J, Ceravolo R, Qamhawi Z, Lee JY, Deuschl G, Brooks DJ, et al. Progression of tremor in early stages of Parkinson's disease: A clinical and neuroimaging study. <i>Brain</i> . 2018;141(3):811-21.	9
673	Pasquini J, Pavese N. Striatal dopaminergic denervation and hypomimia in Parkinson's disease. <i>European Journal of Neurology</i> . 2021;28(1):e2-e3.	9
674	Paterson C, Robinson J, Smith S, Martin W. Quantification of striatal uptake in DaTscan dopamine transporter imaging: Effect of systematically reduced count density on diagnostic accuracy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1:S300.	4
675	Pedrosa DJ, Kahraman D, Schmidt M, Drzezga A, Timmermann L, Eggers C. Parkinson's disease with a predominant right-sided putaminal FP-CIT SPECT deficiency shows stronger decline of asymmetry over time. <i>Basal Ganglia</i> . 2014;4(3-4):101-8.	9
676	Pellaprat J, Dellapina E, Adel D, Harroch E, Ory-Magne F, Payoux P, et al. Correlation study between [123I]-FP-CIT binding and nociceptive threshold in Parkinson's disease. <i>Fundamental and Clinical Pharmacology</i> . 2014;1):26.	10
677	Pellaprat J, Dellapina E, Adel D, Harroch E, Payoux P, Ory-Magne F, et al. Correlation study between [123I]-FP-CIT binding and nociceptive threshold in Parkinson's disease. <i>Movement Disorders</i> . 2014;1):S89.	4
678	Pellecchia MT, Picillo M, Santangelo G, Longo K, Moccia M, Erro R, et al. Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: A preliminary study. <i>Acta Neurologica Scandinavica</i> . 2015;131(5):275-81.	9
679	Pencharz DR, Hanlon P, Chakravartty R, Navalkisoor S, Quigley AM, Hall M, et al. Automated quantification with BRASS reduces equivocal reporting of DaTSCAN (123I-FP-CIT) SPECT studies. <i>Nuclear Medicine Review</i> . 2014;17(2):65-9.	9
680	Perez Saldana MT, Perez Velasco R, Burguera JA. Diagnosis of vascular parkinsonism: Correlation of the symptoms with neuroimaging and utility of SPECT with 123I-ioflupane. [Spanish]. <i>Neurologia</i> . 2008;23(9):566-74.	3
681	Perlaki G, Szekeres S, Janszky J, Dezso D, Aschermann Z, Zambo K, et al. The applicability of 123I-FP-CIT SPECT dopamine transporter imaging in clinical practice. [Hungarian]. <i>Ideggyogyaszati Szemle</i> . 2019;72(11-12):381-8.	3
682	Perlaki G, Szekeres S, Orsi G, Papp L, Suha B, Nagy SA, et al. Validation of an automated morphological MRI-based 123I-FP-CIT SPECT evaluation method. <i>Parkinsonism and Related Disorders</i> . 2016;29:24-9.	10
683	Pifarre P, Cuberas G, Hernandez J, Lorenzo C, Miquel F, Castell-Conesa J. Cortical and subcortical patterns of I-123 iodobenzamide SPECT in striatal D2 receptor parkinsonisms. <i>Clinical Nuclear Medicine</i> . 2010;35(4):228-33.	9
684	Pilotto A, Di Cola FS, Premi E, Grasso R, Turrone R, Gipponi S, et al. Cortical dopamine depletion and cognition in Lewy bodies disorders: A 123I-FPCIT single-subject study. <i>Journal of Prevention of Alzheimer's Disease</i> . 2018;5(1):S76.	4
685	Pilotto A, SchianodiCola F, Premi E, Grasso R, Turrone R, Gipponi S, et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: A 123I-FP-CIT study. <i>Movement Disorder</i> . 2019;34(Supplement 2):S821.	4
686	Pina G, De Charry C, Vighetto A, Scheiber C. SPECT/CT imaging of dopamine transporters in diagnosis of corticobasal degeneratio. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;2):S296.	4
687	Piperkova E, Georgiev R, Daskalov M, Orosova M, Milanova M, Danon S, et al. SPECT 123-I-[FP-CIT] diagnostic in the presynaptic parkinsonism. [Bulgarian]. <i>Rentgenologiya i Radiologiya</i> . 2005;44(1):35-40.	3
688	Pirker W. SPECT in the diagnosis of Parkinsonism. [German]. <i>Journal fur Neurologie, Neurochirurgie und Psychiatrie</i> . 2015;16(2):60-71.	3
689	Pitkonen M, Hippeläinen E, Wang S, Andressoo J, Garcia-Horsman A, Bergstrom K. Dynamic imaging of fp-cit spect in the mice brain using high resolution preclinical SPECT-CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S405.	1
690	Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: Study on 72 patients *. <i>Journal of Neural Transmission</i> . 2005;112(5):677-92.	7

691	Plotkin M, Amthauer H, Quill S, Marzinik F, Klostermann F, Klaffke S, et al. Imaging of dopamine transporters and D2 receptors in vascular parkinsonism: A report of four cases. <i>Journal of Neural Transmission</i> . 2005;112(10):1355-61.	9
692	Plotkin M, Schreiner S, Lobsien E, Kupsch A, Schreiber S, Brenner W, et al. Hyperechogenicity of the substantia nigra (SN) in idiopathic Parkinson's disease (IPS) does not correlate with dopaminergic degeneration as shown by FP-CIT-SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2):S218.	9
693	Poli GL, Bianchi C, Guerra UP. Use of the BasGan algorithm for [123I]FP-CIT SPECT quantification: A phantom study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;57(4):391-400.	9
694	Polito C, Berti V, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. <i>Neurobiology of Aging</i> . 2012;33(1):e29-206.	9
695	Polychronis S, Dervenoulas G, Pagano G, Niccolini F, Politis M. Swallowing difficulties and Parkinson's disease. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):566.	9
696	Polychronis S, Dervenoulas G, Yousaf T, Niccolini F, Pagano G, Politis M. Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naive Parkinson's patients. <i>PLoS ONE</i> . 2019;14(7) (no pagination)(e0214352).	9
697	Polychronis S, Niccolini F, Pagano G, Politis M. Speech difficulties are linked to striatal dopaminergic deficits and cognitive decline in early de novo patients with Parkinson's disease. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):567.	9
698	Polychronis S, Niccolini F, Pagano G, Yousaf T, Politis M. Speech difficulties in early de novo patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> . 2019;64:256-61.	9
699	Polychronis S, Pagano G, Politis M. The role of striatal dopaminergic terminals in early de novo PD patients with speech impairment. <i>Movement Disorders</i> . 2016;31(Supplement 2):S411.	4
700	Polychronis S, Pagano G, Politis M. The role of diabetes mellitus and hyperglycemia in early de novo Parkinson's disease patients. <i>Movement Disorders</i> . 2016;31(Supplement 2):S148.	4
701	Pontico M, Frantellizzi V, Locuratolo N, Fattapposta F, De Vincentis G. Correlation between neuroreceptorial DAT/MIBG imaging and DAT gene methylation in Parkinsonian syndromes. <i>Clinical and Translational Imaging</i> . 2019;7(Supplement 1):S30.	4
702	Posada JJ, Dominguez-Gonzalez C, Manrique-Legaz A, Hernandez-Lain A, Martin-Casanueva MA, Bornstein B. 123I-FP-CIT SPECT alteration without Parkinsonism in ataxia neuropathy spectrum phenotype due to POLG mutations. <i>Movement Disorders</i> . 2014;1):S123.	4
703	Posada JJ, Gallardo ME, Dominguez C, Rivera H, Cabello A, Arenas J, et al. 123I-FP-CIT SPECT alteration without parkinsonism in SANDO phenotype due to POLG mutations. <i>Movement Disorders</i> . 2011;2):S344.	4
704	Posada-Rodriguez I, Dominguez-Gonzalez C. Association of Charcot-Marie-Tooth disease, Parkinson's disease and FIG4 mutations. <i>Movement Disorder</i> . 2019;34(Supplement 2):S421.	4
705	Pozzi NG, Arnulfo G, Steigerwald F, Maltese V, Palmisano C, Brumberg J, et al. Subthalamic Nucleus Activity at gait initiation in Parkinson disease: Report of three cases. <i>Neurological Sciences</i> . 2015;36(2 Supplement 1):S194.	4
706	Premi E, Calhoun VD, Garibotto V, Turrone R, Alberici A, Cottini E, et al. Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging. <i>Molecular Imaging and Biology</i> . 2017;19(5):772-8.	9
707	Premi E, Pilotto A, Garibotto V, Bigni B, Turrone R, Alberici A, et al. Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome? <i>Parkinsonism and Related Disorders</i> . 2016;30:62-6.	9
708	Prosser A, Bolt L, Kemp P, Kipps C. Occipital cortex hypoperfusion in (99m) TC-HMPAO SPECT predicts 123-I FP-CIT SPECT (DaTscan) status. <i>Alzheimer's and Dementia</i> . 2014;4):P706-P7.	9
709	Prunier-Aesch C, Allainmat L, Le Borgne A, Pina-Jomir G, Moreau-Triby C, Djemoussi FC, et al. SPECT-CTand quantification of 123I-FPCIT: Evaluation of CT contribution. <i>Medecine Nucleaire</i> . 2011;35(5):292.	9
710	Puccini G, Ceravolo R, Frosini D, Guidoccio F, Bonuccelli U, Chiacchio S, et al. Association between 123I-FP-CIT SPECT and cognitive outcome in Parkinson's disease: A longitudinal study at 5 years of follow-up. <i>Clinical and Translational Imaging</i> . 2015;1):S91-S2.	4
711	Puccini G, Ceravolo R, Guidoccio F, Frosini D, Chiacchio S, Gennaro M, et al. Correlation between 123I-FP-CIT SPECT and cognitive outcome in Parkinson's disease: 5 years of follow-up. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S276.	4
712	Puligheddu M, Figorilli M, Serra A, Laccu I, Congiu P, Tamburrino L, et al. REM Sleep without atonia correlates with abnormal vestibular-evoked myogenic potentials in isolated REM sleep behavior disorder. <i>Sleep</i> . 2019;42(9) (no pagination)(zsz128).	9
713	Punal Rioboo J, Varela Lema L, Serena Puig A, Ruano-Ravina A. Effectiveness of 123I-ioflupane (DaTSCAN®) in the diagnosis of Parkinsonian syndromes. A systematic review. [Spanish]. <i>Revista Espanola de Medicina Nuclear</i> . 2007;26(6):375-84.	3

714	Qamhawi Z, Towey D, Pagano G, Seibyl J, Marek K, Borghammer P, et al. Clinical correlates of raphe serotonergic system dysfunction in early Parkinson's disease. Neurology Conference: 67th American Academy of Neurology Annual Meeting, AAN. 2015;84(SUPPL. 14).	4
715	Qamhawi Z, Towey D, Shah B, Pagano G, Seibyl J, Marek K, et al. Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease. Brain. 2015;138(10):2964-73.	9
716	Queiroga M, Silva D, Elias M, Serrano J, Madrid J, Carolino E, et al. Implementation of a new reference values's database for semiquantification in 123I-FP-CIT brain single photon emission tomography. European Journal of Nuclear Medicine and Molecular Imaging. 2015;1):S832-S3.	4
717	Ragno M, Berbellini A, Cacchio G, Manca A, Di Marzio F, Pianese L, et al. Parkinsonism is a late, not rare, feature of CADASIL a study on Italian patients carrying the R1006C mutation. Stroke. 2013;44(4):1147-9.	9
718	Ragno M, Scarcella MG, Cacchio G, Capellari S, Di Marzio F, Parchi P, et al. Striatal [123I] FP-CIT SPECT demonstrates dopaminergic deficit in a sporadic case of Creutzfeldt-Jakob disease. Acta Neurologica Scandinavica. 2009;119(2):131-4.	6
719	Rahman M, Islam M, Tsujikawa T, Kiyono Y, Okazawa H. A new method for [123I]FP-CIT specific binding ratio estimation in evaluation of striatal function. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2018;59(Supplement 1).	4
720	Rahman MGM, Islam MM, Tsujikawa T, Kiyono Y, Okazawa H. Count-based method for specific binding ratio calculation in [I-123]FP-CIT SPECT analysis. Annals of Nuclear Medicine. 2019;33(1):14-21.	7
721	Rahman MGM, Islam MM, Tsujikawa T, Okazawa H. A novel automatic approach for calculation of the specific binding ratio in [I-123]FP-CIT SPECT. Diagnostics. 2020;10(5) (no pagination)(diagnostics10050289).	7
722	Railo H, Olkonemi H, Eeronheimo E, Paakkonen O, Joutsa J, Kaasinen V. Dopamine and eye movement control in Parkinson's disease: Deficits in corollary discharge signals? PeerJ. 2018;2018(12) (no pagination)(e6038).	9
723	Ramani L, Malek N, Patterson J, Nissen T, Newman EJ. Relationship between [123I]-FP-CIT SPECT and clinical progression in Parkinson's disease. Acta Neurologica Scandinavica. 2017;135(4):400-6.	9
724	Reininger CB. The role of brain histopathology in neuro-pet and spect tracer development. Neuropathology. 2013;33(3):333.	2
725	Reis J, Benbrick E, Bonnetere V, Spencer PS. Parkinson's disease and solvents: Is there a causal link? Revue Neurologique. 2016;172(12):761-5.	9
726	Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressive symptoms and Tower of London task performance in Parkinson's disease. Movement Disorders. 2008;23(11):1580-7.	9
727	Remy P. Is functional imaging useful the clinical evaluation of Parkinson's disease?. [French]. Revue Neurologique. 2003;159(5 II):3S57-3S61.	3
728	Ribacoba R, Vega-Villar J, Mauri-Capdevila G, Zeidan-Ramon N, Suarez-San Martin E. FP-CIT datscan did not useful in differential diagnoses of Parkinson's disease subgroups. Parkinsonism and Related Disorders. 2012;2):S94.	9
729	Ricci M, Sollaku S, Frantellizzi V, Lazri J, Monteleone F, Liberatore M. Midbrain Serotonin transporter (SERT) evaluation by 123I-FP-CIT: A one-year retrospective study. European Journal of Nuclear Medicine and Molecular Imaging. 2017;44(2 Supplement 1):S593.	9
730	8iterations,	4
731	8iterations,	4
732	Rissanen E, Kaasinen V, Sonninen P, Roytta M, Paivarinta M. Brain dopamine transporter binding and glucose metabolism in progressive supranuclear palsy-like Creutzfeldt-Jakob disease. Case Reports in Neurology. 2014;6(1):28-33.	6
733	Roberta B, Paolo B, Massimo F, Roberto E. Unexpected (123I)FP-CIT SPECT findings: SWIDD, SWEDD and all DAT. Journal of Neurology. 2021.	2
734	Roberts G, Donaghy PC, Lloyd J, Durcan R, Petrides G, Colloby SJ, et al. Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. British Journal of Psychiatry. 2021;218(5):276-82.	9
735	Roiter B, Pigato G, Antonini A. Prevalence of Extrapyrmidal Symptoms in In-Patients With Severe Mental Illnesses: Focus on Parkinsonism. Frontiers in Neurology. 2020;11 (no pagination)(593143).	9
736	Romagnolo A, Fabbri M, Merola A, Montanaro E, Palermo S, Martone T, et al. Beyond 35 years of Parkinson's disease: a comprehensive clinical and instrumental assessment. Journal of Neurology. 2018;265(9):1989-97.	4
737	Romagnolo A, Rizzone MG, Dematteis F, Zibetti M, Merola A, Rizzi L, et al. Beyond 30 years of parkinson's disease: A comprehensive characterization of long-surviving patients. Movement Disorders. 2016;31(Supplement 2):S598.	4

738	Roselli F, Pisciotta N, Aniello M, Gigante A, De Caro M, Ferrannini E, et al. Errata to Midbrain SERT in degenerative parkinsonisms: A 123I-FP-CIT SPECT study. [Mov Disord (2010), 25, 12, 1853-1859]. Movement Disorders. 2010;25(14):2478.	9
739	Roselli F, Pisciotta NM, Pennelli M, Aniello MS, Gigante A, De Caro MF, et al. Midbrain SERT in degenerative parkinsonisms: A 123I-FP-CIT SPECT study. Movement Disorders. 2010;25(12):1853-9.	9
740	Roselli F, Pisciotta NM, Perneckzy R, Pennelli M, Aniello MS, De Caro MF, et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with lewy bodies: A123I-FP-CIT SPECT study. Movement Disorders. 2009;24(14):2097-103.	10
741	Rossi C, Genovesi D, Marzullo P, Giorgetti A, Filidei E, Corsini GU, et al. Striatal dopamine transporter modulation after rotigotine: Results from a pilot single-photon emission computed tomography study in a group of early stage Parkinson disease patients. Clinical Neuropharmacology. 2017;40(1):34-6.	9
742	Rossi C, Volterrani D, Nicoletti V, Manca G, Frosini D, Kiferle L, et al. "Parkinson-dementia" diseases: A comparison by double tracer SPECT studies. Parkinsonism and Related Disorders. 2009;15(10):762-6.	9
743	Roussakis A, Politis M, Towey D, Piccini P. Parkinson's disease progression is associated with increased putaminal serotonin to dopamine transporter ratio: Relevance for dyskinesias. Neurology Conference: 67th American Academy of Neurology Annual Meeting, AAN. 2015;84(SUPPL. 14).	4
744	Roussakis AA, Patel NH, Gennaro M, Bowen C, Phillips J, Piccini P. The role of semi-quantification of 123I-FPCIT SPECT scans in improving the quality of reporting. European Journal of Neurology. 2020;27(Supplement 1):973.	4
745	Roussakis AA, Politis M, Towey D, Piccini P. Serotonin-to-dopamine transporter ratios in the striatum of patients with parkinson's disease: Impact on levodopa-induced dyskinesias. Journal of Neurology, Neurosurgery and Psychiatry Conference: Association of British Neurologists, ABN. 2015;86(11).	9
746	Roussakis AA, Politis M, Towey D, Piccini P. Levodopa induced dyskinesias: Increased serotonin to dopamine transporter ratios in the putamen of Parkinson's disease patients. European Journal of Neurology. 2015;1:195.	4
747	Roussakis AA, Towey D, Piccini P. Longitudinal single-photon emitted computed tomography (SPECT) study of striatal dopamine transporter (DAT) density: Relevance to levodopa-induced dyskinesias in Parkinson's disease. Journal of the Neurological Sciences. 2017;381(Supplement 1):949.	9
748	Rupprecht S, Schultze T, Gunther A, Walther B, Steenbeck J, Gudziol H, et al. Risk marker for development of neurodegenerative disease in idiopathic REM sleep behaviour disorder using I-FP-CIT SPECT, transcranial sonography and olfactory function testing. Somnologie. 2011;1:92-3.	9
749	Ryoo N, Bae YJ, Song YS, Kim JM. Altered glymphatic function in Parkinson's disease. Movement Disorder. 2021;36(SUPPL 1):S374.	4
750	Sainz-Esteban A, Garcia-Talavera P, Marco J, Tola-Arribas M, Ruiz M, Gonzalez-Selma M, et al. Correlation between 123I-IBZM SPECT and clinical diagnosis in parkinsonian syndrome. European Journal of Nuclear Medicine and Molecular Imaging. 2011;2:S330.	4
751	Sakamoto F, Shiraishi S, Kitajima M, Ogasawara K, Tsuda N, Tomiguchi S, et al. Diagnostic Performance of 123I-FP-CIT SPECT Specific Binding Ratio in Progressive Supranuclear Palsy: Use of Core Clinical Features and MRI for Comparison. American Journal of Roentgenology. 2020;215(6):1443-8.	10
752	Sakamoto F, Shiraishi S, Tsuda N, Tomiguchi S, Yamashita Y. Efficacy of the combined use of DAT SPECT and MIBG myocardial scintigraphy for diagnosing parkinson's syndrome. Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI. 2016;57(SUPPL. 2).	4
753	Sakurai T, Hirano S, Nakano Y, Ishikawa A, Kojima K, Li H, et al. Corticobasal syndrome subjects and scans without evidences of dopaminergic deficit; A retrospective neuroimaging study. Journal of the Neurological Sciences. 2017;381(Supplement 1):949-50.	9
754	Salas-Gonzalez D, Gorriz JM, Ramirez J, I AI, Padilla P, Martinez-Murcia FJ, et al. Affine registration of [123I]FP-CIT SPECT brain images. Studies in health technology and informatics. 2014;207:65-73.	9
755	Salas-Gonzalez D, Gorriz JM, Ramirez J, Illan IA, Lang EW. Linear intensity normalization of FP-CIT SPECT brain images using the alpha-stable distribution. NeuroImage. 2013;65:449-55.	9
756	Salas-Gonzalez D, Gorriz JM, Ramirez J, Illan IA, Padilla P, Martinez-Murcia FJ, et al. Building a FP-CIT SPECT Brain Template Using a Posterization Approach. Neuroinformatics. 2015;13(4):391-402.	9
757	Saletti P, Berti V, Bottoncetti A, Fedele D, Gori C, Pupi A. Dosimetry in Parkinson de novo patients after administration of 124I-beta-CIT. Clinical and Translational Imaging. 2013;1):S129.	9
758	Salhi H, Montaut S, Devos D, Chelly J, Galacteros F, Brugieres P, et al. Kufor-Rakeb syndrome and a rare ATP13A2 missense mutation in a Portuguese patient. Movement Disorders. 2018;33(Supplement 2):S633.	4

759	Salvatore E, Varrone A, Sansone V, Nolano M, Bruni AC, De Rosa A, et al. Characterization of nigrostriatal dysfunction in spinocerebellar ataxia 17. <i>Movement Disorders</i> . 2006;21(6):872-5.	9
760	Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, et al. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> . 2015;21(5):489-93.	9
761	Santonicola A, Cascianelli S, Fravolini ML, Tambasco N, Minestrini M, Scialpi M, et al. Differential diagnosis of movement disorders by means of 123I-FP-CIT brain SPECT data by using an artificial neural network classifier: The classification tree. <i>Clinical and Translational Imaging</i> . 2017;5(Supplement 1):S118.	4
762	Sasaki S. High prevalence of parkinsonism in patients with MCI or mild Alzheimer's disease. <i>Alzheimer's and Dementia</i> . 2018;14(12):1615-22.	9
763	Sasaki S. A Case of Logopenic Variant of Primary Progressive Aphasia with Parkinsonism and Anosmia. <i>Journal of Alzheimer's Disease Reports</i> . 2020;4(1):61-6.	6
764	Sasaki S. High Prevalence of Early Parkinson's Disease in Patients With Subtle Parkinsonian Signs. <i>Frontiers in Neurology</i> . 2021;12 (no pagination)(656679).	9
765	Sawada H, Orimo S. Relationship between striatal 123I-FP-CIT uptake and cognitive functions in Parkinson's disease. [Japanese]. <i>Clinical Neurology</i> . 2019;59(12):799-805.	4
766	Sawada H, Orimo S, Inaba A, Takahashi M. Relationship between cognitive dysfunction and striatal uptake of 123I-FP-CIT in patients with Parkinson's disease. <i>Movement Disorders</i> . 2017;32(Supplement 2):629.	9
767	Sawada H, Sekiguchi T, Takahashi M, Inaba A, Orimo S. Relationship between cognitive functions and striatal 123I-FP-CIT uptake in Parkinson's disease. <i>Movement Disorders</i> . 2016;31(Supplement 2):S100.	4
768	Sawada H, Takahashi M, Inaba A, Kojo T, Orimo S. Relationship between cognitive dysfunction and striatal uptake of 123I-FP-CIT in patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):731.	9
769	Sawada H, Takahashi M, Inaba A, Orimo S. Relationship between cognitive functions and striatal 123I-fp-cit uptake in Parkinson's disease. <i>Neurodegenerative Diseases</i> . 2017;17(Supplement 1):1590.	9
770	Scalorbi F, Bressan S, Favaretto S, Berti S, Pompanin S, Cagnin A, et al. Absolute quantitative evaluation of 123I-FP-CIT: Is it possible? <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S567-S8.	4
771	Scarlattèi M, Musio F, Cidda C, Belletti A, Mazza R, Baldari G, et al. Semi-quantitative assessment of striatal 123I-FP-CIT uptake in parkinson's disease. Comparison with the qualitative analysis and impact on medical reporting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2):S257.	4
772	Schapira AHV, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinson's disease (PROUD): A randomised delayed-start trial. <i>The Lancet Neurology</i> . 2013;12(8):747-55.	9
773	Scheiber C, Platsch G, Gouttard S, Thobois S, Zuehlsdorff S, Fahmi R. 123I-FP-CIT reference values from subjects with nondegenerative Parkinsonism, comparable to values from healthy volunteers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2019;46(1 Supplement 1):S96.	4
774	Schilaci O, Chiaravaloti A, Pierantozzi M, Di Pietro B, Koch G, Bruni C, et al. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: Molecular imaging with 123I-FP-CIT SPECT. <i>International Journal of Molecular Medicine</i> . 2011;28(5):881-6.	10
775	Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2005;32(12):1452-6.	9
776	Schmitz-Steinkruger H, Lange C, Apostolova I, Amthauer H, Lehnert W, Klutmann S, et al. Impact of the size of the normal database on the performance of the specific binding ratio in dopamine transporter SPECT. <i>EJNMMI Physics</i> . 2020;7(1) (no pagination)(34).	8
777	Schmitz-Steinkruger H, Lange C, Apostolova I, Mathies FL, Frings L, Klutmann S, et al. Impact of age and sex correction on the diagnostic performance of dopamine transporter SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2021;48(5):1445-59.	7
778	Schotsmans K, de Cauwer H, Baets J, Ceysens S, van den Hauwe L, Deconinck T, et al. Cerebrotendinous xanthomatosis presenting with asymmetric parkinsonism: A case with I-123-FP-CIT SPECT imaging. <i>Acta Neurologica Belgica</i> . 2012;112(3):287-9.	6
779	Schreiner S, Lobsien E, Kupsch A, Plotkin M, Schreiber SJ, Doepp F. Hyperechogenicity of the substantia nigra (SN) in idiopathic Parkinson's disease (IPS) does not correlate with dopaminergic degeneration as shown by I123-FP-CIT SPECT. <i>European Journal of Medical Research</i> . 2010;1):127.	9
780	Schwartz M, Groshar D, Inzelberg R, Hocherman S. Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities for detection of early stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> . 2004;10(6):385-9.	9
781	Schwingschuh P, Ruge D, Edwards MJ, Terranova C, Katschnig P, Carrillo F, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study. <i>Movement Disorders</i> . 2010;25(5):560-9.	9

782	Seckin ZI, Whitwell JL, Utianski RL, Botha H, Ali F, Duffy JR, et al. Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech. <i>Journal of Neurology</i> . 2020;267(9):2603-11.	9
783	Sedaghat F, Gotzamani-Psarrakou A, Dedousi E, Arnaoutoglou M, Psarrakos K, Baloyannis I, et al. Evaluation of dopaminergic function in frontotemporal dementia using 123I-FP-CIT single photon emission computed tomography. <i>Neurodegenerative Diseases</i> . 2007;4(5):382-5.	9
784	Seibyl JP. Single-Photon Emission Computed Tomography and Positron Emission Tomography Evaluations of Patients With Central Motor Disorders. <i>Seminars in Nuclear Medicine</i> . 2008;38(4):274-86.	2
785	Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. <i>Journal of Nuclear Medicine</i> . 1998;39(9):1500-8.	7
786	Sevillano MD, Cacabelos P, Tamayo P, Montes C, Perez E, Martin E. Differences in striatal dopamine transporter levels regarding predominant motor symptom in Parkinson's disease. <i>Journal of Parkinson's Disease</i> . 2013;1:122.	9
787	Shiiba T, Takaki A. Comparison of diagnostic performance of deep convolutional neural network using fine-tuning and feature extraction on dopamine transporter single photon emission tomography images. <i>Journal of Nuclear Medicine Conference</i> . 2019;60(Supplement 1).	9
788	Shimizu BS, Namioka N, Kanetaka H, Hirao K, Takenoshita N, Umahara T, et al. Correlation between clinical symptoms and striatal DAT uptake in patients with DL. <i>Neurodegenerative Diseases</i> . 2017;17(Supplement 1):107.	9
789	Shimizu S, Hirao K, Kanetaka H, Namioka N, Hatanaka H, Hirose D, et al. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(1):184-92.	9
790	Shimizu S, Hirao K, Kanetaka H, Umahara T, Sakurai H, Hanyu H. The utility of a combined study of DAT SPECT and MIBG myocardial scintigraphy in distinguishing dementia with Lewy bodies from Alzheimer's disease. <i>Alzheimer's and Dementia</i> . 2015;1:P421.	9
791	Shimizu S, Hirose D, Namioka N, Kanetaka H, Hirao K, Hatanaka H, et al. Correlation between clinical symptoms and striatal DAT uptake in patients with DLB. <i>Annals of Nuclear Medicine</i> . 2017;31(5):390-8.	9
792	Shimizu S, Namioka N, Hirao K, Kanetaka H, Umahara T, Sakurai H, et al. Correlation between DAT-SPECT uptake pattern and clinical symptoms in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> . 2016;12(7 Supplement):P707.	9
793	Shin S, Kim K, Lee JM, Kim EJ, Kim SJ, Kim JJ, et al. Effect of single-nucleotide polymorphisms on decline of dopamine transporter availability in Parkinson's disease. <i>Journal of Clinical Neurology (Korea)</i> . 2019;15(1):102-7.	9
794	Shirai S, Yabe I, Matsushima M, Kano T, Takahashi I, Yamazaki K, et al. 3-year follow up evaluation of the Parkinson's disease patients who received deep brain stimulation. <i>Clinical Neurology</i> . 2019;59(Supplement 1):S376.	4
795	Shoji H, Himeno Y, Katsuragi M, Mukasa K. DAT scan in dementia with Lewy bodies: A comparative study among striatal DAT scan decline, HOENH and YHR severity, and MMSE. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):844.	9
796	Siepel FJ, Bronnick KS, Booij J, Ravina BM, Lebedev AV, Gruner R, et al. Cognitive impairment in early Parkinson's disease: An [123I]FPCIT SPECT study. <i>Movement Disorders</i> . 2014;1):S363-S4.	4
797	Siepel FJ, Bronnick KS, Booij J, Ravina BM, Lebedev AV, Pereira JB, et al. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease. <i>Movement Disorders : official journal of the Movement Disorder Society</i> . 2014;29(14):1802-8.	7
798	Siepel FJ, Dalen I, Alves GW, Gruner R, Booij J, Bronnick KS, et al. Dopamine deficiency and clinical symptoms in suspected Lewy body dementia: A quantitative [123I]FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S323.	9
799	Siepel FJ, Dalen I, Gruner R, Booij J, Bronnick KS, Buter TC, et al. Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies. <i>Movement Disorders</i> . 2016;31(1):118-25.	9
800	Siepel FJ, Rongve A, Buter TC, Beyer MK, Ballard CG, Booij J, et al. (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: A longitudinal case study. <i>BMJ Open</i> . 2013;3(4) (no pagination)(e002642).	10
801	Silva D, Queiroga M, Elias M, Serrano J, Madrid J, Carolino E, et al. Clinical classification versus semiquantification with adapted reference values for 123I-FP-CIT SPECT in a nuclear medicine department. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1):S818.	4
802	Silveira-Moriyama L, Petrie A, Williams DR, Evans A, Katzenschlager R, Barbosa ER, et al. The use of a color coded probability scale to interpret smell tests in suspected Parkinsonism. <i>Movement Disorders</i> . 2009;24(8):1144-53.	9

803	Sivakumar V, Anand S. Functional imaging of the nigro-striatal pathway: A clinical review. <i>Indian Journal of Psychiatry</i> . 2011;1):S29.	4
804	Sixel-Doring F, Liepe K, Mollenhauer B, Trautmann E, Trenkwalder C. The role of 123I-FP-CIT-SPECT in the differential diagnosis of Parkinson and tremor syndromes: A critical assessment of 125 cases. <i>Journal of Neurology</i> . 2011;258(12):2147-54.	10
805	Skanjeti A, Angusti T, Iudicello M, Dazzara F, Delgado Yabar GM, Margheron M, et al. Accuracy of BasGan in the evaluation of doubtful 123FP-CIT SPECTs. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2):S550.	4
806	Skanjeti A, Angusti T, Iudicello M, Dazzara F, Delgado Yabar GM, Podio V. Accuracy of BasGan in the evaluation of doubtful 123I-FP-CIT SPECTs. <i>Clinical and Translational Imaging</i> . 2013;1):S91-S2.	4
807	Skanjeti A, Angusti T, Iudicello M, Dazzara F, Delgado Yabar GM, Trevisiol E, et al. Assessing the accuracy and reproducibility of computer-assisted analysis of 123I-FP-CIT SPECT using BasGan (V2). <i>Journal of Neuroimaging</i> . 2014;24(3):257-65.	10
808	Skanjeti A, Castellano G, Angusti T, Zotta M, Dazzara F, Cauda S, et al. Towards 123I-FP-CIT-SPECT standardized evaluation: BasGan accuracy in a two-center study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2):S550.	4
809	Skanjeti A, Castellano G, Elia B, Angusti T, Grimaldi S, Balma M, et al. Standardized semi-quantitative evaluation of 123I-FP-CIT SPECT in a multicenter study: Striata binding potential assessed by BASGAN (V2). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;2):S230.	4
810	Skanjeti A, Castellano G, Elia B, Angusti T, Zotta M, Dazzara F, et al. Standardized semi-quantitative evaluation of 123I-FP-CIT SPECT in a multicenter study: Striatum binding potential assessed by BasGan (V2). <i>Clinical and Translational Imaging</i> . 2013;1):S92.	4
811	Skanjeti A, Castellano G, Elia BO, Zotta M, Dazzara F, Manfredi M, et al. Multicenter Semiquantitative Evaluation of 123I-FP-CIT Brain SPECT. <i>Journal of Neuroimaging</i> . 2015;25(6):1023-9.	10
812	Skanjeti A, Castellano G, Elia BO, Zotta M, Grimaldi S, Balma M, et al. Standardized 123I-FP-CIT SPECT and voxel-based morphometry to explore Parkinson's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S276.	4
813	Skanjeti A, Delgado Yabar GM, Dazzara F, Angusti T, Iudicello M, Margheron M, et al. Accuracy and reproducibility of BasGan, in the evaluation of 123I-FP-CIT-SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2):S361.	4
814	Smilowska K, Burzynska-Makuch M, Brockhuis B, Piekarski R, Friedman A, Popek A, et al. Neuroimaging in Parkinson's Disease: necessity or exaggeration? <i>Neurologia i neurochirurgia polska</i> . 2021;12.	6
815	Sohara K, Sekine T, Tateno A, Mizumura S, Suda M, Sakayori T, et al. Multi-Atlas MRI-Based Striatum Segmentation for 123I-FP-CIT SPECT (DAT-SPECT) Compared With the Bolt Method and SPECT-Atlas-Based Segmentation Method Toward the Accurate Diagnosis of Parkinson's Disease/Syndrome. <i>Frontiers in Medicine</i> . 2021;8 (no pagination)(662233).	9
816	Solla P, Cannas A, Floris G, Polizzi L, Costantino E, Marrosu F, et al. Atypical parkinsonism in a patient with LRRK2 R1441c mutation. <i>European Journal of Neurology</i> . 2010;3):384.	6
817	Solla P, Cannas A, Fonti D, Erriu E, Ciaccio D, Farris R, et al. Correlation between non-motor symptoms and 123I-FP-CIT SPECT in Sardinian Parkinson's disease patients. <i>Neurological Sciences</i> . 2015;36(2 Supplement 1):S184-S5.	4
818	Solla P, Cannas A, Mascia MM, Mancino M, Picciau D, Farris R, et al. Pisa syndrome in a drug-naive Parkinson's disease patient. <i>Movement Disorders</i> . 2016;31(Supplement 2):S510.	4
819	Solla P, Cannas A, Orofino G, Arca R, Meloni M, Fonti D, et al. Focal 123I-FP-CIT SPECT abnormality in a patient with midbrain vascular Parkinsonism. <i>Movement Disorders</i> . 2015;1):S329-S30.	4
820	Sollaku S, Frantellizzi V, Lazri J, Civitelli L, De Vincentis G. Dopamine transporter imaging (DATScan) in suspected tyrosine hydroxylase (TH) deficiency. <i>Clinical and Translational Imaging</i> . 2019;7(Supplement 1):S89-S90.	4
821	Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, et al. Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT. <i>Movement Disorders</i> . 2004;19(10):1196-202.	9
822	Song YS, Kim JM, Kim KJ, Yun JY, Kim SE. Serum ceruloplasmin and striatal dopamine transporter density in Parkinson disease: Comparison with 123I-FP-CIT spect. <i>Clinical Nuclear Medicine</i> . 2017;42(9):675-9.	10
823	Song YS, Kim SE. Correlation of serum ceruloplasmin and related markers with striatal dopamine innervation measured with 123I-FP-CIT SPECT in parkinson's disease patients. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2016;57(SUPPL. 2).	4
824	Spampinato C, Di Stefano A, Pennisi M, Kavasidis I, Pino C, Ullo S, et al. Quantitative analysis of dat SPECT images by 3D striatum reconstruction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2):S308.	4

825	Spiegel J, Hellwig D, Mollers MO, Behnke S, Jost W, Fassbender K, et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. <i>Brain</i> . 2006;129(5):1188-93.	10
826	Spiegel J, Hellwig D, Samnick S, Jost W, Mollers MO, Fassbender K, et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease. <i>Journal of Neural Transmission</i> . 2007;114(3):331-5.	9
827	Spiegel J, Mollers MO, Jost WH, Fuss G, Samnick S, Dillmann U, et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. <i>Movement Disorders</i> . 2005;20(5):552-61.	9
828	Spiegel J, Storch A, Jost WH. Early diagnosis of Parkinson's disease. <i>Journal of Neurology</i> . 2006;253(SUPPL. 4):IV/2-IV/7.	2
829	Staff RT, Ahearn TS, Wilson K, Counsell CE, Taylor K, Caslake R, et al. Shape analysis of 123I-N-omega-fluoropropyl-2-beta- carbomethoxy-3beta-(4-iodophenyl) nortropane single-photon emission computed tomography images in the assessment of patients with parkinsonian syndromes. <i>Nuclear Medicine Communications</i> . 2009;30(3):194-201.	8
830	Stathaki M, Koukouraki S, Simos P, Boura I, Papadaki E, Bourogianni O, et al. Is There Any Clinical Value of Adding 123I-Metaiodobenzylguanidine Myocardial Scintigraphy to 123I-Ioflupane (DaTscan) in the Differential Diagnosis of Parkinsonism? <i>Clinical Nuclear Medicine</i> . 2020;45(8):588-93.	10
831	Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. <i>Brain</i> . 2005;128(1):126-37.	9
832	Stoessel AJ. Radionuclide scanning to diagnose Parkinson disease: Is it cost-effective? <i>Nature Clinical Practice Neurology</i> . 2009;5(1):10-1.	2
833	Stogbauer J, Rosar F, Dillmann U, Fassbender K, Ezziddin S, Spiegel J. Striatal dopamine transporters and cognitive function in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> . 2020;142(4):385-91.	9
834	Stojkovic T, Stefanova E, Brajkovic L, Kostic VS. Correlation of dopamine transporter imaging with parkinsonian motor handicap. <i>Movement Disorders</i> . 2013;1):S65.	4
835	Stokkel MPM, Dibbets-Schneider P, Koestering E, Dragoiescu C, Blokland KAK. Reproducibility of a standardized quantitative analysis using fixed regions of interest to differentiate movement disorders on 123I-FP-CIT SPECT. <i>Journal of Nuclear Medicine Technology</i> . 2007;35(1):21-6.	10
836	Suarez Contreras V, Tayyabah Y, Caminiti S, Politis M. Drooling in Parkinson's Disease: A [123I]FP-CIT SPECT study. <i>Movement Disorder</i> . 2019;34(Supplement 2):S452.	4
837	Suarez Contreras V, Tayyabah Y, Caminiti S, Politis M. Gait impairment in Parkinson's Disease: An [123I]FP-CIT SPECT study. <i>Movement Disorder</i> . 2019;34(Supplement 2):S452.	10
838	Suarez Contreras VC, Tayyabah Y, Caminiti S, Politis M. Drooling in Parkinson's disease: An [123I] FP-CIT SPECT study. <i>European Journal of Neurology</i> . 2019;26(Supplement 1):315.	10
839	Suarez Contreras VC, Tayyabah Y, Caminiti SP, Politis M. Gait impairment in Parkinson's disease: An [123I]FP-CIT SPECT study. <i>European Journal of Neurology</i> . 2019;26(Supplement 1):845.	9
840	Suarez-Pinera M, Prat L, Fuertes J, Mojal S, Balaguer E. Interobserver agreement in the visual and semi-quantitative analysis of the 123IFP-CIT SPECT images in the diagnosis of Parkinsonian syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2):S329-S30.	4
841	Suarez-Pinera M, Prat ML, Mestre-Fusco A, Fuertes J, Mojal S, Balaguer E. Interobserver agreement in the visual and semi-quantitative analysis of the 123I-FP-CIT SPECT images in the diagnosis of Parkinsonian syndrome. [Spanish]. <i>Revista Espanola de Medicina Nuclear</i> . 2011;30(4):229-35.	3
842	Sumi Y, Matsuo M, Takao N, Kuriyama K, Yamada N, Kadotani H. Decrease of dopamine transporter correlates cognitive decline in rapid eye movement behavior disorder patients. <i>Sleep Medicine</i> . 2017;40(Supplement 1):e318.	9
843	Sung SY, Lee WW, Lee BC, Kim SE. Progressive changes of clinical Parkinson's disease symptoms. <i>Journal of Nuclear Medicine Conference</i> . 2019;60(Supplement 1).	4
844	Surasi DS, Peller PJ, Szabo Z, Mercier G, Subramaniam R. Dopamine transporter SPECT imaging in parkinson disease and dementia. <i>PET Clinics</i> . 2013;8(4):459-67.	9
845	Suwijn SR, Verschuur CVM, Slim MA, Booij J, de Bie RMA. Reliability of visual assessment by non-expert nuclear medicine physicians and appropriateness of indications of [123I]FP-CIT SPECT imaging by neurologists in patients with early drug-naive Parkinson's disease. <i>EJNMMI Research</i> . 2019;9(1) (no pagination)(63).	9
846	Sydoiff M, Lizana H, Mattsson S, Stabin MG, Leide-Svegborn S. Determination of the biodistribution and dosimetry of 123I-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT/CT imaging. <i>Applied Radiation and Isotopes</i> . 2013;82:300-7.	10
847	Tachibana K, Matsuura K, Shindo A, Matsuyama H, Ii Y, Taniguchi A, et al. Symptomatic characteristics of Parkinson's disease induced by neuroleptic drugs, based on a functional neuroimaging diagnosis. <i>Internal Medicine</i> . 2020;59(4):485-90.	8
848	Tachibana K, Y HI, Katoh N, Ishikawa H, Shimada T, Shindo A, et al. Differentiation of drug-induced parkinsonism and PD; Utility of 123I-FP-CIT SPECT(DaTscan). <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):954.	9
849	Tada S, Ando R, Iwaki H, Tsujii T, Yabe Y, Nishikawa N, et al. The MIBG scintigraphy and dat spect contribute to the diagnosis of PD and other related disorders, and evaluations of the course and stage of PD. <i>Parkinsonism and Related Disorders</i> . 2016;2):e162.	4

850	Tada S, Nomoto M, Yamanishi Y, Miyae N, Ando R, Yabe H, et al. The marked decrease in cardiac MIBG-uptake correlates with the severity of sleep disturbance in patients with Parkinson's disease. <i>Sleep and Biological Rhythms</i> . 2020;18(2):131-6.	9
851	Tada S, Ohtsubo H, Yamanishi Y, Miyae N, Ando R, Yabe H, et al. The combination of the MIBG myocardial scintigraphy and DATSPECT contributes to the diagnosis of Parkinson's disease and other related disorders. <i>Movement Disorders</i> . 2017;32(Supplement 2):1007-8.	4
852	Takada S, Yoshimura M, Shindo H, Saito K, Koizumi K, Utsumi H, et al. New semiquantitative assessment of 123I-FP-CIT by an anatomical standardization method. <i>Annals of Nuclear Medicine</i> . 2006;20(7):477-84.	10
853	Takano H, Saito Y, Ogawa M, Sako K, Taki Y, Hirano S, et al. Voxel-based analysis of the effect of age and gender on dopamine transporter availability in a large sample from a Japanese database of 123I-ioflupane SPECT. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2018;59(Supplement 1).	9
854	Takaya S, Sawamoto N, Okada T, Okubo G, Fukuyama H, Takahashi R. Differentiation between Lewy body diseases and atypical parkinsonian syndromes using combined brain SPECTs. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):401.	9
855	Takaya S, Sawamoto N, Okada T, Okubo G, Nishida S, Togashi K, et al. Discriminating atypical Parkinsonian syndromes from lewy body diseases using striatal dopamine transporter activity and regional perfusion images. <i>Journal of the Neurological Sciences</i> . 2017;381(Supplement 1):125-6.	9
856	Takaya S, Sawamoto N, Okada T, Okubo G, Nishida S, Togashi K, et al. Differential diagnosis of parkinsonian syndromes using dopamine transporter and perfusion SPECT. <i>Parkinsonism and Related Disorders</i> . 2018;47:15-21.	9
857	Takehisa Y, Takahashi Y, Abe K. Construction of the fractal analysis system for DaT-SPECT. <i>Journal of Cerebral Blood Flow and Metabolism</i> . 2019;39(1 Supplement):487.	4
858	Takeshima S, Takeda I, Kobatake K, Yamashita T, Abe K, Kuriyama M. SCA6 presenting parkinsonism without ataxia - A case report. [Japanese]. <i>Clinical Neurology</i> . 2015;55(4):243-7.	3
859	Tamayo P, Montes C, Gomez-Caminero F, Sevillano D, Cacabelos P, Martin E, et al. Evaluation of parkinsons disease progression with statistical parametric analysis of 123I-FP-CIT SPECT: Preliminary results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2):S330.	4
860	Tamayo P, Montes C, Sevillano D, Cacabelos P, Diaz L, Martin E, et al. Different patterns of striatal 123I-FP-CIT uptake in patients with Parkinson's disease regarding predominant motor symptom. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2014;2):S627-S8.	4
861	Tappa MC, Farsad M, Aspmair E, Fracchetti A, Zanigni S, Golemi A, et al. 123I-FP-CIT SPECT imaging in movement disorders: Comparison of visual assessment and an automated evaluation method. <i>Clinical and Translational Imaging</i> . 2013;1):S91.	4
862	Tateno F, Sakakibara R, Ogata T, Aiba Y, Takahashi O, Sugiyama M. The relationship between lower urinary tract function and 123I-ioflupane scintigraphy in drug-naive Parkinson's disease. <i>Autonomic Neuroscience: Basic and Clinical</i> . 2021;233 (no pagination)(102813).	9
863	Tatsch K, Buchert R, Bartenstein P, Barthel H, Boecker H, Brust P, et al. Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCAN TM). [German]. <i>NuklearMedizin</i> . 2019;58(1):5-16.	3
864	Tatsch K, Poepperl G. Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: An update. <i>Journal of Nuclear Medicine</i> . 2013;54(8):1331-8.	2
865	Taylor JC, Romanowski C, Lorenz E, Lo C, Bandmann O, Fenner J. Computer-aided diagnosis for (123I)FP-CIT imaging: impact on clinical reporting. <i>EJNMMI Research</i> . 2018;8 (no pagination)(36).	9
866	Taylor JC, Vennart N, Negus I, Holmes R, Bandmann O, Lo C, et al. The subresolution DaTSCAN phantom: A cost-effective, flexible alternative to traditional phantom technology. <i>Nuclear Medicine Communications</i> . 2018;39(3):268-75.	9
867	Terashi H, Taguchi T, Ueta Y, Mitoma H, Aizawa H. Relationship between 123I-FP-CIT-SPECT and motor severity in drug-naive patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> . 2021;426 (no pagination)(117476).	9
868	Teune LK, Leenders KL. Molecular imaging in Parkinson's disease. <i>Molecular Imaging in the Clinical Neurosciences</i> . 2012;NeuroMethods. 71:359-75.	2
869	Thilsing-Hanseni K, Simonsen J, Hvidsten S. Performance evaluation of a clinical multi-pinhole brain SPECT system: comparison with a conventional SPECT system. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2021;62(SUPPL 1).	9
870	Thiriez C, Itti E, Fenelon G, Evangelista E, Meignan M, Cesaro P, et al. Clinical routine use of dopamine transporter imaging in 516 consecutive patients. <i>Journal of Neurology</i> . 2015;262(4):909-15.	9
871	Thiriez C, Itti E, Fenelon G, Malek Z, Cesaro P, Meignan M, et al. Retrospective monocentric study of the unrestricted clinical use of [123I]FP-CIT SPECT in 618 consecutive patients. <i>Movement Disorders</i> . 2010;2):S395.	4

872	Thomas A, Attems J, Colloby SJ, O'Brien JT, McKeith IG, Walker R, et al. Validation by neuropathology of FP-CIT neuroimaging in dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> . 2017;13(7):P1462.	9
873	Thomsen B, Jensen S, Clausen A, Karlsborg M, Brodsgaard E, Friberg L, et al. Can preoperative dopamine transporter imaging predict the long-term outcome of deep brain stimulation in patients with Parkinson's disease? <i>Movement Disorders</i> . 2018;33(Supplement 2):S675-S6.	4
874	Tiepolo S, Luthardt J, Hesse S, Oehlwein C, Seese A, Rullmann M, et al. Dopamine transporter and receptor SPECT in patients with parkinsonism with or without dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2(2):S436.	4
875	Tijero B, Gomez-Esteban JC, Llorens V, Lezcano E, Gonzalez-Fernandez MC, De Pancorbo MM, et al. Cardiac sympathetic denervation precedes nigrostriatal loss in the E46K mutation of the alpha-synuclein gene (SNCA). <i>Clinical Autonomic Research</i> . 2010;20(4):267-9.	9
876	Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. <i>Journal of Neurology</i> . 2009;256(6):910-5.	9
877	Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, et al. Clinical and [123I] FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. <i>Journal of Neurology</i> . 2009;2(2):S29.	10
878	Tinazzi M, Cipriani A, Matinella A, Cannas A, Solla P, Nicoletti A, et al. [123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. <i>Schizophrenia Research</i> . 2012;139(1-3):40-5.	10
879	Tinazzi M, Cipriani A, Matinella A, Cannas A, Solla P, Nicoletti A, et al. [123I]FP-CIT single photon emission computed tomography findings in drug-induced parkinsonism. <i>Movement Disorders</i> . 2012;1(1):S39.	9
880	Tinazzi M, Cipriani A, Matinella A, Cannas A, Solla P, Nicoletti A, et al. Corrigendum to [123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism [Schizophr. Res. 113 (2009) 41-48]. <i>Schizophrenia Research</i> . 2012;142(1-3):251.	4
881	Tinazzi M, Matinella A, Erro R, Brigo F. [123I]FP-CIT SPECT (DaTSCAN) in unclear parkinsonism: A useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonism. <i>Journal of Neurology</i> . 2014;1(1):S244.	10
882	Tinazzi M, Matinella A, Erro R, Brigo F. [123I]FP-CIT SPECT (DaTSCAN) in unclear parkinsonism: A useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonism. <i>European Journal of Neurology</i> . 2014;1(1):364.	4
883	Tinazzi M, Morgante F, Matinella A, Bovi T, Cannas A, Solla P, et al. Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: A 2-year follow-up multicenter study. <i>Schizophrenia Research</i> . 2014;152(2-3):344-9.	9
884	Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. <i>Movement Disorders</i> . 2008;23(13):1825-9.	10
885	Tiraboschi P, Corso A, Guerra U, Nobili F, Piccardo A, Calcagni M, et al. Comparative value of [(123I)]-FP-CIT SPECT and [(123I)]-MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and other types of dementia. <i>Journal of Alzheimer's Disease</i> . 2016;52(Supplement 1):S3-S4.	4
886	Tiraboschi P, Corso A, Guerra UP, Nobili F, Piccardo A, Calcagni ML, et al. 123I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and 123I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study. <i>Annals of Neurology</i> . 2016;80(3):368-78.	10
887	Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AGM, Van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2/beta-carbomethoxy3beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. <i>Journal of Nuclear Medicine</i> . 1998;39(7):1143-8.	7
888	Tissot H, Frismand S, Marie PY, Gospodarou N, Verger A. 123I-FP-CIT-SPECT in Encephalitis Involving Substantia Nigra. <i>Clinical Nuclear Medicine</i> . 2016;02.	6
889	Todisco M, Pozzi NG, Zangaglia R, Minafra B, Servello D, Ceravolo R, et al. Pisa syndrome in Idiopathic Normal Pressure Hydrocephalus. <i>Parkinsonism and Related Disorders</i> . 2019;66:40-4.	9
890	Todisco M, Zangaglia R, Minafra B, Pisano P, Trifiro G, Bossert I, et al. Clinical Outcome and Striatal Dopaminergic Function After Shunt Surgery in Patients With Idiopathic Normal Pressure Hydrocephalus. <i>Neurology</i> . 2021;96(23):e2861-e73.	9
891	Todorova A, Buxton-Thomas M, Ray Chaudhuri K. Non-motor symptoms of Parkinson's disease and nigrostriatal dopaminergic degeneration: A study with Datscan. <i>Journal of Neurology</i> . 2010;1(1):S133.	9
892	Tondeur MC, Hambye AS, Dethy S, Ham HR. Interobserver reproducibility of the interpretation of I-123 FP-CIT single-photon emission computed tomography. <i>Nuclear Medicine Communications</i> . 2010;31(8):717-25.	9

893	Toriihara A, Daisaki H, Yamaguchi A, Kobayashi M, Furukawa S, Yoshida K, et al. Semiquantitative analysis using standardized uptake value in 123I-FP-CIT SPECT/CT. <i>Clinical Imaging</i> . 2018;52:57-61.	9
894	Toriihara A, Yamaguchi A, Daisaki H, Kobayashi M, Furukawa S, Yoshida K, et al. Semiquantitative analysis using standardized uptake value in 123I-FP-CIT SPECT/CT. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2017;58(Supplement 1).	4
895	Towey D, Bain P, Nijran K. Machine learning for the automatic classification of dopamine transporter SPECT images. <i>Journal of Nuclear Medicine Conference: Society of Nuclear Medicine and Molecular Imaging Annual Meeting, SNMMI</i> . 2015;56(SUPPL. 3).	8
896	Towey DJ, Bain PG, Nijran KS. Automatic classification of 123I-FP-CIT (DaTSCAN) SPECT images. <i>Nuclear Medicine Communications</i> . 2011;32(8):699-707.	10
897	Trapali GX, Armeniakos I, Georgakopoulos A, Karabina P, Stefanoyannis A, Bakalis S, et al. The contribution of 123I-MIBG and 123I-FP-CIT SPECT (DaTscan) imaging in the detection of early Parkinson's disease the contribution of 123I. <i>Movement Disorders</i> . 2010;3:S636.	4
898	Treglia G, Cason E, Cortelli P, Gabellini A, Liguori R, Terlizzi R, et al. 123I-MIBG scintigraphy and 123I-FP-CIT SPECT in lewy body diseases: Complementary or alternative techniques? <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2:S160.	4
899	Trocello JM, Zanotti-Fregonara P, Roze E, Apartis E, Legrand AP, Habert MO, et al. Dopaminergic deficit is not the rule in orthostatic tremor. <i>Movement Disorders</i> . 2008;23(12):1733-8.	9
900	Turunen S, Hippelainen E, Eerola-Rautio J, Nikkinen P, Ahonen A. Comparison of different ROI selections in 123I-beta-CIT DAT studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2:S503.	8
901	Udo N, Hashimoto N, Toyonaga T, Isoyama T, Oyanagi Y, Narita H, et al. Apathy in Alzheimer's Disease Correlates with the Dopamine Transporter Level in the Caudate Nuclei. <i>Dementia and Geriatric Cognitive Disorders Extra</i> . 2020;10(2):86-93.	9
902	Ueda J, Yoshimura H, Shimizu K, Hino M, Kohara N. Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases. <i>Neurological Sciences</i> . 2017;38(7):1187-91.	7
903	Umeh CC, Szabo Z, Pontone GM, Mari Z. Psychogenic Parkinsonism: Does dopamine transporter imaging influence management? <i>Movement Disorders</i> . 2013;1:S65-S6.	4
904	Umehara T, Oka H, Nakahara A, Shiraishi T, Sato T, Matsuno H, et al. Dopaminergic Correlates of Orthostatic Hypotension in de novo Parkinson's Disease. <i>Journal of Parkinson's Disease</i> . 2021;11(2):665-73.	9
905	Unger MM, Moller JC, Stiasny-Kolster K, Mankel K, Berg D, Walter U, et al. Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. <i>Movement Disorders</i> . 2008;23(4):596-9.	4
906	Urso D, Nigro S, Tafuri B, Logroscino G. Brainstem planimetry in Parkinson's disease with REM behaviour disorder. <i>Movement Disorder</i> . 2021;36(SUPPL 1):S381-S2.	9
907	Urso D, Tafuri B, Nigro S, Logroscino G. Paradoxical effect of smoking on motor progression and dopaminergic putaminal denervation in parkinson's disease. <i>Neuroepidemiology</i> . 2021;55(SUPPL 1):99.	9
908	Uyama N, Otsuka H, Shinya T, Otomi Y, Harada M, Sako W, et al. The utility of the combination of a SPECT study with [123I]-FP-CIT of dopamine transporters and [123I]-MIBG myocardial scintigraphy in differentiating Parkinson disease from other degenerative parkinsonian syndromes. <i>Nuclear Medicine Communications</i> . 2017;38(6):487-92.	10
909	Valis M, Masopust J, Talab R, Konupcikova K, Hosak L. 123I-FP-CIT SPECT distinguishes Parkinson's disease from drug-induced Parkinsonism - Two case reports. [Czech]. <i>Ceska a Slovenska Psychiatrie</i> . 2010;106(1):42-5.	3
910	Van Den Heuvel OA, Vriend C, Nordbeck AH, Booij J, Van Der Werf YD, Pattij T, et al. Reduced dopamine transporter binding predates impulse control disorders in Parkinson's disease. <i>European Neuropsychopharmacology</i> . 2013;23(2):S548-S9.	9
911	Van Der Gucht A, Cleret de Langavant L, Belissant O, Rabu C, Cottureau AS, Evangelista E, et al. Brain 18F-FDG, 18F-Florbetaben PET/CT, 123I-FP-CIT SPECT and Cardiac 123I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. <i>Nuclear Medicine and Molecular Imaging</i> . 2016;50(3):258-60.	6
912	Van Der Zande J. Acute refractory psychosis in a patient with dementia with lewy bodies: Report of a successful treatment with electroconvulsive therapy. <i>American Journal of Neurodegenerative Diseases</i> . 2015;1:170.	9
913	Van Der Zande J, Booij J, Raijmakers PGHM, Lemstra AW. Initial negative DAT spect in dementia with lewy bodies: A DLB subtype? <i>Neurodegenerative Diseases</i> . 2015;1:1352.	9
914	van Deursen DN, van den Heuvel OA, Booij J, Berendse HW, Vriend C. Autonomic failure in Parkinson's disease is associated with striatal dopamine deficiencies. <i>Journal of Neurology</i> . 2020;267(7):1922-30.	9
915	Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L, et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. <i>Journal of Nuclear Medicine</i> . 2006;47(3):384-92.	8

916	Van Laere K, Everaert L, Annemans L, Gonce M, Vandenberghe W, Vander Borgh T. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2008;35(7):1367-76.	10
917	Van Steenoven I, Koel-Simmelinck M, Pham T, Van Der Flier W, Jimenez C, Teunissen C, et al. Proteomics identification of novel cerebrospinal fluid biomarker candidates of dementia with lewy bodies. <i>Neurodegenerative Diseases</i> . 2017;17(Supplement 1):1560.	10
918	Van Steenoven I, Koel-Simmelinck MJA, Pham TV, Van Der Flier WM, Jimenez CR, Teunissen CE, et al. Proteomics identification of novel cerebrospinal fluid biomarker candidates of dementia with lewy bodies. <i>Alzheimer's and Dementia</i> . 2017;13(7):P704.	9
919	Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): Age-related effects, gender differences and evaluation of different methods of analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2013;40(2):213-27.	10
920	Varrone A, Pellicchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, et al. Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. <i>Neurology</i> . 2004;63(11):2097-103.	10
921	Varrone A, Salvatore E, De Michele G, Barone P, Sansone V, Pellicchia MT, et al. Reduced Striatal [123I]FP-CIT Binding in SCA2 Patients without Parkinsonism. <i>Annals of Neurology</i> . 2004;55(3):426-30.	7
922	Varrone A, Sansone V, Pellicchia MT, Amboni M, Salvatore E, De Michele G, et al. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2008;35(7):1343-9.	10
923	Vergallo A, Frosini D, Del Gamba C, Unti E, Bonuccelli U, Ceravolo R. Subacute corticobasal syndrome as presentation of sporadic Creutzfeldt-Jakob disease. <i>Journal of Neurology</i> . 2013;1):S238.	4
924	Verstappen CCP, Bloem BR, Haaxma CA, Oyen WJG, Horstink MWIM. Diagnostic value of asymmetric striatal D ₂ receptor upregulation in Parkinson's disease: An [123I]IBZM and [123I]FP-CIT SPECT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2007;34(4):502-7.	9
925	Vilas D, Muxi A, Tolosa E, Compta Y. Parkinsonism with early disautonomic symptoms and normal MIBG scintigraphy related to LRRK2 mutation. <i>Movement Disorders</i> . 2015;1):S412.	4
926	Villain N, Pyatigorskaya N, Lehericy S, Vallabregue R, Fernandez-Vidal S, Habert MO, et al. Motor compensation in Parkinson's disease: A multimodal neuroimaging study. <i>Movement Disorder</i> . 2019;34(Supplement 2):S734-S5.	4
927	Vitinius F, Hoffmann G, Albus C. Psychogenic movement disorders - A systematic review. <i>Journal of Psychosomatic Research</i> . 2011;70(6):620.	2
928	Volterrani D, Ceravolo R, Manca G, Frosini D, Chiacchio S, Paglianiti I, et al. FP-CIT SPECT and cognitive performance in de novo Parkinson's disease patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2011;2):S160-S1.	4
929	Volterrani D, Duce V, Tredici M, Bertoli J, Manca G, Mazzarri S, et al. Interobserver variability of [123I]FP-CIT striatal binding ratios assessment: A comparison between two different methods of analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;2):S553.	4
930	Voon V, Rzos A, Chakravarty R, Mulholland N, Robinson S, Howell NA, et al. Impulse control disorders in Parkinson's disease: Decreased striatal dopamine transporter levels. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2014;85(2):148-52.	10
931	Vriend C, Gerrits NJHM, Berendse HW, Veltman DJ, Van Den Heuvel OA, Van Der Werf YD. Functional deficits in response inhibition in de novo parkinson's disease. <i>Biological Psychiatry</i> . 2014;1):364S.	4
932	Vriend C, Rajmakers P, Veltman DJ, Van Dijk KD, Van Der Werf YD, Foncke EMJ, et al. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2014;85(2):159-64.	9
933	Vriend C, van Balkom TD, van Druningen C, Klein M, van der Werf YD, Berendse HW, et al. Processing speed is related to striatal dopamine transporter availability in Parkinson's disease. <i>NeuroImage: Clinical</i> . 2020;26 (no pagination)(102257).	9
934	Vu JP, Yamin G, Reyes Z, Shin A, Young A, Litvan I, et al. Assessment of Motor Dysfunction with Virtual Reality in Patients Undergoing [123I]FP-CIT SPECT/CT Brain Imaging. <i>Tomography (Ann Arbor, Mich)</i> . 2021;7(2):95-106.	8
935	Wakabayash IY, Takahashi R, Okunaga T, Kubo K, Kanda T, Ishii K. New quantitative assessment of [123I] FP-CIT single-photon emission computed tomography (SPECT) (DaTscan) instead of specificbinding ratio (SBR). <i>Neuroradiology</i> . 2018;60(10):1118.	4
936	Wakabayashi Y, Takahashi R, Kanda T, Zeng F, Nogami M, Ishii K, et al. Semi-quantitative dopamine transporter standardized uptake value in comparison with conventional specific binding ratio in [123I] FP-CIT single-photon emission computed tomography (DaTscan). <i>Neurological Sciences</i> . 2018;39(8):1401-7.	7
937	Walker Z, Costa DC, Walker RWH, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: A comparison. <i>Neurology</i> . 2004;62(9):1568-72.	9

938	Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. <i>Journal of Neurology Neurosurgery and Psychiatry</i> . 2002;73(2):134-40.	9
939	Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Stevens T, et al. Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. <i>Neurology</i> . 2016;87(10):1045-51.	10
940	Walker Z, Thomas A, Inglis F, Tabet N, Stevens T, Whitfield T, et al. Evolution of clinical features in possible DLB depending on 123I-FP-CIT SPECT result. <i>American Journal of Neurodegenerative Diseases</i> . 2015;1:137.	9
941	Walker Z, Thomas A, Inglis F, Tabet N, Stevens T, Whitfield T, et al. The influence of DLB feature and 123I-FP-CIT SPECT scan on diagnosis at 6-months follow-up. <i>American Journal of Neurodegenerative Diseases</i> . 2015;1:48.	4
942	Wang J, Cao R, Huang T, Liu C, Fan Y. Urinary dysfunction is associated with nigrostriatal dopaminergic degeneration in early and untreated patients with Parkinson's disease. <i>Parkinson's Disease</i> . 2020;2020 (no pagination)(4981647).	9
943	Warr L, Walker Z. Identification of biomarkers in Lewy-body disorders. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> . 2012;56(1):39-54.	9
944	Watanabe S, Ueno T, Kimura Y, Mishina M, Sugimoto N. Generative image transformer (GIT): unsupervised continuous image generative and transformable model for [123I]FP-CIT SPECT images. <i>Annals of Nuclear Medicine</i> . 2021;35(11):1203-13.	9
945	Wictor L, Wictorin K, Widner H, Puschmann A. Wilson disease: Acute dystonia during treatment with SSRI or SNRI. <i>Parkinsonism and Related Disorders</i> . 2016;2:e140-e1.	6
946	Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-sectional study. <i>The Lancet Neurology</i> . 2019;18(8):748-59.	9
947	Wilson H, Yousaf T, Pagano G, Politis M. Pain and Parkinson's disease. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):646.	9
948	Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson's disease. <i>European Journal of Neurology</i> . 2005;12(11):842-50.	9
949	Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. <i>Journal of neural transmission (Vienna, Austria : 1996)</i> . 2001;108(8-9):1011-9.	10
950	Winogrodzka A, Bergmans P, Booij J, Van Royen EA, Janssen AGM, Wolters EC. [123I]FP-CIT spect is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. <i>Journal of Neurology</i> . 2001;248(9):1011-9.	9
951	Winz OH, Hellwig S, Mix M, Weber WA, Mottaghy FM, Schafer WM, et al. Image quality and data quantification in dopamine transporter SPECT: Advantage of 3-dimensional OSEM reconstruction? <i>Clinical Nuclear Medicine</i> . 2012;37(9):866-71.	9
952	Wirth T, Namer I, Monga B, Bund C, Iosif A, Gebus O, et al. Progression of nigro-striatal denervation in cerebellar Multiple System Atrophy: A prospective study. <i>Movement Disorder</i> . 2021;36(SUPPL 1):S249-S50.	9
953	Wissel B. Functional neurological disorders in Parkinson disease. <i>Neurology Conference: 70th Annual Meeting of the American Academy of Neurology, AAN</i> . 2018;90(15 Supplement 1).	10
954	Wissel BD, Dwivedi AK, Merola A, Chin D, Jacob C, Duker AP, et al. Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> . 2018;89(6):566-71.	9
955	Wyman-Chick KA, Martin PK, Minar M, Menendez-Gonzalez M, Erickson LO, Alvarez-Avellon T, et al. Neuropsychological Test Performance in Parkinsonism Without Dopaminergic Deficiency on [123I]-FP-CIT SPECT Imaging. <i>Journal of the International Neuropsychological Society : JINS</i> . 2018;24(6):646-51.	9
956	Yamamoto H, Arimura S, Nakanishi A, Shimo Y, Motoi Y, Ishiguro K, et al. Age-related effects and gender differences in Japanese healthy controls for [123I] FP-CIT SPECT. <i>Annals of Nuclear Medicine</i> . 2017;31(5):407-12.	9
957	Yamamoto T, Kawasaki H, Furuya T, Miyake A, Mitsufuji T, Fukuoka T, et al. Levodopa induced dyskinesia in a case of progressive supranuclear palsy. <i>Movement Disorders</i> . 2017;32(Supplement 2):154.	6
958	Yogo M, Omoto S, Kawasaki K, Ariizumi M, Suzuki M. Diagnostic flowchart using FP-CIT and MIBG scintigraphy in differentiating Parkinsonian syndromes in Japan. <i>Movement Disorders</i> . 2015;1:S27-S8.	4
959	Yokoyama K, Imabayashi E, Matsuda H. Application of CT based spatial normalization by DARTEL to quantitative assessment of 123I-FP-CIT SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2015;1:S562.	4
960	Yokoyama K, Imabayashi E, Sako T, Sone D, Kimura Y, Sato N, et al. Computed tomography guided anatomic standardization for quantitative assessment of dopamine transporter SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2016;43(1 Supplement 1):S633.	4

961	Yokoyama K, Imabayashi E, Sumida K, Sone D, Kimura Y, Sato N, et al. Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2017;44(3):366-72.	9
962	Yoshida K, Suzuki Y, Sakashia K, Kishi H, Nomura K, Aburakawa Y, et al. The efficacy of combination 123I-FP-CIT and 123I-MIBG in Parkinson syndrome. <i>European Journal of Neurology</i> . 2016;2:303.	4
963	Yoshii F, Moriya Y, Ohnuki T, Ryo M, Takahashi W, Kohara S, et al. 123I-Meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients showing scans without evidence of dopaminergic deficits (SWEDDs). <i>Clinical Neurology and Neurosurgery</i> . 2017;160:73-7.	9
964	Yoshii F, Takahashi W, Aono K. Levodopa-Responsive Primary Slow Orthostatic Tremor: A Premotor Sign of Parkinson's Disease? <i>Case Reports in Neurology</i> . 2020;12(1):1-6.	6
965	Yoshita M. A comparison of the diagnostic accuracy of mibg, ecd and fp-cit spect for detecting lewy body disease in a memory clinic. <i>Alzheimer's and Dementia</i> . 2016;12(7 Supplement):P910-P1.	9
966	Yoshita M, Otake Y, Hosokawa M, Sakamoto H. [(123i)]Fp-Cit Spect and [(123i)]MIBG scintigraphy between lewy body disease and other neurodegenerative disorders. <i>Neurodegenerative Diseases</i> . 2015;1:1351.	4
967	Yousaf T, Dervenoulas G, Valkimadi PE, Politis M. Neuroimaging in Lewy body dementia. <i>Journal of Neurology</i> . 2019;266(1).	2
968	Yousaf T, Pagano G, Niccolini F, Politis M. Excessive daytime sleepiness is mediated by loss of caudate dopaminergic function in Parkinson's disease. <i>Movement Disorders</i> . 2016;31(Supplement 2):S393.	9
969	Yousaf T, Pagano G, Niccolini F, Politis M. Comorbidity and Parkinson's disease phenotype, dopaminergic function and CSF biomarkers. <i>Movement Disorders</i> . 2016;31(Supplement 2):S92.	4
970	Yousaf T, Pagano G, Niccolini F, Politis M. Predict cognitive decline with non-clinical markers in Parkinson's disease. <i>European Journal of Neurology</i> . 2017;24(Supplement 1):648.	9
971	Yousaf T, Pagano G, Niccolini F, Politis M. Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. <i>Sleep Medicine</i> . 2018;43:25-30.	9
972	Yousaf T, Pagano G, Niccolini F, Politis M. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. <i>Journal of the Neurological Sciences</i> . 2018;387:220-7.	9
973	Yousaf T, Pagano G, Niccolini F, Politis M. Predicting cognitive decline with non-clinical markers in Parkinson's disease (PRECODE-2). <i>Journal of Neurology</i> . 2019;266(5):1203-10.	9
974	Yousaf T, Pagano G, Wilson H, Corcoran B, Vivian G, Politis M. Comparison between [11C]PE2I PET and [123I]FP-CIT SPECT as markers of DAT expression in early Parkinson's disease. <i>Movement Disorder</i> . 2019;34(Supplement 2):S842.	4
975	Zanotti-Fregonara P, Vidailhet M, Kas A, Ozelius LJ, Clot F, Hindie E, et al. [123I]-FP-CIT and [99mTc]-HMPAO single photon emission computed tomography in a new sporadic case of rapid-onset dystonia-parkinsonism. <i>Journal of the Neurological Sciences</i> . 2008;273(1-2):148-51.	10
976	Zaromitidou E, Siabanopoulou MT, Bairaktaris C, El-Mantani Ordoulidis S. The contribution of I-123 ioflupane SPECT in diagnosis of patients with parkinsonian syndromes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> . 2010;2:S402.	4
977	Zhou C, Guan XJ, Guo T, Zeng QL, Gao T, Huang PY, et al. Progressive brain atrophy in Parkinson's disease patients who convert to mild cognitive impairment. <i>CNS Neuroscience and Therapeutics</i> . 2020;26(1):117-25.	9
978	Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacinovic S, Lees AJ, et al. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. <i>Movement Disorders</i> . 2007;22(9):1278-85.	10
979	Zissimopoulos A, Boussios N, Fistouris D, Pardalis V, Karathanos E. 123I-ioflupane spect scintigraphy in patients with movement disorders. <i>Review of Clinical Pharmacology and Pharmacokinetics, International Edition</i> . 2010;24(1):31-4.	5
980	Zoetmulder M, Biernat H, Nikolic M, Friberg L, Korbo L, Pfeiffer H, et al. Prepulse inhibition is correlated with 123I-FP-CIT SPECT and cognition in Parkinson's disease. <i>Journal of Sleep Research</i> . 2012;1:182.	10
981	Zoetmulder M, Biernat HB, Nikolic M, Friberg L, Korbo L, Pfeiffer HCV, et al. Pre-pulse inhibition is correlated with 123I-FP-CIT SPECT and cognition in Parkinson's disease. <i>European Journal of Neurology</i> . 2012;19(SUPPL.1):526.	9
982	Zoetmulder M, Biernat HB, Nikolic M, Korbo L, Friberg L, Jennum PJ. Prepulse inhibition is associated with attention, processing speed, and 123I-FP-CIT SPECT in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> . 2014;4(1):77-87.	10
983	Zoetmulder M, Nikolic M, Biernat H, Korbo L, Friberg L, Jennum P. Increased motor activity during rem sleep is linked with dopamine function in idiopathic rem sleep behaviour disorder and Parkinson's disease. <i>Sleep Medicine</i> . 2013;1:e316.	4

984	Zoetmulder M, Nikolic M, Biernat H, Korbo L, Friberg L, Jennum P. Increased motor activity during rem sleep is linked with dopamine-function in idiopathic rem sleep behaviour disorder and parkinson's disease. <i>Clinical Neurophysiology</i> . 2014;1):S128.	4
985	Zoetmulder M, Nikolic M, Biernat H, Korbo L, Friberg L, Jennum P. Increased motor activity during REM sleep is linked with dopamine-function in idiopathic REM sleep behaviour disorder and Parkinson's disease. <i>Sleep Medicine</i> . 2015;1):S118.	4
986	Zoetmulder M, Nikolic M, Biernat H, Korbo L, Friberg L, Jennum P. Increased motor activity during REM sleep is linked with dopamine function in idiopathic REM sleep behavior disorder and Parkinson disease. <i>Journal of Clinical Sleep Medicine</i> . 2016;12(6):895-903.	7
987	Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. <i>JAMA</i> . 2002;287(13):1653-61.	9
988	Cardiovascular fitness, plasma biomarkers and dopaminergic denervation in Parkinson's disease. <i>Movement disorders</i> . 2020;35(SUPPL 1):S408-.	4
989	Booij J, Pryma D, Dubroff J, Yu J, Agarwal R, Lakhani P, et al. Value of 123I-ioflupane DaT SPECT quantification in the assessment of patients with movement disorders or dementia. <i>European journal of nuclear medicine and molecular imaging Conference: 29th annual congress of the european association of nuclear medicine, EANM 2016 Spain Conference start: 20161015 Conference end: 20161019</i> . 2016;43(1 Supplement 1):S132-S3.	4
990	Broggi M, Redaelli V, Tringali G, Restelli F, Romito L, Schiavolin S, et al. Normal Pressure Hydrocephalus and Parkinsonism: preliminary Data on Neurosurgical and Neurological Treatment. <i>World neurosurgery</i> . 2016;90:348-56.	9
991	Euctr AT. A single-blinded assessment of the short-term effects of cabergoline vs. carbidopa/levodopa on SPECT dopamine transporter density in out-patient subjects with Parkinson's Disease - N/A. https://trialssearchwhooint/Trial2.aspx?TrialID=EUCTR2004-001485-41-AT . 2005.	4
992	Im JH, Chung SJ, Kim JS, Lee MC. Differential patterns of dopamine transporter loss in the basal ganglia of progressive supranuclear palsy and Parkinson's disease: analysis with [(123)I]IPT single photon emission computed tomography. <i>Journal of the neurological sciences</i> . 2006;244(1-2):103-9.	8
993	Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. <i>Journal of nuclear medicine</i> . 2003;44(6):870-6.	8
994	Lomena F, Oliver G, Barber C, Moreno E, Volterrani D, Daumal J, et al. Predictors of dopamine transporter DaTSCANTM (loflupane 123I) SPECT imaging results in subjects with possible Dementia with Lewy Bodie. <i>European journal of nuclear medicine and molecular imaging</i> . 2013;40:S255.	4
995	Mateos JJ, Lomeña F, Parellada E, Mireia F, Fernandez-Egea E, Pavia J, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. <i>Psychopharmacology</i> . 2007;191(3):805-11.	9
996	McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies. <i>Cochrane Database of Systematic Reviews</i> . 2015(1).	2
997	Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. <i>The lancet Neurology</i> . 2013;12(8):747-55.	10
998	Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, et al. Fatigue in levodopa-naive subjects with Parkinson disease. <i>Neurology</i> . 2008;71(7):481-5.	9
999	Seibyl J, Russel D, Marek K. Four year longitudinal assessment of scintigraphic imaging biomarkers in a progressing parkinson disease cohort. <i>Journal of nuclear medicine Conference: society of nuclear medicine and molecular imaging annual meeting, SNMMI 2017 United states</i> . 2017;58(no pagination).	4
1000	Tiraboschi P, Corso A, Guerra UP, Nobili F, Piccardo A, Calcagni ML, et al. 123I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and 123I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: a comparative study. <i>Annals of neurology</i> . 2016;80(3):368-78.	10
1001	Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, et al. Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. <i>British journal of psychiatry</i> . 2015;206(2):145-52.	10
1002	Walker Z, Thomas A, Tabet N, Stevens T, Moreno E, Pizzolato G, et al. Evolution of symptoms and signs over 6-months in subjects with possible dementia with Lewy bodies following DaTSCANTM SPECT imaging. <i>Journal of the neurological sciences</i> . 2013;333:e333.	4
1003	Aarts E, Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, Cools R. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. <i>Neuroimage</i> . 2012;59(4):3339-46.	9
1004	Ahn TB, Kim SY, Kim JY, Park SS, Lee DS, Min HJ, et al. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. <i>Neurology</i> . 2008;70(1):43-9.	9
1005	Albert NL, Unterrainer M, Diemling M, Xiong G, Bartenstein P, Koch W, et al. Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2016;43(7):1315-22.	7

1006	Alvarez-Fischer D, Blessmann G, Trosowski C, Behe M, Schurrat T, Hartmann A, et al. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. <i>Neuroimage</i> . 2007;38(1):5-12.	1
1007	Andringa G, Drukarch B, Bol JG, de Bruin K, Sorman K, Habraken JB, et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. <i>Neuroimage</i> . 2005;26(4):1150-8.	10
1008	Antonini A, Berto P, Lopatriello S, Tamma F, Annemans L, Chambers M. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. <i>Movement Disorders</i> . 2008;23(15):2202-9.	10
1009	Appel L, Jonasson M, Danfors T, Nyholm D, Askmark H, Lubberink M, et al. Use of 11C-PE2I PET in differential diagnosis of parkinsonian disorders. <i>Journal of Nuclear Medicine</i> . 2015;56(2):234-42.	9
1010	Arnaldi D, Chincarini A, Hu MT, Sonka K, Boeve B, Miyamoto T, et al. Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder. <i>Brain</i> . 2021;144(1):278-87.	10
1011	Bae YJ, Kim JM, Kim E, Lee KM, Kang SY, Park HS, et al. Loss of Nigral Hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison With (123) I-FP-CIT SPECT. <i>Movement Disorders</i> . 2016;31(5):684-92.	9
1012	Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2013;84(11):1288-95.	10
1013	Bajaj NP, Gontu V, Birchall J, Patterson J, Grosset DG, Lees AJ. Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video study. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2010;81(11):1223-8.	10
1014	Barrantes S, Sanchez Egea AJ, Gonzalez Rojas HA, Marti MJ, Compta Y, Valdeoriola F, et al. Differential diagnosis between Parkinson's disease and essential tremor using the smartphone's accelerometer. <i>PLoS ONE [Electronic Resource]</i> . 2017;12(8):e0183843.	8
1015	Barrou Z, Boddaert J, Faucounau V, Habert MO, Greffard S, Dieudonne B, et al. Utility of 123I-FP-CIT SPECT for dementia diagnoses and therapeutic strategies in elderly patients. <i>Journal of Nutrition, Health & Aging</i> . 2014;18(1):50-3.	10
1016	Bartova P, Kraft O, Bernatek J, Havel M, Ressner P, Langova K, et al. Transcranial sonography and (123)I-FP-CIT single photon emission computed tomography in movement disorders. <i>Ultrasound in Medicine & Biology</i> . 2014;40(10):2365-71.	7
1017	Benaderette S, Zanotti Fregonara P, Apartis E, Nguyen C, Trocello JM, Remy P, et al. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. <i>Movement Disorders</i> . 2006;21(3):310-7.	10
1018	Benamer HT, Oertel WH, Patterson J, Hadley DM, Pogarell O, Hoffken H, et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. <i>Movement Disorders</i> . 2003;18(9):977-84.	10
1019	Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. <i>Movement Disorders</i> . 2000;15(4):692-8.	9
1020	Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. <i>Movement Disorders</i> . 2000;15(3):503-10.	10
1021	Benitez-Rivero S, Marin-Oyaga VA, Garcia-Solis D, Huertas-Fernandez I, Garcia-Gomez FJ, Jesus S, et al. Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2013;84(2):122-9.	10
1022	Berger HJ, Cools AR, Horstink MW, Oyen WJ, Verhoeven EW, van der Werf SP. Striatal dopamine and learning strategy-an (123)I-FP-CIT SPECT study. <i>Neuropsychologia</i> . 2004;42(8):1071-8.	9
1023	Berti V, Pupi A, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, et al. Clinical correlation of the binding potential with 123I-FP-CIT in de novo idiopathic Parkinson's disease patients. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2008;35(12):2220-6.	9
1024	Beucke JC, Plotkin M, Winter C, Endrass T, Amthauer H, Juckel G, et al. Midbrain serotonin transporters in de novo and L-DOPA-treated patients with early Parkinson's disease--a [123 I]-ADAM SPECT study. <i>European Journal of Neurology</i> . 2011;18(5):750-5.	9
1025	Booij J, Andringa G, Rijks LJ, Vermeulen RJ, De Bruin K, Boer GJ, et al. [123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. <i>Synapse</i> . 1997;27(3):183-90.	1
1026	Booij J, Bergmans P, Winogrodzka A, Speelman JD, Wolters EC. Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. <i>Synapse</i> . 2001;39(2):101-8.	7

1027	Booij J, de Jong J, de Bruin K, Knol R, de Win MM, van Eck-Smit BL. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. <i>Journal of Nuclear Medicine</i> . 2007;48(3):359-66.	9
1028	Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. <i>Journal of Nuclear Medicine</i> . 1998;39(11):1879-84.	10
1029	Booij J, Kemp P. Dopamine transporter imaging with [(123I)]FP-CIT SPECT: potential effects of drugs. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2008;35(2):424-38.	10
1030	Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. <i>European Journal of Nuclear Medicine</i> . 2001;28(3):266-72.	10
1031	Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 1997;62(2):133-40.	10
1032	Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. <i>European Journal of Nuclear Medicine</i> . 1997;24(1):68-71.	9
1033	Bostantjopoulou S, Katsarou Z, Gerasimou G, Costa DC, Gotzamani-Psarrakou A. (123I)-FP-CIT SPET striatal uptake in parkinsonian patients with the alpha-synuclein (G209A) mutation A. <i>Hellenic Journal of Nuclear Medicine</i> . 2008;11(3):157-9.	10
1034	Bouwman AE, Vlaar AM, Mess WH, Kessels A, Weber WE. Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. <i>BMJ Open</i> . 2013;3(4).	10
1035	Bovi T, Antonini A, Ottaviani S, Antonioli A, Cecchini MP, Di Francesco V, et al. The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism. <i>Journal of Neurology</i> . 2010;257(11):1882-9.	10
1036	Brajkovic LD, Svetel MV, Kostic VS, Sobic-Saranovic DP, Pavlovic SV, Artiko VM, et al. Dopamine transporter imaging (123I)-FP-CIT (DaTSCAN) SPET in differential diagnosis of dopa-responsive dystonia and young-onset Parkinson's disease. <i>Hellenic Journal of Nuclear Medicine</i> . 2012;15(2):134-8.	10
1037	Brigo F, Matinella A, Erro R, Tinazzi M. [123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis. <i>European Journal of Neurology</i> . 2014;21(11):1369-e90.	2
1038	Buchert R, Hutton C, Lange C, Hoppe P, Makowski M, Bamouza T, et al. Semiquantitative slab view display for visual evaluation of 123I-FP-CIT SPECT. <i>Nuclear Medicine Communications</i> . 2016;37(5):509-18.	9
1039	Camacho V, Marquie M, Lleo A, Alves L, Artigas C, Flotats A, et al. Cardiac sympathetic impairment parallels nigrostriatal degeneration in Probable Dementia with Lewy Bodies. <i>The Quarterly Journal of Nuclear Medicine & Molecular Imaging</i> . 2011;55(4):476-83.	10
1040	Camisuli DM, Pagni C, Palermo G, Frosini D, Bonaccorsi J, Radicchi C, et al. Mild Cognitive Impairment in de novo Parkinson's Disease: Selective Attention Deficit as Early Sign of Neurocognitive Decay. <i>Frontiers in Psychology</i> . 2021;12:546476.	9
1041	Carrasco Garcia de Leon S, Cabello JP, Ortiz R, Vaamonde J. Parkinsonism Associated with Pathological 123I-FP-CIT SPECT (DaTSCAN) Results as the Initial Manifestation of Sporadic Creutzfeldt-Jakob Disease. <i>Case Reports in Neurological Medicine Print</i> . 2018;2018:5157275.	6
1042	Carrillo Garcia F, Gil Neciga E, Alberca R, Garcia-Solis D, Millan J, Rodriguez Uranga JJ, et al. [Apolipoprotein E4 in dementia with Lewy bodies]. <i>Neurologia</i> . 2008;23(3):152-6.	3
1043	Ceravolo R, Volterrani D, Gambaccini G, Rossi C, Logi C, Manca G, et al. Dopaminergic degeneration and perfusional impairment in Lewy body dementia and Alzheimer's disease. <i>Neurological Sciences</i> . 2003;24(3):162-3.	9
1044	Chen Q, Lowe VJ, Boeve BF, Przybelski SA, Miyagawa T, Senjem ML, et al. beta-Amyloid PET and 123I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. <i>Neurology</i> . 2021;06:06.	9
1045	Chen Y, Goorden MC, Beekman FJ. Convolutional neural network based attenuation correction for 123I-FP-CIT SPECT with focused striatum imaging. <i>Physics in Medicine & Biology</i> . 2021;66(19):24.	9
1046	Chiaravalloti A, Stefani A, Fiorentini A, Lacanfora A, Stanzione P, Schillaci O. Do CSF levels of t-Tau, p-Tau and beta1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2014;41(11):2137-43.	9
1047	Ciarmiello A, Giovacchini G, Guidotti C, Meniconi M, Lazzari P, Carabelli E, et al. Weighted registration of 123I-FP-CIT SPECT images improves accuracy of binding potential estimates in pathologically low striatal uptake. <i>Journal of Cellular Physiology</i> . 2013;228(10):2086-94.	9

1048	Colloby SJ, Firbank MJ, Pakrasi S, Lloyd JJ, Driver I, McKeith IG, et al. A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies. <i>International Psychogeriatrics</i> . 2008;20(6):1124-40.	9
1049	Colloby SJ, O'Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, et al. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. <i>Neuroimage</i> . 2004;23(3):956-66.	9
1050	Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2005;32(10):1176-85.	9
1051	Contrafatto D, Mostile G, Nicoletti A, Dibilio V, Raciti L, Lanzafame S, et al. [(123) I]FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism. <i>Acta Neurologica Scandinavica</i> . 2012;126(1):12-6.	9
1052	Coria F, Gimenez-Garcia M, Samaranch L, Mora FJ, Sampol-Bas C, Pastor P. Nigrostriatal dopaminergic function in subjects with isolated action tremor. <i>Parkinsonism & Related Disorders</i> . 2012;18(1):49-53.	9
1053	Covelli EM, Brunetti A, Di Lauro A, Sullo P, Mazzarella G, Tedeschi E, et al. Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease. <i>Radiologia Medica</i> . 2004;108(4):417-25.	10
1054	Davidsson A, Georgiopoulos C, Dizdar N, Granerus G, Zachrisson H. Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson's disease and Atypical Parkinsonian syndromes using DaTSCAN R SPECT. <i>Annals of Nuclear Medicine</i> . 2014;28(9):851-9.	10
1055	De Rosa A, Carducci C, Carducci C, Peluso S, Lieto M, Mazzella A, et al. Screening for dopa-responsive dystonia in patients with Scans Without Evidence of Dopaminergic Deficiency (SWEDD). <i>Journal of Neurology</i> . 2014;261(11):2204-8.	10
1056	de Souza Silva MA, Mattern C, Decheva C, Huston JP, Sadile AG, Beu M, et al. Intranasal Dopamine Reduces In Vivo [(123)I]FP-CIT Binding to Striatal Dopamine Transporter: Correlation with Behavioral Changes and Evidence for Pavlovian Conditioned Dopamine Response. <i>Frontiers in Behavioral Neuroscience</i> . 2016;10:80.	9
1057	Del Sole A, Perini G, Lecchi M, Mariani C, Lucignani G, Clerici F. Correlation between 123I-FP-CIT brain SPECT and parkinsonism in dementia with Lewy bodies: caveat for clinical use. <i>Clinical Nuclear Medicine</i> . 2015;40(1):32-5.	9
1058	Depboylu C, Maurer L, Matusch A, Hermanns G, Windolph A, Behe M, et al. Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [123I]FP-CIT SPECT and histochemistry. <i>Neuroimage</i> . 2013;79:191-200.	9
1059	Di Giuda D, Calcagni ML, Totaro M, Cocciolillo F, Piano C, Soleti F, et al. Chronic motor cortex stimulation in patients with advanced Parkinson's disease and effects on striatal dopaminergic transmission as assessed by 123I-FP-CIT SPECT: a preliminary report. <i>Nuclear Medicine Communications</i> . 2012;33(9):933-40.	9
1060	Di Giuda D, Camardese G, Bentivoglio AR, Cocciolillo F, Guidubaldi A, Pucci L, et al. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2012;39(12):1937-48.	9
1061	Di Giuda D, Camardese G, Cocciolillo F, Fasano A. Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT study: reply to comment by Erro et al. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2013;40(4):638-9.	9
1062	Djaldetti R, Nageris BI, Lorberboym M, Treves TA, Melamed E, Yaniv E. [(123)I]-FP-CIT SPECT and olfaction test in patients with combined postural and rest tremor. <i>Journal of Neural Transmission</i> . 2008;115(3):469-72.	9
1063	Djaldetti R, Treves TA, Ziv I, Melamed E, Lampl Y, Lorberboym M. Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. <i>Neurological Sciences</i> . 2009;30(4):301-5.	10
1064	Djaldetti R, Treves TA, Ziv I, Melamed E, Lorberboym M. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with recurrent sudden falls: are such falls a distinct entity? <i>Journal of Nuclear Medicine Technology</i> . 2007;35(4):232-6.	9
1065	Donaghy PC, O'Brien JT, Thomas AJ. Prodromal dementia with Lewy bodies. <i>Psychological Medicine</i> . 2015;45(2):259-68.	9
1066	Durcan R, Donaghy PC, Barnett NA, Olsen K, Yarnall AJ, Taylor JP, et al. Prevalence and severity of symptoms suggestive of gastroparesis in prodromal dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> . 2019;34(7):990-8.	9
1067	El Fakhri G, Habert MO, Maksud P, Kas A, Malek Z, Kijewski MF, et al. Quantitative simultaneous (99m)Tc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2006;33(1):87-92.	9
1068	Erro R, Pappata S, Barone P, Pellecchia MT. Comment on Di Giuda et al.: Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2013;40(4):636-7.	9

1069	Evans AH, Costa DC, Gacinovic S, Katzenschlager R, O'Sullivan J D, Heales S, et al. L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings. <i>Movement Disorders</i> . 2004;19(10):1232-6.	10
1070	Fahmi R, Platsch G, Sadr AB, Gouttard S, Thobois S, Zuehlsdorff S, et al. Single-site 123I-FP-CIT reference values from individuals with non-degenerative parkinsonism-comparison with values from healthy volunteers. <i>European Journal Of Hybrid Imaging</i> . 2020;4(1):5.	9
1071	Fekete R. Late onset neurodegeneration with brain-iron accumulation presenting as parkinsonism. <i>Case Reports in Neurological Medicine Print</i> . 2012;2012:387095.	6
1072	Filippi L, Bruni C, Padovano F, Schillaci O, Simonetti G. The Value of Semi-Quantitative Analysis of 123I-FP-CIT SPECT in Evaluating Patients with Parkinson's Disease. <i>Neuroradiology Journal</i> . 2008;21(4):505-9.	7
1073	Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. <i>Nuclear Medicine Communications</i> . 2005;26(5):421-6.	7
1074	Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, et al. 123I-FP-CIT in progressive supranuclear palsy and in Parkinson's disease: a SPECT semiquantitative study. <i>Nuclear Medicine Communications</i> . 2006;27(4):381-6.	9
1075	Frings L, Heimbach B, Meyer PT, Hellwig S. Intrinsic Alertness Is Impaired in Patients with Nigrostriatal Degeneration: A Prospective Study with Reference to [123I]FP-CIT SPECT and [18F]FDG PET. <i>Journal of Alzheimer's Disease</i> . 2020;78(4):1721-9.	9
1076	Frings L, Henninger F, Treppner M, Kober G, Boeker M, Hellwig S, et al. [123I]FP-CIT SPECT in Clinically Uncertain Parkinsonism Predicts Survival: A Data-Driven Analysis. <i>Journal of Parkinsons Disease Print</i> . 2020;10(4):1457-65.	9
1077	Frings L, Henninger F, Treppner M, Kober G, Boeker M, Meyer PT. DAT SPECT Predicts Survival in Patients Assessed for Differential Diagnosis of Dementia. <i>Journal of Alzheimer's Disease</i> . 2021;82(1):215-20.	9
1078	Gamez J, Lorenzo-Bosquet C, Cuberas-Borros G, Carmona F, Hernandez-Vara J, Castillo J, et al. Does reduced [(123I)]-FP-CIT binding in Huntington's disease suggest pre-synaptic dopaminergic involvement? <i>Clinical Neurology & Neurosurgery</i> . 2010;112(10):870-5.	9
1079	Garriga M, Mila M, Mir M, Al-Baradie R, Huertas S, Castejon C, et al. (123I)-FP-CIT SPECT imaging in early diagnosis of dementia in patients with and without a vascular component. <i>Frontiers in Systems Neuroscience</i> . 2015;9:99.	9
1080	Geisler S, Beindorff N, Cremer M, Hoffmann K, Brenner W, Cumming P, et al. Characterization of [123I]FP-CIT binding to the dopamine transporter in the striatum of tree shrews by quantitative in vitro autoradiography. <i>Synapse</i> . 2015;69(10):497-504.	1
1081	Gil-Navarro S, Gelpi E, Lomena F, Montagut N, Llado A, Molinuevo JL, et al. In vivo decreased dopamine transporter uptake in corticobasal degeneration presenting with primary progressive aphasia without parkinsonism. <i>European Journal of Neurology</i> . 2014;21(7):e56-7.	2
1082	Goethals I, Ham H, Dobbeleir A, Santens P, D'Asseler Y. The potential value of a pictorial atlas for aid in the visual diagnosis of 123I FP-CIT SPECT scans. <i>Nuclear-Medizin</i> . 2009;48(4):173-8.	8
1083	Grachev ID. Dopamine transporter imaging with [123I]FP-CIT (DaTSCAN) in Parkinson's disease with depressive symptoms: a biological marker for causal relationships? <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2014;85(2):130-1.	2
1084	Greenbaum L, Smith RC, Lorberboym M, Alkelai A, Zozulinsky P, Lifschytz T, et al. Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients. <i>Psychopharmacology</i> . 2012;220(3):519-28.	9
1085	Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, et al. Gender differences in Parkinson's disease. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2007;78(8):819-24.	10
1086	Haller S, Davidsson A, Tisell A, Ochoa-Figueroa M, Georgiopoulos C. MRI of nigrosome-1: A potential triage tool for patients with suspected parkinsonism. <i>Journal of Neuroimaging</i> . 2021;01:01.	7
1087	Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, et al. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. <i>Brain</i> . 2016;139(Pt 7):2039-49.	7
1088	Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, Toni I. Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. <i>Annals of Neurology</i> . 2011;69(2):269-81.	10
1089	Hernandez Vara J, Rubiera del Fueyo M, Lorenzo Bosquet C, Castell Conesa J, Molina Cateriano CA, Rodriguez FM. [Usefulness of transcranial sonography in Parkinson's disease. A comparative study using 123I-FP-CIT SPECT]. <i>Medicina Clinica</i> . 2008;131(8):285-9.	3
1090	Hosoda N, Ikeda T. Optimization of Reformatting Angle Using Orbitomeatal Base Line in Dopamine Transporter Scintigraphy. <i>Nippon Hoshasen Gijutsu Gakkai Zasshi</i> . 2017;73(8):689-94.	9

1091	Huertas I, Jesus S, Garcia-Gomez FJ, Lojo JA, Bernal-Bernal I, Bonilla-Toribio M, et al. Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson's disease. <i>PLoS ONE [Electronic Resource]</i> . 2017;12(4):e0175560.	9
1092	Huertas-Fernandez I, Garcia-Gomez FJ, Garcia-Solis D, Benitez-Rivero S, Marin-Oyaga VA, Jesus S, et al. Machine learning models for the differential diagnosis of vascular parkinsonism and Parkinson's disease using [(123I)]FP-CIT SPECT. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2015;42(1):112-9.	8
1093	Iranzo A, Lomena F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, et al. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study [corrected]. <i>Lancet Neurology</i> . 2010;9(11):1070-7.	9
1094	Isaias IU, Benti R, Cilia R, Canesi M, Marotta G, Gerundini P, et al. [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. <i>Neuroreport</i> . 2007;18(14):1499-502.	7
1095	Isaias IU, Marotta G, Pezzoli G, Sabri O, Schwarz J, Crenna P, et al. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. <i>BMC Neurology</i> . 2011;11:88.	9
1096	Isaias IU, Marzegan A, Pezzoli G, Marotta G, Canesi M, Biella GE, et al. A role for locus coeruleus in Parkinson tremor. <i>Frontiers in Human Neuroscience</i> . 2011;5:179.	9
1097	Ishiguro M, Uno M, Miyazaki T, Kataoka Y, Toyama H, Ichihara T. [Development of a Striatal and Skull Phantom for Quantitative 123I-FP-CIT SPECT]. <i>Nippon Hoshasen Gijutsu Gakkai Zasshi</i> . 2018;74(2):124-32.	3
1098	Itti E, Villafane G, Malek Z, Brugieres P, Capacchione D, Itti L, et al. Dopamine transporter imaging under high-dose transdermal nicotine therapy in Parkinson's disease: an observational study. <i>Nuclear Medicine Communications</i> . 2009;30(7):513-8.	9
1099	Jakobson Mo S, Larsson A, Linder J, Birgander R, Edenbrandt L, Stenlund H, et al. 123I-FP-Cit and 123I-IBZM SPECT uptake in a prospective normal material analysed with two different semiquantitative image evaluation tools. <i>Nuclear Medicine Communications</i> . 2013;34(10):978-89.	9
1100	Jaukovic L, Ilic TV, Dopudja M, Ajdinovic B. 123I-FP-CIT brain SPECT (DaTSCAN) imaging in the diagnosis of patients with movement disorders--first results. <i>Vojnosanitetski Pregled</i> . 2012;69(2):157-62.	10
1101	Joling M, Vriend C, Raijmakers P, van der Zande JJ, Lemstra AW, Berendse HW, et al. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study. <i>NeuroImage Clinical</i> . 2019;22:101755.	10
1102	Joling M, Vriend C, van den Heuvel OA, Raijmakers P, Jones PA, Berendse HW, et al. Analysis of Extrastriatal 123I-FP-CIT Binding Contributes to the Differential Diagnosis of Parkinsonian Diseases. <i>Journal of Nuclear Medicine</i> . 2017;58(7):1117-23.	10
1103	Joutsa J, Johansson J, Seppanen M, Noponen T, Kaasinen V. Dorsal-to-Ventral Shift in Midbrain Dopaminergic Projections and Increased Thalamic/Raphe Serotonergic Function in Early Parkinson Disease. <i>Journal of Nuclear Medicine</i> . 2015;56(7):1036-41.	10
1104	Kaasinen V, Joutsa J, Noponen T, Johansson J, Seppanen M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease. <i>Neurobiology of Aging</i> . 2015;36(4):1757-63.	9
1105	Kahraman D, Eggers C, Holstein A, Schneider C, Pedrosa DJ, Dietlein M, et al. 123I-FP-CIT SPECT imaging of the dopaminergic state. Visual assessment of dopaminergic degeneration patterns reflects quantitative 2D operator-dependent and 3D operator-independent techniques. <i>Nuclear-Medizin</i> . 2012;51(6):244-51.	7
1106	Kahraman D, Eggers C, Schicha H, Timmermann L, Schmidt M. Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease. <i>Journal of Neurology</i> . 2012;259(2):251-60.	10
1107	Kane JPM, Roberts G, Petrides GS, Lloyd JJ, O'Brien JT, Thomas AJ. 123I-MIBG scintigraphy utility and cut-off value in a clinically representative dementia cohort. <i>Parkinsonism & Related Disorders</i> . 2019;62:79-84.	9
1108	Kanzaki T, Higuchi T, Takahashi Y, Suto T, Tsushima Y. Improvement of diagnostic accuracy of Parkinson's disease on I-123-ioflupane single photon emission computed tomography (123I FP-CIT SPECT) using new Japanese normal database. <i>Asia Oceania Journal of Nuclear Medicine & Biology</i> . 2020;8(2):95-101.	7
1109	Kas A, Payoux P, Habert MO, Malek Z, Cointepas Y, El Fakhri G, et al. Validation of a standardized normalization template for statistical parametric mapping analysis of 123I-FP-CIT images. <i>Journal of Nuclear Medicine</i> . 2007;48(9):1459-67.	10
1110	Katzenschlager R, Costa D, Gacinovic S, Lees AJ. [(123I)]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia. <i>Neurology</i> . 2002;59(12):1974-6.	6
1111	Katzenschlager R, Costa D, Gerschlagler W, O'Sullivan J, Zijlmans J, Gacinovic S, et al. [123I]-FP-CIT-SPECT demonstrates dopaminergic deficit in orthostatic tremor. <i>Annals of Neurology</i> . 2003;53(4):489-96.	9
1112	Kemp PM, Clyde K, Holmes C. Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies: a retrospective study. <i>Nuclear Medicine Communications</i> . 2011;32(4):298-302.	9

1113	Kemp PM, Hoffmann SA, Tossici-Bolt L, Fleming JS, Holmes C. Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. <i>Nuclear Medicine Communications</i> . 2007;28(6):451-6.	9
1114	Kiferle L, Ceravolo R, Giuntini M, Linsalata G, Puccini G, Volterrani D, et al. Caudate dopaminergic denervation and visual hallucinations: evidence from a 123I-FP-CIT SPECT study. <i>Parkinsonism & Related Disorders</i> . 2014;20(7):761-5.	9
1115	Kim JM, Hong S, Kim GP, Choi YJ, Kim YK, Park SS, et al. Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism. <i>Archives of Neurology</i> . 2007;64(10):1510-8.	6
1116	Krygowska-Wajs A, Kachergus JM, Hulihan MM, Farrer MJ, Searcy JA, Boojj J, et al. Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. <i>Journal of Neural Transmission</i> . 2005;112(11):1487-502.	10
1117	Kuya K, Shinohara Y, Miyoshi F, Fujii S, Tanabe Y, Ogawa T. Correlation between neuromelanin-sensitive MR imaging and (123I)-FP-CIT SPECT in patients with parkinsonism. <i>Neuroradiology</i> . 2016;58(4):351-6.	9
1118	Leung K. (1R,2S,3S,5S)-Methyl-8-[[[(1S,2S)-2-[[18F]fluoromethyl)cyclopropyl]methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-2-carboxylate. National Center for Biotechnology Information. 2004.	9
1119	Leung K. N-4-[18F]Fluorobut-2-yn-1-yl-2beta-carbomethoxy-3beta-phenyltropane. National Center for Biotechnology Information. 2004.	2
1120	Leung K. N-4-Fluorobut-2-yn-1-yl-2beta-carbo-[11C]methoxy-3beta-phenyltropane. National Center for Biotechnology Information. 2004.	2
1121	Leung K. 8-((E)-4-Fluoro-but-2-enyl)-3beta-p-tolyl-8-aza-bicyclo[3.2.1]octane-2beta-carboxylic acid [11C]methyl ester. National Center for Biotechnology Information. 2004.	2
1122	Leung K. 2beta-Carbomethoxy-3beta-(4-chlorophenyl)-8-(2-[18F]fluoroethyl)nortropane. National Center for Biotechnology Information. 2004.	9
1123	Leung K. 3-beta-(4-Iodophenyl)tropane-2-beta-carboxylic acid 2-[18F]fluoroethyl ester. National Center for Biotechnology Information. 2004.	2
1124	Leung K. N-(3-[18F]Fluoropropyl)-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane. National Center for Biotechnology Information. 2004.	2
1125	Leung K. N-(3-Fluoropropyl)-2beta-carbomethoxy-3beta-(4-[123I]iodophenyl)nortropane. National Center for Biotechnology Information. 2004.	2
1126	Lobsien E, Schreiner S, Plotkin M, Kupsch A, Schreiber SJ, Doepp F. No correlation of substantia nigra echogenicity and nigrostriatal degradation in Parkinson's disease. <i>Movement Disorders</i> . 2012;27(3):450-3.	10
1127	Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. <i>Movement Disorders</i> . 2006;21(4):510-4.	10
1128	Lorenzo Bosquet C, Cuberas Borros G, Miquel Rodriguez F, Caresia P, Aguade Bruix S, Castell Conesa J. [Quantitative evaluation of 123I-FP-CIT SPECT: validation of a semiautomated method]. <i>Revista Espanola de Medicina Nuclear</i> . 2005;24(4):244-9.	3
1129	Lorenzo Bosquet C, Miquel Rodriguez F, Roca Bielsa I, Mila M, Aguade Bruix S, Castell Conesa J. [Differential diagnosis of parkinsonism using dopamine transporters brain SPECT]. <i>Medicina Clinica</i> . 2004;122(9):325-8.	3
1130	Ma KKY, Lin S, Mok VCT. Neuroimaging in Vascular Parkinsonism. <i>Current Neurology & Neuroscience Reports</i> . 2019;19(12):102.	2
1131	Marquie Sayagues M, Da Silva Alves L, Molina-Porcel L, Alcolea Rodriguez D, Sala Matavera I, Sanchez-Saudinos MB, et al. [(123I)-MIBG myocardial scintigraphy in the diagnosis of Lewy body dementia]. <i>Neurologia</i> . 2010;25(7):414-21.	3
1132	Marshall VL, Reiningner CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. <i>Movement Disorders</i> . 2009;24(4):500-8.	7
1133	Martinez del Valle Torres MD, Ramos Moreno E, Amrani Raissouni T, Ortega Lozano SJ, Sanz Viedma S, Jimenez-Hoyuela JM. [Functional assessment of nigro-striatal pathway with FP-CIT in patients with multiple system atrophy subtype C]. <i>Medicina Clinica</i> . 2011;137(10):440-3.	3
1134	Martinez-Valle Torres MD, Ortega Lozano SJ, Gomez Heredia MJ, Amrani Raissouni T, Ramos Moreno E, Moya Espinosa P, et al. Longitudinal evaluation using FP-CIT in patients with parkinsonism. <i>Neurologia</i> . 2014;29(6):327-33.	9
1135	Mateos JJ, Lomena F, Parellada E, Font M, Fernandez E, Pavia J, et al. [Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone]. <i>Revista Espanola de Medicina Nuclear</i> . 2006;25(3):159-65.	3
1136	Mateos JJ, Lomena F, Parellada E, Font M, Fernandez E, Pavia J, et al. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. <i>Psychopharmacology</i> . 2005;181(2):401-6.	10
1137	Matsutomo N, Nagaki A, Yamao F, Sasaki M. Optimization of iterative reconstruction parameters with 3-dimensional resolution recovery, scatter and attenuation correction in 123I-FP-CIT SPECT. <i>Annals of Nuclear Medicine</i> . 2015;29(7):636-42.	8

1138	McKeith I, O'Brien J, Walker Z, Tatsch K, Booi J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. <i>Lancet Neurology</i> . 2007;6(4):305-13.	9
1139	McNeill A, Wu RM, Tzen KY, Aguiar PC, Arbelo JM, Barone P, et al. Dopaminergic neuronal imaging in genetic Parkinson's disease: insights into pathogenesis. <i>PLoS ONE [Electronic Resource]</i> . 2013;8(7):e69190.	9
1140	Meyer PT, Amtage F, Hellwig S. [Differential diagnostics of Parkinson's disease with nuclear medicine procedures]. <i>Nervenarzt</i> . 2014;85(6):680-9.	2
1141	Meyer PT, Winz OH, Dafotakis M, Werner CJ, Krohn T, Schafer WM. Improved visual [(123I)]FP-CIT SPECT interpretation for evaluation of parkinsonism by visual rating of parametric distribution volume ratio images. <i>The Quarterly Journal of Nuclear Medicine & Molecular Imaging</i> . 2011;55(3):301-9.	7
1142	Miyagawa T, Przybelski SA, Maltais D, Min HK, Jordan L, Lesnick TG, et al. The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. <i>Neurobiology of Aging</i> . 2021;99:11-8.	9
1143	Morgan S, Kemp P, Booi J, Costa DC, Padayachee S, Lee L, et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2012;83(11):1063-70.	9
1144	Morgante F, Barbui C, Tinazzi M, Italian DIPsg. Parkinsonian axial signs in schizophrenia. <i>Parkinsonism & Related Disorders</i> . 2017;36:89-92.	9
1145	Mossa EP, Niccoli Asabella A, Luele F, Stabile Ianora AA, Giganti M, Rubini G. [Striatal dopamine transporter levels in patients with REM sleep behavior disorder: assessment with 123I-FP-CIT SPECT]. <i>Recenti Progressi in Medicina</i> . 2012;103(11):500-4.	3
1146	Mukaetova-Ladinska EB, Scully A. Relevance of 123I-FP-CIT SPECT brain scans in routine clinical settings. <i>British Journal of Psychiatry</i> . 2015;207(4):364.	4
1147	Nakadate M, Miyamoto N, Starkey J, Torihiro A, Tateishi U. Anterograde Degeneration of the Nigrostriatal Pathway Visualized by 123I-FP-CIT SPECT in a Patient With Artery of Percheron Infarction. <i>Clinical Nuclear Medicine</i> . 2016;41(6):483-4.	6
1148	Navarro-Otano J, Gaig C, Muxi A, Lomena F, Compta Y, Buongiorno MT, et al. 123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease. <i>Parkinsonism & Related Disorders</i> . 2014;20(2):192-7.	9
1149	Neishi H, Ikawa M, Okazawa H, Tsujikawa T, Arishima H, Kikuta KI, et al. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT. <i>European Neurology</i> . 2017;78(3-4):161-8.	9
1150	Nicastro N, Garibotto V, Poncet A, Badoud S, Burkhard PR. Establishing On-Site Reference Values for (123I)-FP-CIT SPECT (DaTSCAN R) Using a Cohort of Individuals with Non-Degenerative Conditions. <i>Molecular Imaging & Biology</i> . 2016;18(2):302-12.	9
1151	Niccoli Asabella A, Gigante AF, Ferrari C, Di Palo A, Rubini D, Mossa EP, et al. Role of dopaminergic neurotransmission in pathophysiology of action tremor in Parkinson's disease. <i>Hellenic Journal of Nuclear Medicine</i> . 2015;18 Suppl 1:11-6.	9
1152	Nikolaus S, Larisch R, Vosberg H, Beu M, Wirtwar A, Antke C, et al. Pharmacological challenge and synaptic response - assessing dopaminergic function in the rat striatum with small animal single-photon emission computed tomography (SPECT) and positron emission tomography (PET). <i>Reviews in the Neurosciences</i> . 2011;22(6):625-45.	1
1153	Nikolaus S, Wirtwar A, Antke C, Arkian S, Schramm N, Muller HW, et al. Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2005;32(3):308-13.	1
1154	Ninerola-Baizan A, Rojas S, Bonastre M, Tudela R, Lomena F, Pavia J, et al. In vivo evaluation of the dopaminergic neurotransmission system using [123I]FP-CIT SPECT in 6-OHDA lesioned rats. <i>Contrast Media & Molecular Imaging</i> . 2015;10(1):67-73.	1
1155	Ninerola-Baizan A, Rojas S, Roe-Vellve N, Lomena F, Ros D, Pavia J. Dopamine transporter imaging in the aged rat: a [123I]FP-CIT SPECT study. <i>Nuclear Medicine & Biology</i> . 2015;42(4):395-8.	1
1156	Nissen T, Malek N, Grosset KA, Newman EJ, Patterson J, Hadley D, et al. Baseline [(123) I]FP-CIT SPECT (DaTSCAN) severity correlates with medication use at 3 years in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> . 2014;129(3):204-8.	9
1157	O'Brien JT, McKeith IG, Walker Z, Tatsch K, Booi J, Darcourt J, et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. <i>British Journal of Psychiatry</i> . 2009;194(1):34-9.	9
1158	Okizaki A, Nakayama M, Nakajima K, Katayama T, Uno T, Morikawa F, et al. Inter- and intra-observer reproducibility of quantitative analysis for FP-CIT SPECT in patients with DLB. <i>Annals of Nuclear Medicine</i> . 2017;31(10):758-63.	9
1159	Olivares Romero J, Arjona Padillo A. Diagnostic accuracy of 123 I-FP-CIT SPECT in diagnosing drug-induced parkinsonism: a prospective study. <i>Neurologia</i> . 2013;28(5):276-82.	3
1160	Oliveira FP, Borges Faria D, Campos Costa D, Tavares JM. A robust computational solution for automated quantification of a specific binding ratio based on [123I]fp-cit SPECT images. <i>The Quarterly Journal of Nuclear Medicine & Molecular Imaging</i> . 2014;58(1):74-84.	8

1161	Oliveira FP, Castelo-Branco M. Computer-aided diagnosis of Parkinson's disease based on [(123)I]FP-CIT SPECT binding potential images, using the voxels-as-features approach and support vector machines. <i>Journal of Neural Engineering</i> . 2015;12(2):026008.	8
1162	Oliveira FPM, Faria DB, Costa DC, Castelo-Branco M, Tavares J. Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson's disease based on [(123)I]FP-CIT SPECT images. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2018;45(6):1052-62.	10
1163	Oliveira FPM, Walker Z, Walker RWH, Attems J, Castanheira JC, Silva A, et al. 123I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease: a new quantitative analysis of autopsy confirmed cases. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2021;04:04.	10
1164	Ortega Lozano SJ, Martinez Del Valle Torres MD, Jimenez-Hoyuela Garcia JM, Delgado Garcia A, Campos Arillo V. [Application of 123I-FP-CIT in the clinical practice in Parkinsonism patients]. <i>Revista Espanola de Medicina Nuclear</i> . 2005;24(4):224-33.	3
1165	Ottaviani S, Tinazzi M, Pasquin I, Nothdurfter W, Tomelleri G, Fincati E, et al. Comparative analysis of visual and semi-quantitative assessment of striatal [(123)I]FP-CIT-SPET binding in Parkinson's disease. <i>Neurological Sciences</i> . 2006;27(6):397-401.	9
1166	Palumbo B, Fravolini ML, Buresta T, Pompili F, Forini N, Nigro P, et al. Diagnostic accuracy of Parkinson disease by support vector machine (SVM) analysis of 123I-FP-CIT brain SPECT data: implications of putaminal findings and age. <i>Medicine</i> . 2014;93(27):e228.	10
1167	Palumbo B, Fravolini ML, Nuvoli S, Spanu A, Paulus KS, Schillaci O, et al. Comparison of two neural network classifiers in the differential diagnosis of essential tremor and Parkinson's disease by (123)I-FP-CIT brain SPECT. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2010;37(11):2146-53.	8
1168	Papathanasiou N, Rondogianni P, Chroni P, Themistocleous M, Boviatsis E, Pedeli X, et al. Interobserver variability, and visual and quantitative parameters of (123)I-FP-CIT SPECT (DaTSCAN) studies. <i>Annals of Nuclear Medicine</i> . 2012;26(3):234-40.	9
1169	Pardini M, Nobili F, Arnaldi D, Morbelli S, Bauckneht M, Rissotto R, et al. 123I-FP-CIT SPECT validation of nigro-putaminal MRI tractography in dementia with Lewy bodies. <i>European Radiology Experimental</i> . 2020;4(1):27.	9
1170	Park HR, Ha S, Lee DS, Im HJ, Paek SH. Determination of Parkinson Disease Laterality After Deep Brain Stimulation Using 123I FP-CIT SPECT. <i>Clinical Nuclear Medicine</i> . 2020;45(4):e178-e84.	9
1171	Pasquini J, Durcan R, Wiblin L, Gersel Stokholm M, Rochester L, Brooks DJ, et al. Clinical implications of early caudate dysfunction in Parkinson's disease. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2019;90(10):1098-104.	9
1172	Perlaki G, Szekeres S, Janszky J, Dezso D, Aschermann Z, Zambo K, et al. [The applicability of 123I-FP-CIT SPECT dopamine transporter imaging in clinical practice]. <i>Ideggyogyaszati Szemle</i> . 2019;72(11-12):381-8.	3
1173	Perlaki G, Szekeres S, Orsi G, Papp L, Suha B, Nagy SA, et al. Validation of an automated morphological MRI-based (123)I-FP-CIT SPECT evaluation method. <i>Parkinsonism & Related Disorders</i> . 2016;29:24-9.	7
1174	Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. <i>Journal of Neural Transmission</i> . 2005;112(5):677-92.	10
1175	Remy P. [Is functional imaging useful in the clinical evaluation of Parkinson's disease?]. <i>Revue Neurologique</i> . 2003;159(5 Pt 2):3S57-61.	3
1176	Roberts G, Durcan R, Donaghy PC, Lawley S, Ciafone J, Hamilton CA, et al. Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies. <i>Neurology</i> . 2021;96(23):e2801-e11.	9
1177	Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. <i>Movement Disorders</i> . 2009;24(14):2097-103.	9
1178	Roussakis AA, Gennaro M, Lao-Kaim NP, Towey D, Piccini P. Dopamine Transporter Density in de novo Parkinson's Disease Does Not Relate to the Development of Levodopa-Induced Dyskinesias. <i>Journal Of Neuroinflammation And Neurodegenerative Diseases</i> . 2019;3(1):10000.	7
1179	Roussakis AA, Piccini P, Politis M. Clinical utility of DaTscan TM (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes. <i>Degenerative Neurological & Neuromuscular Disease</i> . 2013;3:33-9.	2
1180	Sakamoto F, Shiraishi S, Kitajima M, Ogasawara K, Tsuda N, Tomiguchi S, et al. Diagnostic Performance of 123I-FPCIT SPECT Specific Binding Ratio in Progressive Supranuclear Palsy: Use of Core Clinical Features and MRI for Comparison. <i>AJR American Journal of Roentgenology</i> . 2020;215(6):1443-8.	9
1181	Sakamoto F, Shiraishi S, Ogasawara K, Tsuda N, Nakagawa M, Tomiguchi S, et al. A diagnostic strategy for Lewy body disease using DAT-SPECT, MIBG and Combined index. <i>Annals of Nuclear Medicine</i> . 2020;34(6):415-23.	9
1182	Sawada H, Orimo S. [Relationship between striatal 123I-FP-CIT uptake and cognitive functions in Parkinson's disease]. <i>Rinsho Shinkeigaku - Clinical Neurology</i> . 2019;59(12):799-805.	4

1183	Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. <i>Lancet Neurology</i> . 2013;12(8):747-55.	10
1184	Schillaci O, Chiaravalloti A, Pierantozzi M, Di Pietro B, Koch G, Bruni C, et al. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT. <i>International Journal of Molecular Medicine</i> . 2011;28(5):881-6.	9
1185	Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with(123)I-FP-CIT in patients with Parkinson's disease. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2005;32(12):1452-6.	10
1186	Sedaghat F, Gotzamani-Psarrakou A, Dedousi E, Arnaoutoglou M, Psarrakos K, Baloyannis I, et al. Evaluation of dopaminergic function in frontotemporal dementia using I-FP-CIT single photon emission computed tomography. <i>Neurodegenerative Diseases</i> . 2007;4(5):382-5.	9
1187	Shimizu S, Kanetaka H, Hirao K, Fukasawa R, Namioka N, Hatanaka H, et al. Neuroimaging for diagnosing dementia with Lewy bodies: What is the best neuroimaging technique in discriminating dementia with Lewy bodies from Alzheimer's disease? <i>Geriatrics & gerontology international</i> . 2017;17(5):819-24.	9
1188	Shimizu S, Namioka N, Hirose D, Kanetaka H, Hirao K, Hatanaka H, et al. Comparison of diagnostic utility of semi-quantitative analysis for DAT-SPECT for distinguishing DLB from AD. <i>Journal of the Neurological Sciences</i> . 2017;377:50-4.	9
1189	Siepel FJ, Rongve A, Buter TC, Beyer MK, Ballard CG, Booi J, et al. (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. <i>BMJ Open</i> . 2013;3(4).	9
1190	Sinha N, Firbank M, O'Brien JT. Biomarkers in dementia with Lewy bodies: a review. <i>International Journal of Geriatric Psychiatry</i> . 2012;27(5):443-53.	2
1191	Skanjeti A, Angusti T, Iudicello M, Dazzara F, Delgado Yabar GM, Trevisiol E, et al. Assessing the accuracy and reproducibility of computer-assisted analysis of (123) I-FP-CIT SPECT using BasGan (V2). <i>Journal of Neuroimaging</i> . 2014;24(3):257-65.	9
1192	Skanjeti A, Castellano G, Elia BO, Zotta M, Dazzara F, Manfredi M, et al. Multicenter Semiquantitative Evaluation of (123)I-FP-CIT Brain SPECT. <i>Journal of Neuroimaging</i> . 2015;25(6):1023-9.	7
1193	Solla P, Cannas A, Arca R, Fonti D, Orofino G, Marrosu F. Focal (123)I-FP-CIT SPECT Abnormality in Midbrain Vascular Parkinsonism. <i>Case Reports in Neurological Medicine Print</i> . 2015;2015:642764.	6
1194	Song YS, Kim JM, Kim KJ, Yun JY, Kim SE. Serum Ceruloplasmin and Striatal Dopamine Transporter Density in Parkinson Disease: Comparison With 123I-FP-CIT SPECT. <i>Clinical Nuclear Medicine</i> . 2017;42(9):675-9.	9
1195	Soret M, Koulibaly PM, Darcourt J, Buvat I. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2006;33(9):1062-72.	9
1196	Spehl TS, Frings L, Hellwig S, Weiller C, Hull M, Meyer PT, et al. Role of semiquantitative assessment of regional binding potential in 123I-FP-CIT SPECT for the differentiation of frontotemporal dementia, dementia with Lewy bodies, and Alzheimer's dementia. <i>Clinical Nuclear Medicine</i> . 2015;40(1):e27-33.	9
1197	Spiegel J, Hellwig D, Jost WH, Farmakis G, Samnick S, Fassbender K, et al. Cerebral and Extracranial Neurodegeneration are Strongly Coupled in Parkinson's Disease. <i>The Open Neurology Journal</i> . 2007;1:1-4.	9
1198	Spiegel J, Hellwig D, Mollers MO, Behnke S, Jost W, Fassbender K, et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. <i>Brain</i> . 2006;129(Pt 5):1188-93.	9
1199	Spiegel J, Mollers MO, Jost WH, Fuss G, Samnick S, Dillmann U, et al. FP-CIT and MIBG scintigraphy in early Parkinson's disease. <i>Movement Disorders</i> . 2005;20(5):552-61.	10
1200	Staff RT, Ahearn TS, Wilson K, Counsell CE, Taylor K, Caslake R, et al. Shape analysis of 123I-N-omega-fluoropropyl-2-beta-carbomethoxy-3beta-(4-iodophenyl) nortropane single-photon emission computed tomography images in the assessment of patients with parkinsonian syndromes. <i>Nuclear Medicine Communications</i> . 2009;30(3):194-201.	10
1201	Stogbauer J, Rosar F, Dillmann U, Fassbender K, Ezziddin S, Spiegel J. Striatal dopamine transporters and cognitive function in Parkinson's disease. <i>Acta Neurologica Scandinavica</i> . 2020;142(4):385-91.	10
1202	Stokkel MP, Dibbets-Schneider P, Koestering E, Dragoiescu C, Blokland KA. Reproducibility of a standardized quantitative analysis using fixed regions of interest to differentiate movement disorders on 123I-FP-CIT SPECT. <i>Journal of Nuclear Medicine Technology</i> . 2007;35(1):21-6.	9
1203	Suarez-Pinera M, Prat ML, Mestre-Fusco A, Fuertes J, Mojal S, Balaguer E. [Interobserver agreement in the visual and semi-quantitative analysis of the 123I-FP-CIT SPECT images in the diagnosis of Parkinsonian syndrome]. <i>Revista Espanola de Medicina Nuclear</i> . 2011;30(4):229-35.	3
1204	Sydoiff M, Lizana H, Mattsson S, Stabin MG, Leide-Svegborn S. Determination of the biodistribution and dosimetry of 123I-FP-CIT in male patients with suspected Parkinsonism or Lewy body dementia using planar and combined planar and SPECT/CT imaging. <i>Applied Radiation & Isotopes</i> . 2013;82:300-7.	9

1205	Tadokoro K, Ohta Y, Sato K, Maeki T, Sasaki R, Takahashi Y, et al. A Japanese Encephalitis Patient Presenting with Parkinsonism with Corresponding Laterality of Magnetic Resonance and Dopamine Transporter Imaging Findings. <i>Internal Medicine</i> . 2018;57(15):2243-6.	6
1206	Takada S, Yoshimura M, Shindo H, Saito K, Koizumi K, Utsumi H, et al. New semiquantitative assessment of 123I-FP-CIT by an anatomical standardization method. <i>Annals of Nuclear Medicine</i> . 2006;20(7):477-84.	8
1207	Takehisa S, Takeda I, Kobatake K, Yamashita T, Abe K, Kuriyama M. [SCA6 presenting parkinsonism without ataxia--A case report]. <i>Rinsho Shinkeigaku - Clinical Neurology</i> . 2015;55(4):243-7.	3
1208	Tatsch K, Buchert R, Bartenstein P, Barthel H, Boecker H, Brust P, et al. [Dopamine Transporter SPECT with I-123 labelled FP-CIT (DaTSCAN TM)]. <i>Nuclear-Medizin</i> . 2019;58(1):5-16.	3
1209	Taylor JP, Colloby SJ, McKeith IG, Burn DJ, Williams D, Patterson J, et al. Cholinesterase inhibitor use does not significantly influence the ability of 123I-FP-CIT imaging to distinguish Alzheimer's disease from dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2007;78(10):1069-71.	9
1210	Thomas AJ, Attems J, Colloby SJ, O'Brien JT, McKeith I, Walker R, et al. Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. <i>Neurology</i> . 2017;88(3):276-83.	9
1211	Tinazzi M, Cipriani A, Matinella A, Cannas A, Solla P, Nicoletti A, et al. [123I]FP-CIT single photon emission computed tomography findings in drug-induced Parkinsonism. <i>Schizophrenia Research</i> . 2012;139(1-3):40-5.	10
1212	Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. <i>Movement Disorders</i> . 2008;23(13):1825-9.	9
1213	Tiraboschi P, Corso A, Guerra UP, Nobili F, Piccardo A, Calcagni ML, et al. (123) I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography and (123) I-metaiodobenzylguanidine myocardial scintigraphy in differentiating dementia with lewy bodies from other dementias: A comparative study. <i>Annals of Neurology</i> . 2016;80(3):368-78.	9
1214	Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. <i>Journal of Nuclear Medicine</i> . 1998;39(7):1143-8.	10
1215	Towey DJ, Bain PG, Nijran KS. Automatic classification of 123I-FP-CIT (DaTSCAN) SPECT images. <i>Nuclear Medicine Communications</i> . 2011;32(8):699-707.	9
1216	Van Der Gucht A, Cleret de Langavant L, Belissant O, Rabu C, Cottureau AS, Evangelista E, et al. Brain (18)F-FDG, (18)F-Florbetaben PET/CT, (123)I-FP-CIT SPECT and Cardiac (123)I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. <i>Nuclear Medicine & Molecular Imaging</i> . 2016;50(3):258-60.	10
1217	van der Zande JJ, Booij J, Scheltens P, Rajmakers PG, Lemstra AW. [(123)I]FP-CIT SPECT scans initially rated as normal became abnormal over time in patients with probable dementia with Lewy bodies. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2016;43(6):1060-6.	9
1218	van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, et al. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An 123I-FP-CIT SPECT study. <i>NeuroImage Clinical</i> . 2020;25:102062.	9
1219	Van Laere K, Everaert L, Annemans L, Gonc M, Vandenberghe W, Vander Borght T. The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2008;35(7):1367-76.	9
1220	Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2013;40(2):213-27.	9
1221	Varrone A, Pellecchia MT, Amboni M, Sansone V, Salvatore E, Ghezzi D, et al. Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease. <i>Neurology</i> . 2004;63(11):2097-103.	7
1222	Varrone A, Salvatore E, De Michele G, Barone P, Sansone V, Pellecchia MT, et al. Reduced striatal [123 I]FP-CIT binding in SCA2 patients without parkinsonism. <i>Annals of Neurology</i> . 2004;55(3):426-30.	10
1223	Varrone A, Sansone V, Pellecchia MT, Amboni M, Salvatore E, De Michele G, et al. Comparison between a dual-head and a brain-dedicated SPECT system in the measurement of the loss of dopamine transporters with [123I]FP-CIT. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2008;35(7):1343-9.	9
1224	Verger A, Horowitz T, Chawki MB, Eusebio A, Bordonne M, Azulay JP, et al. From metabolic connectivity to molecular connectivity: application to dopaminergic pathways. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2020;47(2):413-24.	9
1225	Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [123I]IBZM and [123I]FP-CIT SPECT study. <i>European Journal of Nuclear Medicine & Molecular Imaging</i> . 2007;34(4):502-7.	10
1226	Villain N, Bera G, Habert MO, Kas A, Aubert J, Jaubert O, et al. Dopamine denervation in the functional territories of the striatum: a new MR and atlas-based 123I-FP-CIT SPECT quantification method. <i>Journal of Neural Transmission</i> . 2021;27:27.	8

1227	Vlaar AM, de Nijs T, Kessels AG, Vreeling FW, Winogrodzka A, Mess WH, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. <i>European Neurology</i> . 2008;59(5):258-66.	10
1228	Voon V, Rizos A, Chakravartty R, Mulholland N, Robinson S, Howell NA, et al. Impulse control disorders in Parkinson's disease: decreased striatal dopamine transporter levels. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2014;85(2):148-52.	9
1229	Vriend C, Raijmakers P, Veltman DJ, van Dijk KD, van der Werf YD, Foncke EM, et al. Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2014;85(2):159-64.	10
1230	Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. <i>Neurology</i> . 2004;62(9):1568-72.	10
1231	Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2002;73(2):134-40.	10
1232	Walker Z, Cummings JL. [123I]N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropine single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies. <i>Alzheimer's & Dementia</i> . 2012;8(1):74-83.	9
1233	Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. <i>Journal of Neurology, Neurosurgery & Psychiatry</i> . 2007;78(11):1176-81.	9
1234	Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, et al. Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. <i>British Journal of Psychiatry</i> . 2015;206(2):145-52.	9
1235	Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Stevens T, et al. Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. <i>Neurology</i> . 2016;87(10):1045-51.	9
1236	Zanotti-Fregonara P, Vidailhet M, Kas A, Ozelius LJ, Clot F, Hindie E, et al. [123I]-FP-CIT and [99mTc]-HMPAO single photon emission computed tomography in a new sporadic case of rapid-onset dystonia-parkinsonism. <i>Journal of the Neurological Sciences</i> . 2008;273(1-2):148-51.	9
1237	Ziebell M. Evaluation of the superselective radioligand [123I]PE2I for imaging of the dopamine transporter in SPECT. <i>Danish Medical Bulletin</i> . 2011;58(5):B4279.	2
1238	Zijlmans J, Booij J, Valk J, Lees A, Horstink M. Posttraumatic tremor without parkinsonism in a patient with complete contralateral loss of the nigrostriatal pathway. <i>Movement Disorders</i> . 2002;17(5):1086-8.	6
1239	Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacinovic S, Lees AJ, et al. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. <i>Movement Disorders</i> . 2007;22(9):1278-85.	9
1240	Zoetmulder M, Biernat HB, Nikolic M, Korbo L, Friberg L, Jennum PJ. Prepulse inhibition is associated with attention, processing speed, and 123I-FP-CIT SPECT in Parkinson's disease. <i>Journal of Parkinsons Disease Print</i> . 2014;4(1):77-87.	9

별첨2. 배제문헌 목록(국내)

배제사유

- 1 동물연구 또는 전임상연구
- 2 원저가 아닌 연구(종설, letter, comment 등)
- 3 한국어 또는 영어로 출판되지 않은 문헌
- 4 회색문헌(초록만 발표된 연구, 학위논문, 기관보고서 등 peer-review를 거치지 않은 경우)
- 5 원문 확보 불가
- 6 증례보고(3인 이하)
- 7 환자대조군이 명확하지 않은 경우
- 8 SPECT 검사를 수행하지 않거나 중재검사의 분석방법이 혼재된 경우
- 9 적절한 의료결과가 하나이상 보고되지 않은 경우
- 10 중복문헌

연번	서지정보	배제사유
1	Sang Eun K, Yearn Seong C, Seung Jun O, Joon Young C, Dae Yoon C, Gyeong Moon K, et al. PET IMAGING OF DOPAMINE TRANSPORTERS IN THE HUMAN BRAIN IN HEALTH AND PARKINSON `S DISEASE WITH [f - 18] β - CIT - FP. 핵의학분자영상. 1997;31(2):145-.	8
2	Sang Eun K, Yearn Seong C, Seung Jun O, Joon Young C, Dae Yoon C, Gyeong Moon K, et al. Pet Imaging of Dopamine Transporters in the Human Brain in Health and Parkinson`s Disease with [F-18]β-CIT-FP (초록). 대한핵의학회 춘계학술발표초록집. 1997;1997(0):145-.	4
3	김범산, 장성준, 어재선, 박은경, 김유경, 김종민, et al. 원저 : 도파민운반체 영상의 파킨슨증 감별진단 성능: (123)I-FP-CIT SPECT 연구. 핵의학분자영상. 2007;41(4):272-9.	10
4	오소원, 김유경, 이병철, 김범산, 김지선, 김종민, et al. 원저 : 123I-FP-CIT SPECT를 이용한 다중계위축증 및 조기 파킨슨병에서의 평가. 핵의학분자영상. 2009;43(1):10-8.	10
5	이강욱, 곽병수, 최시완, 강승식, 박기남, 전은석, et al. 원저 : 심실내 전도장애 환자에서의 99mTc-RBC Gated Blood-Pool Scintigraphy 을 통한 Phase Image Analysis. 핵의학분자영상. 1994;28(1):44-51.	10
6	홍일기, 김덕윤. 특집 : PET의 최신지견: F-18 FP-CIT를 이용한 도파민 운반체 영상. 경희의학. 2010;26(1):10-6.	8
7	최오지김최이김최오. 도파민운반체 방사성추적자 N-(3-[¹⁸ F]Fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane의 합성. 대한핵의학회지. 1999;33(3):298-305.	10
8	Kwon S-D, 천경아, 공은정, 조인호. Comparison of the Performances of 18F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study. Nuclear Medicine and Molecular Imaging. 2016;50(3):219-27.	8
9	Shin S-H, 김근영, 이재민, 김은주, 김성장, 김인주, et al. Effect of Single-Nucleotide Polymorphisms on Decline of Dopamine Transporter Availability in Parkinson's Disease. Journal of Clinical Neurology. 2019;15(1):102-7.	10
10	Sung C-H, 이재현, Oh Jung-Su S, 오민영, 이상주, 오승준, et al. Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson's Disease. Nuclear Medicine and Molecular Imaging. 2017;51(4):304-13.	9

11	Van Der Gucht A, De Langavant Laurent C, Belissant O, Rabu C, Cottureau Anne S, Evangelista E, et al. Brain 18F-FDG, 18F-Florbetaben PET/CT, 123I-FP-CIT SPECT and Cardiac 123I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. Nuclear Medicine and Molecular Imaging. 2016;50(3):258-60.	10
12	권형진, 최진욱, 이형진, 우재룡, 김유경. 18F-Florbetaben 주사 시 Activity 손실과 통증 감소를 위한 방법. 핵의학기술. 2016;20(2):42-5.	8
13	김동욱, 임석태, 정환정, 손명희. 18F-플루오린 표지를 위한 신개념 반응용매에서 친핵성 불소화 반응. Nuclear Medicine and Molecular Imaging. 2009;43(2):91-9.	10
14	김범산, 박은경, 어재선, 김유경, 김상은, 이원우, et al. 도파민운반체 영상의 파킨슨증 감별진단 성능: 123I-FP-CIT SPECT 연구. Nuclear Medicine and Molecular Imaging. 2007;41(4):272-9.	8
15	김승유, 송인욱, 정용안, 최은경, 오진경. Brain MRI, Tc-99m HMPAO SPECT and F-18 FP-CIT PET/CT Findings in a Patient with Wilson Disease: A Case Report. Nuclear Medicine and Molecular Imaging. 2014;48(4):303-5.	9
16	김용일, 임형준, 팽진철, 이재성, 어재선, 김동현, et al. Validation of Simple Quantification Methods for 18F-FP-CIT PET Using Automatic Delineation of Volumes of Interest Based on Statistical Probabilistic Anatomical Mapping and Isocontour Margin Setting. Nuclear Medicine and Molecular Imaging. 2012;46(4):254-60.	8
17	김재승. 도파민 운반체 영상의 임상이용을 위한 실제적 접근. Nuclear Medicine and Molecular Imaging. 2008;42(6):425-34.	10
18	김정수, 박찬록. 두개골-선조체 팬텀을 이용한 선량 저감화 방안 연구. 방사선기술과학. 2017;40(4):595-603.	10
19	박소현, 송요성, 문병석, 이병철, 박현수, 김상은. Combination of In Vivo [123I]FP-CIT SPECT and Microdialysis Reveals an Antipsychotic Drug Haloperidol-induced Synaptic Dopamine Availability in the Rat Midbrain and Striatum. Experimental Neurobiology. 2019;28(5):602-11.	1
20	박은경, 황유미, 이찬녕, 김수진, 오선영, 김용철, et al. Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [18F]FP-CIT PET/CT. Nuclear Medicine and Molecular Imaging. 2014;48(2):106-13.	6
21	박은경, 황유미, 주민경, 정기영. Increased Brainstem Serotonergic Transporter Availability in Adult Migraineurs: an [18F]FP-CIT PET Imaging Pilot Study. Nuclear Medicine and Molecular Imaging. 2016;50(1):70-5.	10
22	박정미, 유영훈, 안정훈, 이자연, 김지민, 권한별, et al. 파킨슨병 의심 환자에서 18F FP-CIT PET/CT의 임상적 유용성 평가 및 기존진단법과의 비교효과연구. 연구결과보고서. 2016;1(2):1-74.	10
23	배성우, 최홍윤, 위원석, 팽진철, 천기정, 강건욱, et al. Spatial Normalization Using Early-Phase [18F]FP-CIT PET for Quantification of Striatal Dopamine Transporter Binding. Nuclear Medicine and Molecular Imaging. 2020;54(6):305-14.	10
24	배진원, 조재욱, 김대진, 류철형, 이재혁. 신경퇴행성 질환의 전 증상으로 여겨지는 특발성 렘수면 행동 장애 1예. 수면. 2011;8(1):14-6.	6
25	서민정, 오민영, 조민정, 정선주, 이종식, 김재승. The Effect of SSRIs on the Binding of 18F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study. Nuclear Medicine and Molecular Imaging. 2014;48(4):287-94.	9
26	서영덕, 박경준, 남현열, 석주원, 이명준, 김은주, et al. Effect of rs3910105 in the Synuclein Gene on Dopamine Transporter Availability in Healthy Subjects. Yonsei Medical Journal. 2018;59(6):787-92.	10
27	신광호, 박수아, Kim S-Y, 이상주, 오승준, 김재승. Effect of Animal Condition and Fluvoxamine on the Result of [18F]N-3-Fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) Nortropane ([18F]FP-CIT) PET Study in Mice. Nuclear Medicine and Molecular Imaging. 2012;46(1):27-33.	10
28	신은실, 황온유, 황유식, Suh Jun-Kyo F, 전영일, 전상룡. Enhanced Efficacy of Human Brain-Derived Neural Stem Cells by Transplantation of Cell Aggregates in a Rat Model of Parkinson's Disease. Journal of Korean Neurosurgical Society. 2014;56(5):383-9.	9
29	안정훈, 이자연, 김지민, 권한별, 신민경, 류형철, et al. 파킨슨병 의심 환자에서 18F FP-CIT PETCT의 임상적 유용성 평가 및 기존진단법과의 비교효과연구. 연구결과보고서. 2014;1(1):1-55.	10

30	양영순, 천미주, 곽용태. Is Parkinson's Disease with History of Agent Orange Exposure Different from Idiopathic Parkinson's Disease? Dementia and Neurocognitive Disorders. 2016;15(3):75-81.	10
31	양영순, 천미주, 곽용태. 18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease. Dementia and Neurocognitive Disorders. 2017;16(3):57-63.	10
32	오소원, 김유경, 이병철, 김범산, 김지선, 김종민, et al. 123I-FP-CIT SPECT를 이용한 다중계위축증 및 조기 파킨슨병에서의 평가. Nuclear Medicine and Molecular Imaging. 2009;43(1):10-8.	8
33	오승준. 뇌 신경물질 운반체 영상용 방사성의약품. Nuclear Medicine and Molecular Imaging. 2007;41(2):118-31.	9
34	오응석, 김종민, 김영은, 윤지영, 김지선, 김상은, et al. The Prevalence of Essential Tremor in Elderly Koreans. Journal of Korean Medical Science. 2014;29(12):1694-8.	8
35	오진경, 유익동, 서예영, 정용안, 유이령, 김성훈, et al. Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease. Nuclear Medicine and Molecular Imaging. 2011;45(4):255-60.	8
36	윤준원, 안재범, 권은아, Ahn J-H, 박형우, Heo H, et al. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy. Tissue Engineering and Regenerative Medicine. 2016;13(1):100-9.	10
37	윤형호, 김용환, 신은실, 전상룡. A Rat Model of Striatonigral Degeneration Generated by Simultaneous Injection of 6-Hydroxydopamine into the Medial Forebrain Bundle and Quinolinic Acid into the Striatum. Journal of Korean Medical Science. 2014;29(11):1555-61.	10
38	이선아, 임동규, 김지은, 허재혁. 도파민 영상과 뇌척수액 검사로 진단된 루이소체 치매 1예. 임상노인의학회지. 2016;17(1):42-5.	10
39	이선희, 김진형, 정진희. 18F-FLT 양전자방출단층촬영, 18F-FLT 양전자방출전산화단층촬영. 신의료기술평가 보고서. 2012;1(37):1-99.	10
40	이선희, 이민, 정유진. 123I-FP-CIT 뇌 단일광자단층촬영. 신의료기술평가 보고서. 2012;1(44):1-113.	10
41	이선희, 이민, 정지영. [18F]FP-CIT뇌양전자방출단층촬영,양전자방출전산화단층촬영. 신의료기술평가 보고서. 2012;1(38):1-71.	8
42	이성하, 김한결, 이영건, 류철형, 안성준, 이명식. Clinical Features Indicating Nigrostriatal Dopaminergic Degeneration in Drug-Induced Parkinsonism. Journal of Movement Disorders. 2017;10(1):35-9.	10
43	이지영, 윤은진, 김유경, 신채원, 남현우, 정재민, et al. Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment. Journal of Movement Disorders. 2019;12(2):103-12.	10
44	이채영, 최봄, 황보승, 손명진, 이민우, 유진혁, et al. 클레보프라이드에 의한 파킨슨증. 대한신경과학회지. 2016;34(3):261-3.	8
45	정석중, 유한수, 이양현, 이필휴, Sohn Young H. Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson's Disease: Impact on Clinical Features. Journal of Movement Disorders. 2019;12(2):113-9.	10
46	정유진, 오선영, Park K-S, 이찬녕, 박건우, 이재성, et al. Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson's Disease. Nuclear Medicine and Molecular Imaging. 2013;47(2):73-80.	10
47	진소영, 오민영, 오승준, Oh Jung-Su S, 이상주, 정선주, et al. Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. Nuclear Medicine and Molecular Imaging. 2013;47(1):44-51.	10
48	최재민, 김경식, 남궁창경, 남기표, 임기천. The Influence of Iteration and Subset on True X method in 18F-FP-CIT Brain Imaging. 대한핵의학기술학회지. 2009;13(4):34-5.	9

49	호성희, 송인욱, 정용안. 초기 파킨슨병에서의 Cardiac 123I-Metaiodobenzylguanidine Image를 통한 임상적 예후 평가에 대한 연구(예비연구). 임상노인의학회지. 2016;17(2):74-8.	8
50	홍일기, 김덕윤. PET의 최신지견: F-18 FP-CIT를 이용한 도파민 운반체 영상. 경희의학. 2010;26(1):10-6.	9
51	황인하, 하상원, 양영순, 김승민. Hydrocephalus in Patient with Multiple System Atrophy: Innocent Bystander or Guilty Party? Dementia and Neurocognitive Disorders. 2016;15(2):49-51.	9
52	Bae S, Choi H, Whi W, Paeng JC, Cheon GJ, Kang KW, et al. Spatial Normalization Using Early-Phase [¹⁸ F]FP-CIT PET for Quantification of Striatal Dopamine Transporter Binding. Nucl Med Mol Imaging. 2020;54(6):305-14.	10
53	Chung SJ, Yoo HS, Lee YH, Lee PH, Sohn YH. Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson's Disease: Impact on Clinical Features. J Mov Disord. 2019;12(2):113-9.	10
54	Hwang I, Ha SW, Yang Y, Kim SM. Hydrocephalus in Patient with Multiple System Atrophy: Innocent Bystander or Guilty Party? Dement Neurocogn Disord. 2016;15(2):49-51.	10
55	Jeong E, Oh SY, Pakh K, Lee CN, Park KW, Lee JS, et al. Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson's Disease. Nucl Med Mol Imaging. 2013;47(2):73-80.	8
56	Jin S, Oh M, Oh SJ, Oh JS, Lee SJ, Chung SJ, et al. Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. Nucl Med Mol Imaging. 2013;47(1):44-51.	10
57	Kim BS, Jang SJ, Eo JS, Park EK, Kim YK, Kim JM, et al. The Discriminating Nature of Dopamine Transporter Image in Parkinsonism: The Competency of Dopaminergic Transporter Imaging in Differential Diagnosis of Parkinsonism: 123I-FP-CIT SPECT Study. Nucl Med Mol Imaging. 2007;41(4):272-9.	10
58	Kim JS. Practical Approach for the Clinical Use of Dopamine Transporter Imaging. Nucl Med Mol Imaging. 2008;42(6):425-34.	2
59	Kwon S, Chun K, Kong E, Cho I. Comparison of the Performances of ¹⁸ F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study. Nucl Med Mol Imaging. 2016;50(3):219-27.	9
60	Kwon S, Chun K, Kong E, Cho I. Comparison of the Performances of ¹⁸ F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study. Nucl Med Mol Imaging. 2016;50(3):219-27.	8
61	Lee CY, Choi B, Hwang B, Son MJ, Lee M, Yoo J, et al. Clebopride-Induced Parkinsonism. J Korean Neurol Assoc. 2016;34(3):261-3.	8
62	Lee JY, Yoon EJ, Kim YK, Shin CW, Nam H, Jeong JM, et al. Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment. J Mov Disord. 2019;12(2):103-12.	10
63	Lee SH, Kim HK, Lee YG, Lyoo CH, Ahn SJ, Lee MS. Clinical Features Indicating Nigrostriatal Dopaminergic Degeneration in Drug-Induced Parkinsonism. J Mov Disord. 2017;10(1):35-9.	10
64	Oh ES, Kim JM, Kim YE, Yun JY, Kim JS, Kim SE, et al. The Prevalence of Essential Tremor in Elderly Koreans. J Korean Med Sci. 2014;29(12):1694-8.	10
65	Oh JK, Yoo ID, Seo YY, Chung YA, Yoo IR, Kim SH, et al. Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease. Nucl Med Mol Imaging. 2011;45(4):255-60.	8
66	Oh SJ. Radiopharmaceuticals for Neurotransmitter Imaging. Nucl Med Mol Imaging. 2007;41(2):118-31.	9
67	Oh SW, Kim YK, Lee BC, Kim BS, Kim JS, Kim JM, et al. Evaluation of Multiple System Atrophy and Early Parkinson's Disease Using (123I)-FP-CIT SPECT. Nucl Med Mol Imaging. 2009;43(1):10-8.	10

68	Park E, Hwang YM, Lee CN, Kim S, Oh SY, Kim YC, et al. Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [18F]FP-CIT PET/CT. Nucl Med Mol Imaging. 2014;48(2):106-13.	10
69	Seo M, Oh M, Cho M, Chung SJ, Lee CS, Kim JS. The Effect of SSRIs on the Binding of 18F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study. Nucl Med Mol Imaging. 2014;48(4):287-94.	6
70	Shin ES, Hwang O, Hwang YS, Suh JKF, Chun YI, Jeon SR. Enhanced Efficacy of Human Brain-Derived Neural Stem Cells by Transplantation of Cell Aggregates in a Rat Model of Parkinson's Disease. J Korean Neurosurg Soc. 2014;56(5):383-9.	10
71	Shin S, Kim K, Lee JM, Kim EJ, Kim SJ, Kim IJ, et al. Effect of Single-Nucleotide Polymorphisms on Decline of Dopamine Transporter Availability in Parkinson's Disease. J Clin Neurol. 2019;15(1):102-7.	10
72	Sung C, Lee JH, Oh JS, Oh M, Lee SJ, Oh SJ, et al. Longitudinal Decline of Striatal Subregional [척척척추척]FP-CIT Uptake in Parkinson's Disease. Nucl Med Mol Imaging. 2017;51(4):304-13.	10
73	Van Der Gucht A, Cleret de Langavant L, BÃ©lissant OI, Rabu C, Cottureau ASgn, Evangelista E, et al. Brain ¹⁸ F-FDG, ¹⁸ F-Florbetaben PET/CT, ¹²³ I-PP-CIT SPECT and Cardiac ¹²³ I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. Nucl Med Mol Imaging. 2016;50(3):258-60.	8
74	Yang Y, Cheon M, Kwak YT. Is Parkinson's Disease with History of Agent Orange Exposure Different from Idiopathic Parkinson's Disease? Dement Neurocogn Disord. 2016;15(3):75-81.	10
75	Yang Y, Cheon M, Kwak YT. 18F-FP-CIT Positron Emission Tomography for Correlating Motor and Cognitive Symptoms of Parkinson's Disease. Dement Neurocogn Disord. 2017;16(3):57-63.	8
76	Yoon HH, Kim YH, Shin ES, Jeon SR. A Rat Model of Striatonigral Degeneration Generated by Simultaneous Injection of 6-Hydroxydopamine into the Medial Forebrain Bundle and Quinolinic Acid into the Striatum. J Korean Med Sci. 2014;29(11):1555-61.	10
77	Yun JW, Ahn JB, Kwon E, Ahn JH, Park HW, Heo H, et al. Behavior, PET and Histology in Novel Regimen of MPTP Marmoset Model of Parkinson's Disease for Long-Term Stem Cell Therapy. Tissue Eng Regen Med. 2016;13(1):100-9.	9
78	An HJ, Seo S, Kang H, Choi H, Cheon GJ, Kim H-J, et al. MRI-Based Attenuation Correction for PET/MRI Using Multiphase Level-Set Method. The Journal of nuclear medicine. 2016;57(4):587-93.	10
79	Chi DY, Oh SJ, Choe YS, Choi Y, Kim SE, Kim BT, et al. PET IMAGING OF DOPAMINE TRANSPORTERS IN THE HUMAN BRAIN IN HEALTH AND PARKINSON `S DISEASE WITH [f - 18] β - CIT - FP. 핵의학 분자영상. 1997;31(2):145-.	10
80	Choi H, Cheon GJ, Kim H-J, Choi SH, Lee JS, Kim Y-i, et al. Segmentation-Based MR Attenuation Correction Including Bones Also Affects Quantitation in Brain Studies: An Initial Result of ¹⁸ F-FP-CIT PET/MR for Patients with Parkinsonism. The Journal of nuclear medicine. 2014;55(10):1617-22.	8
81	Gucht AVD, de Langavant LC, Belissant O, Rabu C, Cottureau A-S, Evangelista E, et al. Brain ¹⁸ F-FDG, ¹⁸ F-Florbetaben PET/CT, ¹²³ I-PP-CIT SPECT and Cardiac ¹²³ I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. 핵의학 분자영상. 2016;50(3):258-60.	10
82	Hwang D, Kim KY, Kang SK, Seo S, Paeng JC, Lee DS, et al. Improving the Accuracy of Simultaneously Reconstructed Activity and Attenuation Maps Using Deep Learning. The Journal of nuclear medicine. 2018;59(10):1624-9.	10
83	Im H-J, Hwang DW, Lee HK, Jang J, Lee S, Youn H, et al. In vivo visualization and monitoring of viable neural stem cells using noninvasive bioluminescence imaging in the 6-hydroxydopamine-induced mouse model of Parkinson disease. Molecular imaging. 2013;12(4):224-34.	10
84	Jin S, Oh M, Oh SJ, Oh JS, Lee SJ, Chung SJ, et al. Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism. Clinical nuclear medicine. 2017;42(2):80-7.	8
85	Jincheol S, Youngjeon L, Hyeon-Gu Y, Chang-Yeop J, Kang-Jin J, Seung-Ho P, et al. Novel strategy of MPTP administration for stable parkinsonian symptoms in non-human primates. 한국실험 동물학회 학술발표대회 논문집. 2017;2017(2):110-.	8
86	Kim J, Kim J-M, Kim YK, Shin JW, Choi SH, Kim SE, et al. Dopamine Transporter SPECT of a Liver Cirrhotic with Atypical Parkinsonism. Industrial health. 2007;45(3):497-500.	8

87	Kim J-S, Park C-R. The Study of Radiation Exposure Reduction by Developing Corpus Striatum Phantom. 방사선기술과학. 2017;40(4):595-603.	10
88	Kim YK, Yoon I, x, Y, Kim J, x, et al. The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behavior disorder. EUROPEAN JOURNAL OF NEUROLOGY. 2010;17(3):487-92.	10
89	Kwon S, Chun K, Kong E, Cho I. Comparison of the Performances of ¹⁸ F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study. 핵의학 분자영상. 2016;50(3):219-27.	8
90	Lee CS, Kim SJ, Oh SJ, Kim HO, Yun SC, Doudet D, et al. Uneven age effects of [18F]FP-CIT binding in the striatum of Parkinson's disease. Annals of nuclear medicine. 2014;28(9):874-9.	9
91	Lee J-Y, Seo SH, Kim YK, Yoo HB, Kim YE, Song IC, et al. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. Journal of neurology, neurosurgery and psychiatry. 2014;85(1):23-30.	8
92	Noh Y, Sung YH, Lee J, Kim EY. Nigrosome 1 Detection at 3T MRI for the Diagnosis of Early-Stage Idiopathic Parkinson Disease: Assessment of Diagnostic Accuracy and Agreement on Imaging Asymmetry and Clinical Laterality. American journal of neuroradiology = AJNR. 2015;36(11):2010-6.	10
93	Oh J-K, Yoo I-D, Seo Y-Y, Chung Y-A, Yoo I-R, Kim S-H, et al. Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease. 핵의학 분자영상. 2011;45(4):255-60.	10
94	Oh Y-S, Kim J-S, Hwang E-J, Lyoo CH. Striatal dopamine uptake and olfactory dysfunction in patients with early Parkinson's disease. Parkinsonism & related disorders. 2018;56(-):47-51.	10
95	Park B-N, Kim J-H, Lee K, Park SH, An Y-S. Improved dopamine transporter binding activity after bone marrow mesenchymal stem cell transplantation in a rat model of Parkinson's disease: small animal positron emission tomography study with F-18 FP-CIT. EUROPEAN RADIOLOGY. 2015;25(5):1487-96.	2
96	Park HK, Kim JS, Im KC, Oh SJ, Kim MJ, Lee J-H, et al. Functional brain imaging in pure akinesia with gait freezing: [¹⁸ F] FDG PET and [¹⁸ F] FP-CIT PET analyses. Movement disorders. 2009;24(2):237-45.	2
97	Shin ES, Hwang O, Hwang Y-S, Suh J-KF, Chun Yi, Jeon SR. Enhanced Efficacy of Human Brain-Derived Neural Stem Cells by Transplantation of Cell Aggregates in a Rat Model of Parkinson's Disease. Journal of Korean neurosurgical society. 2014;56(5):383-9.	9
98	Song I-U, Kim Y-D, Cho H-J, Chung S-W, Chung Y-A. An FP-CIT PET Comparison of the Differences in Dopaminergic Neuronal Loss Between Idiopathic Parkinson Disease With Dementia and Without Dementia. Alzheimer disease and associated disorders. 2013;27(1):51-5.	8
99	Song YS, Kim J-M, Kim KJ, Yun JY, Kim SE. Serum Ceruloplasmin and Striatal Dopamine Transporter Density in Parkinson Disease: Comparison With 123I-FP-CIT SPECT. Clinical nuclear medicine. 2017;42(9):675-9.	9
100	Sung C, Lee JH, Oh JS, Oh M, Lee SJ, Oh SJ, et al. Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson's Disease. 핵의학 분자영상. 2017;51(4):304-13.	9
101	Ye-rin K, 김현기, 이교철, 이용진, 박상원, Javeria Z, et al. Comparison of Reconstruction Algorithms for F-18 FP CIT PET Images. THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY. 2019;74(12):1129-34.	10
102	Yiseul C, Eun Sang L, Jang Woo P, Youn Kyoung J, Mijeong P, Hye Kyung C. Evaluation method based non-invasive imaging in Parkinson's disease models. 한국실험동물학회 학술발표대회 논문집. 2021;2021(7):219-.	9
103	Yu AR, Jin Su K, Hee-Joung K, Jisook M, Yun Young C, Joo Hyun K, et al. Assessment of Early Phase ^{18}F -FP-CIT PET as an Alternative Method of FDG PET for Voxel Based Statistical Analysis: Application for Parkinson's Disease Rat Model. IEEE transactions on nuclear science. 2013;60(2):820-3.	9
104	Yu KJ, Lee BJ, Han J, Park D. Usefulness of F-18 FP-CIT PET to predict dopamine-responsive hand tremor in patients other than Parkinson's disease : Two case reports. Medicine. 2018;97(22):10983.	8
105	Yun J-W, Ahn J-B, Kwon E, Ahn JH, Park HW, Heo H, et al. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson's disease for long-term stem cell therapy. 조직공학과 재생의학. 2016;13(1):100-9.	10

106	강용길, 홍시영. Parkinson's disease에서 [18F]-FP-CIT을 이용한 Brain PET/CT영상의 유용성. 김천대학교 논문집. 2009;30(-).	10
107	김범산, 장성준, 어재선, 박은경, 김유경, 김종민, et al. 도파민운반체 영상의 파킨슨증 감별진단 성능 : (123I)-FP-CIT SPECT 연구. 핵의학 분자영상. 2007;41(4):272-9.	9
108	김정수, 박찬록. The Study of Radiation Exposure Reduction by Developing Corpus Striatum Phantom. 방사선기술과학. 2017;40(4):595-603.	8
109	박은경, 황유미, 이찬녕, 김수진, 오선영, 김영철, et al. Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [18F]FP-CIT PET/CT. 핵의학 분자영상. 2014;48(2):106-13.	10
110	성창환, 이재현, 오정수, 오민영, 이상주, 오승준, et al. Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson's Disease. 핵의학 분자영상. 2017;51(4):304-13.	10
111	신승현, 김근영, 이재민, 김은주, 김성장, 김인주, et al. Effect of Single-Nucleotide Polymorphisms on Decline of Dopamine Transporter Availability in Parkinson's Disease. Journal of Clinical Neurology. 2019;15(1):102-7.	9
112	양영순, Miju C, 광용태. Is Parkinson's Disease with History of Agent Orange Exposure Different from Idiopathic Parkinson's Disease? Dementia and Neurocognitive Disorders. 2016;15(3):75-81.	10
113	오응석, 김종민, 김영은, 윤지영, 김지선, 김상은, et al. The Prevalence of Essential Tremor in Elderly Koreans. Journal of Korean medical science. 2014;12(12):1694-8.	9
114	윤형호, Yong Hwan K, Eun Sil S, Sang Ryong J. A Rat Model of Striatonigral Degeneration Generated by Simultaneous Injection of 6-Hydroxydopamine into the Medial Forebrain Bundle and Quinolinic Acid into the Striatum. Journal of Korean medical science. 2014;29(11):1555-61.	10
115	이승하, 김한결, 이영건, 류철형, 안성준, 이명식. Clinical Features Indicating Nigrostriatal Dopaminergic Degeneration in Drug-Induced Parkinsonism. Journal Of Movement Disorders. 2017;10(1):35-9.	9
116	전기평, 나승희. 추체외로 증상이 추가적으로 발생한 알츠하이머치매 환자. 대한임상노인의학회지. 2017;18(2):113-7.	6
117	정석중, 유한수, 이양현, 이필휴, 손영호. Heterogeneous Patterns of Striatal Dopamine Loss in Patients with Young- versus Old-Onset Parkinson's Disease: Impact on Clinical Features. Journal Of Movement Disorders. 2019;12(2):113-9.	9
118	정유진, 오선영, 박기수, 이찬녕, 박건우, 이재성, et al. Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson's Disease. 핵의학 분자영상. 2013;47(2):73-80.	9
119	진소영, 이종식, 오승준, 정선주, 김재승, 오정수, et al. Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. 핵의학 분자영상. 2013;47(1):44-51.	6
120	Axel Van Der G. Brain 18F-FDG, 18F-Florbetaben PET/CT, 123I-FP-CIT SPECT and Cardiac 123I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. Brain 18F-FDG, 18F-Florbetaben PET/CT, 123I-FP-CIT SPECT and Cardiac 123I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. 2016;, 50(3):258-60.	2
121	Hwang I, Ha S-W, Yang Y, Kim SM. Hydrocephalus in Patient with Multiple System Atrophy: Innocent Bystander or Guilty Party? Dementia and neurocognitive disorders : official journal of the Korean Dementia Association. 2016;15(2):49-51.	9
122	Kim S-E, Choe Y-S, Oh S-J, Choi J-Y, Chi D-Y, Kim G-M, et al. PET IMAGING OF DOPAMINE TRANSPORTERS IN THE HUMAN BRAIN IN HEALTH AND PARKINSON'S DISEASE WITH [F-18] ^{18}F-FP-CIT. 대한핵의학회 1997년도 제36차 춘계학술대회 초록집. 1997;1997(5):145-.	10
123	Lee J-Y, Yoon EJ, Kim YK, Shin CW, Nam H, Jeong JM, et al. Nonmotor and Dopamine Transporter Change in REM Sleep Behavior Disorder by Olfactory Impairment. Journal of movement disorders. 2019;12(2):103-12.	10
124	Shin S, Kim K, Lee JM, Kim E-J, Kim S-J, Kim IJ, et al. Effect of Single-Nucleotide Polymorphisms on Decline of Dopamine Transporter Availability in Parkinson's Disease. Journal of clinical neurology. 2019;15(1):102-7.	10

125	권상돈. Comparison of the Performances of 18F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study. Comparison of the Performances of 18F-FP-CIT Brain PET/MR and Simultaneous PET/CT: a Preliminary Study. 2016;, 50(3):219-27.	10
126	김범산. 도파민운반체 영상의 파킨슨증 감별진단 성능: 123I-FP-CIT SPECT 연구. Nuclear Medicine and Molecular Imaging. 2007;, 41(4):272-9.	9
127	김범산, 장성준, 어재선, 박은경, 김유경, 김종민, et al. 도파민운반체 영상의 파킨슨증 감별진단 성능: ^{123}I -FP-CIT SPECT 연구. The Discriminating Nature of Dopamine Transporter Image in Parkinsonism: The Competency of Dopaminergic Transporter Imaging in Differential Diagnosis of Parkinsonism: ^{123}I -FP-CIT SPECT Study. 2007;41(4):272-9.	6
128	박은경. Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [18F]FP-CIT PET/CT. Differential Diagnosis of Patients with Inconclusive Parkinsonian Features Using [18F]FP-CIT PET/CT. 2014;, 48(2):106-13.	10
129	서민정. The Effect of SSRIs on the Binding of 18F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study. The Effect of SSRIs on the Binding of 18F-FP-CIT in Parkinson Patients: A Retrospective Case Control Study. 2014;, 48(4):287-94.	10
130	성창환. Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson's Disease. Longitudinal Decline of Striatal Subregional [18F]FP-CIT Uptake in Parkinson's Disease. 2017;, 51(4):304-13.	9
131	오소원. 123I-FP-CIT SPECT를 이용한 다중계위축증 및 조기 파킨슨병에서의 평가. Evaluation of Multiple System Atrophy and Early Parkinson's Disease Using 123I-FP-CIT SPECT. 2009;, 43(1):10-8.	9
132	오소원, 김유경, 이병철, 김범산, 김지선, 김종민, et al. ^{123}I -FP-CIT SPECT를 이용한 다중계위축증 및 조기 파킨슨병에서의 평가. Evaluation of Multiple System Atrophy and Early Parkinson's Disease Using ^{123}I -FP-CIT SPECT. 2009;43(1):10-8.	6
133	오응석. The Prevalence of Essential Tremor in Elderly Koreans. The Prevalence of Essential Tremor in Elderly Koreans. 2014;12(12):1694-8.	9
134	오진경. Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease. Clinical Significance of F-18 FP-CIT Dual Time Point PET Imaging in Idiopathic Parkinson's Disease. 2011;, 45(4):255-60.	10
135	정유진. Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson's Disease. Feasibility of PET Template-Based Analysis on F-18 FP-CIT PET in Patients with De Novo Parkinson's Disease. 2013;, 47(2):73-80.	8
136	진소영. Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. 2013;, 47(1):44-51.	4